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Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for
blood cancers. The success of allo-HSCT is restricted by the development of deadly graftversus-host disease (GVHD), in 50% of allo-HSCT recipients. GVHD develops when
donor T cells in the transplant (graft) become reactive against the recipient (host),
triggering severe inflammatory damage. There are currently are no effective therapies for
GVHD. Two key strategies for reducing GVHD are identifying biomarkers in allo-HSCT
donors that may predict GVHD and developing therapeutics that target donor T cells.
This thesis aimed to identify predictive donor GVHD biomarkers and develop novel
therapeutic strategies to prevent GVHD that target reactive donor T cells.
Purinergic signalling is an important extracellular signalling network that is implicated in
GVHD. Activation of the purinergic ATP-gated P2X7 receptor enhances GVHD in mice.
Although P2X7 is present on donor and host cells in allo-HSCT, how donor P2X7 impacts
GVHD is unclear. Chapter 3 demonstrates that P2X7 activity on human leukocyte subsets
important in GVHD is influenced by gain-of-function (GOF) and loss-of-function (LOF)
single nucleotide polymorphisms (SNPs) in the human P2RX7 gene. To determine if donor
P2RX7 genotype influenced GVHD, NOD-SCID-IL2Rγnull (NSG) mice were injected
with human peripheral blood mononuclear cells (hPBMCs) from GOF or LOF P2RX7
genotype donors. Donor P2RX7 genotype did not impact GVHD severity in humanised
NSG mice.
The purinergic ecto-nucleotidase ecto-nucleoside triphosphate diphosphohydrolase-1
(CD39) hydrolyses extracellular ATP and is important for regulatory T cells (Tregs) to
prevent GVHD. CD39 expression on human Tregs is influenced by the rs10748643
(AG) SNP in the human ENTPD1 gene. Chapter 4 demonstrates that the G allele of the
ii

rs10748643 (AG) SNP correlates with increased proportions of CD39+ Tregs in
Australian donors. The intra-peritoneal (i.p.) injection of hPBMCs encoding the G allele
into NSG mice caused more severe GVHD, including increased weight loss and
hCD4+:hCD8+ T cell ratios, alongside reduced survival compared to hPBMCs
homozygous for the A allele.
Post-transplant cyclophosphamide (PTCy) reduces clinical GVHD. However, how PTCy
impacts donor T cells and reduces GVHD is unclear. Chapter 5 investigated the effect of
PTCy on reactive human donor T cells and GVHD in humanised NSG mice. NSG mice
were injected i.p. with hPBMCs, followed by PTCy (33 mg.kg-1 on days 3 and 4) or saline.
PTCy reduced reactive hCD3+ T cells, corresponding to reduced GVHD severity, weight
loss and histological liver damage, and prolonged survival. However, PTCy lowered
human Tregs which are thought to be necessary for PTCy to reduce GVHD. Therefore,
Chapter 6 investigated combining PTCy with low-dose interleukin (IL)-2, to enhance
human Tregs. NSG mice were injected i.p. with hPBMCs followed by PTCy (as above)
and low-dose IL-2 (0.3 mega international units from day 0-4, then thrice weekly).
Although this improved human Treg survival, it did not further reduce GVHD compared
to PTCy alone.
In conclusion, this thesis demonstrates that donor rs10748643 genotype, but not P2RX7
genotype, may be a predictive GVHD biomarker. Further, this thesis demonstrates that
PTCy depletes reactive human donor T cells and reduces GVHD in humanised NSG mice,
but combining PTCy with low dose IL-2 does not further reduce GVHD.
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Introduction

Blood cancers

Blood cancers, or haematological malignancies, originate in the bone marrow and lymph
nodes and result in abnormalities to the production and function of blood cells. There are
3 main types of blood cancers; leukaemia, lymphoma and myeloma, which account for
15,000 new cancer diagnoses and 7,500 cancer related deaths in Australia each year
(Leukaemia Foundation, 2019). Currently, hematopoietic stem cell transplantation
(HSCT) is one of the few curative therapy for these diseases.
1.2

HSCT

HSCT is the transfer of functional hematopoietic stem and progenitor cells from a donor
(graft) into an immunocompromised recipient (or host) with defective bone marrow. This
allows the re-establishment of a functional immune system in the host (Passweg et al.,
2012). Aside from blood cancers, HSCT is used to treat other diseases associated with
abnormal haematopoiesis, such as sickle cell anaemia (Vermylen et al., 1991) and severe
combined immunodeficiency (SCID) diseases (Cowan et al., 2008). As a result, over
50,000 HSCTs are performed annually worldwide (WHO, 2020)

xix

HSCT is classed as either autologous or allogeneic (allo-HSCT), depending on the source
of the graft (Passweg et al., 2012). In autologous HSCT immunocompetent progenitor
cells are harvested from an individual, and later-reinfused into that same person following
high-dose chemotherapy or radiotherapy to treat their underlying malignancy (Passweg
et al., 2012). To facilitate immune reconstitution, harvested cells can be expanded either
ex vivo, prior to their transplantation, or in vivo, in the host. Whilst this allows the host to
overcome the bone marrow aplasia that often follows high-dose therapy (Wang et al.,
2006), any anti-tumour effects are solely due to the chemotherapy or radiotherapy and
not the autologous HSCT.
In cases where autologous transplantation is not suitable, such as when patients have a
long history of chemotherapy or radiotherapy, or if the patients’ blood or bone marrow is
contaminated with tumour cells, allo-HSCT is used (Hosing and Champlin, 2002). In alloHSCT immunocompetent progenitor cells are obtained from a healthy donor, originating
from either bone marrow, peripheral blood or cord blood, and transplanted into the host
(Cheuk, 2013). This allows immune reconstitution, but also provides the graft-versustumour (GVT) effect whereby healthy donor immune cells recognise and facilitate the
destruction of malignant host cells (Welniak et al., 2007).
Unfortunately, the same principles responsible for the GVT effect allow transplanted
donor immune cells to also recognise healthy host cells and initiate an inflammatory
response against host tissue (Fowler, 2006). This results in very severe and lifethreatening inflammatory damage, known as graft-versus-host disease (GVHD). GVHD
was first reported by Barnes et al. (1962), and to this day there are limited effective
therapies against this disease. Therefore, GVHD is still a major problem in allo-HSCT,
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occurring in up to 50% of allo-HSCT recipients with a mortality rate of 15-30% (Jagasia
et al., 2012, Storb et al., 2013).
1.3

GVHD

Over 50 years ago, Billingham (1966) described three criteria for the development of
GVHD following allo-HSCT; i) the graft must contain immunocompetent cells, ii) the
donor and host must be immunologically disparate and iii) the host must not be able to
mount an immune response against transplanted donor cells. Therefore, in order to
minimise GVHD, allo-HSCT donors and recipients are assessed for immunological
disparity using major histocompatibility complexes (MHC) (Bertaina and Andreani,
2018). In humans MHC are found on antigen presenting cells (APCs) as well as most
human tissues, and are responsible for the activation of T cells (Hennecke and Wiley,
2001). Human MHC is also referred to as human leukocyte antigen (HLA) (Marsh et al.,
2002) and all genes that encode HLA antigens are found on Chromosome six (Petersdorf,
2017). Donor matching is first assessed on related siblings since there is a 25% chance of
them being HLA identical (Passweg et al., 2012). If no familial donor is found, which
occurs in 70% of patients in Western countries (Tiercy, 2016), HLA-matching is
performed on unrelated individuals. However, the probability of finding an HLA-matched
unrelated donor is low due to small donor pools. In these cases a partial HLA-matched
(haploidentical) or HLA-mismatch allo-HSCT is performed, which is one of the strongest
risk factors for GVHD (Petersdorf, 2017). GVHD still occurs following HLA-matched
allo-HSCT due to differences in donor and host minor histocompatibility antigens
(MiHAgs) (Dzierzak-Mietla et al., 2012).
GVHD develops as either acute or chronic forms, depending on a number of factors such
as the specific organs targeted (Zeiser and Blazar, 2017b). Acute GVHD was originally
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defined as GVHD developing within 100 days of transplant, with chronic GVHD
developing post 100 days (Martin et al., 1990, Sullivan et al., 1991). However, recent data
indicates that chronic and acute GVHD have unique cellular and cytokine profiles
(Schultz et al., 2020). For example, children suffering from chronic GVHD show
increased cytotoxic T cells and loss of regulatory natural killer (NK) cells in peripheral
blood whereas those suffering from acute GVHD demonstrated decreased transitional B
cells and increased cytolytic NK cells compared to non-GVHD controls (Schultz et al,
2020). Notably, acute GVHD can occur post 100 days (Ferrara et al., 2009). This has led
to the identification of overlap chronic GVHD where patients demonstrate signs of both
forms (Lee, 2017). This thesis focusses on acute GVHD, therefore “GVHD” will refer to
acute GVHD hereafter.
The skin is the principle target organ of GVHD, being affected in 80% of cases and is
usually the first organ targeted (Martin et al., 1990). GVHD also commonly impacts the
liver (50% of cases) (Farthing et al., 1982), small-intestines (62% of cases) (McDonald,
2016) and the lungs (up to 20% of cases) (Cengiz Seval et al., 2018). Skin involvement
manifests itself as a large rash and peeling of the external dermis layers. Patients suffering
chronic liver damage develop jaundice, resulting in yellowing of the skin and eyes. The
involvement of the lung and small-intestines results in severe breathing difficulties and
nausea, vomiting, diarrhoea and dramatic weight loss, respectively (Zeiser and Blazar,
2017a). The pathophysiology of GVHD is complex and multi-faceted, encompassing a
number of immune cell subsets.
1.3.1

GVHD pathophysiology

GVHD is primarily mediated by donor T cells and its pathophysiology has been
conceptualized into three phases: (1) activation of host APCs (afferent phase); (2) donor
4

T cell activation and differentiation (efferent phase); and (3) target tissue destruction
(effector phase) (Ferrara and Reddy, 2006, Schroeder and DiPersio, 2011, Ferrara et al.,
1999) (Fig. 1.1). The complex pathophysiology has, in part, limited the development of
effective therapeutic strategies against GVHD. Therefore, two key approaches to improve
GVHD outcomes are to identify biomarkers to predict GVHD development or to develop
strategies that manipulate donor T cells in the graft.
The afferent phase of GVHD (Fig. 1.1) involves damage to recipient tissue from the
underlying haematological malignancy or the conditioning regime for allo-HSCT
(Ferrara and Reddy, 2006). This causes the release of pro-inflammatory cytokines,
including tumour necrosis factor (TNF)-α, interleukin (IL)-6 and interferon (IFN)-γ, and
damage-associated molecular patterns (DAMPs) such as adenosine 5′-triphosphate (ATP)
(Wilhelm et al., 2010). ATP can promote maturation of host APCs through upregulation
of MHC and other co-stimulatory molecules, such as CD80 and CD86, which are required
for T cell activation (Ferrara and Reddy, 2006, Wilhelm et al., 2010). Reduced-intensity
conditioning has been shown to minimise host APC maturation (Nakasone et al., 2015),
and although this lowers the incidence of GVHD, patients receiving reduced-intensity
conditioning can still develop severe GVHD and have an increased susceptibility to graftrejection and cancer relapse (Nakasone et al., 2015, Baron et al., 2012, Estey et al., 2006,
Shahin et al., 2017).
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Figure 1.1 The three-stage pathophysiology of GVHD. The afferent phase of GVHD begins prior to alloHSCT. Tissue damage due to the underlying haematological malignancy or the HSCT conditioning regime
causes the release of DAMPS, including extracellular ATP, and pro-inflammatory cytokines that promote
the maturation of host APCs. Post allo-HSCT, mature APCs can activate donor T cells in the graft and
initiate the efferent phase of GVHD. Donor T cells differentiate into a number of inflammatory T cell
subsets and migrate to GVHD target organs to initiate the effector phase. At target organs, donor T cells
mediate severe inflammatory damage by releasing a number of inflammatory cytokines in a “cytokine
storm”. This promotes further tissue damage and extracellular DAMP release, propagating GVHD in a
positive feedback loop.

The efferent phase of GVHD (Fig. 1.1) involves the activation of alloreactive donor T
cells by host APCs, depending on immunological disparity between donor and host MHC
and MiHAgs (Ferrara et al., 1999). Alloreactivity refers to the ability of T cells to become
activated against antigens not encountered during thymic development (Felix and Allen,
2007). Donor CD4+ T cells and CD8+ T cells are the main mediators of GVHD (Truitt
and Atasoylu, 1991, Sprent et al., 1988) and are activated as a result of variations in MHC
class II (Sprent et al., 1988) and MHC class I (Goulmy et al., 1996), respectively.
Activated donor T cells can then proliferate and differentiate into a number of subsets that
become reactive against the host and play important roles in GVHD. For example CD4+
T cells can differentiate into T helper (Th) 1, Th2 and Th17 phenotypes which can release
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pro-inflammatory cytokines such as IFNγ, IL–13 (Mosmann et al., 1986) and IL-17 (Park
et al., 2005), respectively, to promote GVHD. CD8+ T cells can differentiate into memory
T cell subsets, including central memory (CM) and effector memory (EM) cells, the latter
of which may predict GVHD onset (Khandelwal et al., 2020, Khandelwal et al., 2015).
Consequently, targeting T cell activation using strategies such as calcineurin inhibitors
(Villa et al., 2016) or CD28 blockade (Watkins et al., 2018, Dillinger et al., 2017) has
been investigated for GVHD prophylaxis. Given the importance of alloreactive donor T
cells on the development of GVHD, the direct depletion of these cells using agents such
as antithymocyte globulin (ATG) (Kekre and Antin, 2017, Bacigalupo, 2017) and
cyclophosphamide (Cy) (Kanakry et al., 2016) are commonly used strategies to reduce
clinical GVHD. However, broadly depleting donor T cells can also impact the GVT
effect, one of the main benefits of allo-HSCT.
The effector phase of GVHD (Fig. 1.1) involves the migration of activated alloreactive
donor T cells to GVHD target organs (liver, small intestines, lung and skin), where they
initiate severe inflammatory damage via the release of the aforementioned proinflammatory cytokines in a “cytokine storm” (Ferrara and Reddy, 2006, Sun et al., 2007)
(Fig. 1.1). T cell migration can be influenced by the expression of homing molecules,
such as regenerating islet-derived 3-alpha (Reg3α), CC chemokine-receptor 7 (CCR7)
and cutaneous leukocyte antigen (CLA) which attract T cells towards the small intestines
(Ferrara et al., 2011), lymphoid organs (Kittan and Hildebrandt, 2010) and skin (Ali et
al., 2012), respectively. The resulting tissue damage can also release additional DAMPs
and further promote GVHD in a positive feedback cycle

7

1.4

Immune cell subsets in GVHD

CD4+ and CD8+ T cells are the main mediators of GVHD in humans and mice (Sprent et
al., 1988, Truitt and Atasoylu, 1991), however these cells are initially activated by host
APCs. CD4+ and CD8+ memory T cell subsets can have pathogenic roles in GVHD
(Khandelwal et al., 2015, Loschi et al., 2015, Zhang et al., 2005a), but can also mediate
the GVT effect (Zheng et al., 2008). Conversely, regulatory T cells (Tregs) are important
for preventing GVHD development in allo-HSCT recipients (Di Ianni et al., 2011,
Ruggeri et al., 2014). Although GVHD is mainly propagated by donor T cells, other
leukocytes subsets do influence the disease. For example, natural killer (NK) cells are
thought to mediate the GVT effect (Ruggeri et al., 2002). However, the role of NK cells
in GVHD remains unclear since NK cells can have pathogenic roles in GVHD (Shah et
al., 2015). The role of the different immune cell subsets in the development of GVHD are
discussed in more detail below (Fig. 1.2).
1.4.1

APCs

APCs are essential for the induction of GVHD following allo-HSCT (Shlomchik et al.,
1999) and can originate from both the donor and the host. Host APCs are the dominant
APC population immediately following allo-HSCT and are necessary for the initial
priming of alloreactive donor T cells (Shlomchik et al., 1999). However, as host APCs
decline, donor APCs become the main APC population. Therefore, donor APCs are also
required for maximal GVHD development (Matte et al., 2004). Host APCs are important
for GVHD mediated by CD8+ T cells (MacDonald et al., 2013), whereas both donor and
host APCs are necessary for GVHD mediated by CD4+ T cells (Matte et al., 2004,
Shlomchik et al., 1999, Koyama et al., 2011).
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Figure 1.2 The role of immune cell subsets in GVHD. Naive CD4+ and CD8+ T cells can be activated by
recognising MHC class II and MHC class I, respectively, on DCs. Following activation, the presence of
different cytokines and transcription factors (Tbet, GATA3, RORγt and FoxP3) can direct T cell
differentiation into a number of subsets which can have pathogenic (green arrows) and regulatory (red lines)
roles in GVHD. Th1 cells can propagate GVHD by releasing pro-inflammatory cytokines (IFNγ, IL-2 and
IL-12). Th2 cells can have pathogenic and inhibitory roles in GVHD by releasing anti-inflammatory
cytokines (IL-4) and cytokines which have both inflammatory and anti-inflammatory roles in GVHD (IL5 and IL-13). Similarly, Th17 cells release IL-17 and IL-22 which can have pathogenic and inhibitory
functions in GVHD. Naive CD4+ T cells can also form Tregs which protect against GVHD through the
release of TGFβ and IL-10. IL-10 is also released by NK cells, however NK cells may also propagate
GVHD due to the release of IFNγ and TNFα. Naive CD8+ T cells primarily become cytotoxic and propagate
GVHD through the release granzyme, perforin, IFNγ and TNFα. CD4+ and CD8+ T cells can also form
memory subsets (not shown) which have pathogenic roles in GVHD but may also mediate the GVT effect.

9

Whilst there are a number of APC subsets, including B cells and macrophages, that play
roles in GVHD (Shimabukuro-Vornhagen et al., 2009), dendritic cells (DCs) are the most
potent professional APC involved in GVHD pathogenesis (MacDonald et al., 2013,
Markey et al., 2009). DCs express both MHC class I and class II and thus can activate
both CD4+ and CD8+ T cells, respectively (Banchereau and Steinman, 1998). In response
to inflammatory stimuli, DCs can promote the differentiation of pro-inflammatory T cell
subsets, including Th1, Th2 and Th17 cells (Sandy et al., 2013, Benlahrech et al., 2015),
that drive GVHD. DCs can also initiate the differentiation of Tregs which protect against
GVHD (Lu et al., 2012). Based on these findings, manipulation of donor and host DCs
has been investigated as a potential strategy to treat GVHD (Sato et al., 2003, Wilson et
al., 2005, Li et al., 2019, Thomson and Ezzelarab, 2018).
1.4.2

T cells

Donor T cells are the primary mediators of GVHD (Sprent et al., 1988, Korngold and
Sprent, 1978) and become alloreactive following interactions with DCs in allo-HSCT
recipients (Fig. 1.2). This involves binding of the T cell receptor (TCR) on T cells with
antigens held within MHC on the surface of APCs (Harding and Unanue, 1990). The
TCR/MHC interactions are stabilised by binding of CD4 or CD8 to MHC class II and
class I, respectively. T cell activation also requires co-stimulation, which is achieved by
binding of co-stimulatory molecules, such as CD28 on T cells with CD80 and CD86 on
APCs (Linsley et al., 1994, Azuma et al., 1993).
Depending on the presence of specific cytokines and transcription factors, activated T
cells can differentiate into a number of subsets that express different markers and have
specific roles in GVHD. All mature T cells express CD3 (Yanagi et al., 1984, Hedrick et
al., 1984), however mature T cells mainly express either CD4 or CD8. Whilst mature T
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cells expressing both CD4 and CD8 have been identified in humans (Bohner et al., 2019,
Matsuzaki et al., 2019), the function of these double positive cells remains controversial
and their role in GVHD is unclear.
Naive CD4+ T cells can form conventional T cell (Tcons) subsets, including Th1, Th2
and Th17 cells that are the main propagators of GVHD (Tawara et al., 2008, Yi et al.,
2009). Naive CD4+ T cells can also form other Tcon subsets such as Th9 and Th22 cells,
however these subsets will not be discussed further. For a detailed review of the role of
these cells in GVHD see Coghill et al. (2011) and Fu et al. (2014). Conversely, CD4+ T
cells may also become Tregs that are essential for suppressing the activity of Tcons,
thereby protecting against GVHD (Di Ianni et al., 2011, Ruggeri et al., 2014). CD8+ T
cells generally become cytotoxic and promote GVHD pathogenesis (Rus et al., 1995).
Furthermore, both CD4+ and CD8+ T cells can form memory T cell subsets that may be
important in mediating the GVT effect (Zheng et al., 2008) or predicting GVHD onset
(Khandelwal et al., 2020, Khandelwal et al., 2015) (Fig. 1.2). Moreover, mature T cells
expressing an invariant TCR (Vα24-Jα18) with NK cell markers have been identified
(Porcelli et al., 1993). These cells have suppressive roles in GVHD by up regulating Th2
(Hashimoto et al., 2005) and Treg (Schneidawind et al., 2015) responses.
1.4.2.1 Th1 cells
Th1 cells are a subset of CD4+ Tcons that release IL-2, IFNγ and TNFα (Mosmann et al.,
1986) and have been known to be important in GVHD for over 20 years (Krenger and
Ferrara, 1996). Th1 cell differentiation is initiated by IL-12, which is released by APCs,
and controlled by the transcription factor T-bet (Szabo et al., 2000) (Fig. 1.2). Increased
amounts of Th1 cytokines are associated with more severe GVHD, and earlier disease
onset in preclinical mouse models (Hill et al., 1997, Hill and Ferrara, 2000, Fu et al.,
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2016) and clinical allo-HSCT (Fu et al., 2014). Moreover, Th1 cells may have a role in
directing organ specific GVHD since they are believed to drive damage to the gastrointestinal tract and liver (Burman et al., 2007, Yi et al., 2009). Consistent with this, the
use of donor T cells with targeted disruption to T-bet caused attenuated GVHD,
particularly in the gut, compared to wild type T cells in an allogeneic mouse model (Yu
et al., 2011).
Th1 cells can also influence the differentiation of other T cell subsets. For example, IFNγ
release by Th1 cells can inhibit the production of Th2 cells which drive GVHD in the
lungs (Yi et al., 2009). Similarly, IFNγ negatively regulates alloreactive CD8+ T cells in
allogeneic mouse models of GVHD (Yang et al., 2002, Asavaroengchai et al., 2007).
However, the exact role of IFNγ in GVHD remains unclear since IFNγ is a key proinflammatory cytokine in GVHD pathogenesis (Blazar et al., 2012). IL-2 release by Th1
cells is required for the priming and expansion of CD4+ Tcons and cytotoxic CD8+ T cells
that exacerbate GVHD (Rus et al., 1995). Paradoxically, IL-2 has a critical role in the
development, maintenance and function of Tregs (Barron et al., 2010). The effects of
these cytokines may be dose-dependent, and in the case of IL-2, may arise from the
sensitivity of Tregs and Tcons to IL-2. Consequently, low-dose IL-2 is being investigated
as a potential GVHD therapeutic to potentially enhance Tregs without impacting GVHD
effector T cell subsets (Kennedy-Nasser et al., 2014, Matsuoka et al., 2013, Pérol et al.,
2014) (Fig. 1.2).
1.4.2.2 Th2 cells
Naive CD4+ T cells differentiate into Th2 cells in the presence of IL-25 and IL-4. Th2
cells express the transcription factor GATA3 (Kurata et al., 1999, Fort et al., 2001) and
produce IL-4, IL-5, IL-10, and IL-13 (Mosmann et al., 1986, Nurieva and Chung, 2010)
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(Fig. 1.2). Initial studies indicated that Th2 cells protect against GVHD since
transplantation of Th2 cells alongside donor splenocytes reduced GVHD in the gut and
liver in allogeneic mouse models (Foley et al., 2008, Nikolic et al., 2000). This was most
likely due to Th2 cells releasing IL-4 and restricting the development of Th1 cells that
direct GVHD damage to those organs. Subsequently, Th2 cells have been found to
mediate GVHD damage to the skin and lung (Yi et al., 2009, Burman et al., 2007).
Consistent with this, IL-5 is increased in the serum of human GVHD patients (Imoto et
al., 2000) and data indicates that the concentrations of IL-13 may be a strong predictor
for GVHD (Kumar et al., 2017). Recently, however, a study identified that Th2 cytokines
were necessary for myeloid derived suppressor cells to reduce GVHD in allogeneic mice,
presenting as a potential therapeutic strategy (Messmann et al., 2015). Whilst it appears
that GVHD may not be solely mediated by Th1 cells, the exact role of Th2 cells in GVHD
requires further investigation.
1.4.2.3 Th17 cells
Th17 cells are responsible for the production of IL-17A, IL-17F (Harrington et al., 2005)
and IL-22 (Chung et al., 2006). Th17 differentiation is regulated by the transcription
factor RORγt (Ivanov et al., 2006) and is promoted by the presence of TGFβ, IL-6 and
IL-1β (Korn et al., 2009) (Fig. 1.2). Whilst Th17 cells have been implicated in GVHD
(Serody and Hill, 2012), their pathogenicity in the disease has not been fully defined.
Donor cells deficient in RORγt, but not those deficient in both Tbet and RORγt, are still
capable of causing GVHD in allogeneic mouse models (Yu et al., 2011), indicating that
Th1 cells are more important for GVHD pathogenesis. This has been observed in other
studies where mice transferred with IL-17 deficient CD4+ T cells still develop GVHD,
although disease development was delayed compared to mice injected with non-altered T
cells (Kappel et al., 2009). The release of IL-17A from human Th17 cells can exacerbate
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GVHD in humanised mice (Delens et al., 2018). Similarly, IL-22 release from Th17,
worsens GVHD by reducing Treg expansion and increasing CD8+ T cell infiltration
(Couturier et al., 2013).
Conversely, other studies demonstrate a beneficial effect for Th17 cells in GVHD.
Deficiency of IL-17A producing donor CD4+ T cells significantly exacerbates GVHD in
in allogeneic mice, due to increased IFNγ production from Th1 cells that promotes
inflammation (Yi et al., 2008). A recent study by Cai et al. (2018) demonstrated that Th17
cells increase Th1 cell responses, however in that same study IL-17A reduced Th1 cell
infiltration in GVHD target organs, leading to therapeutic effects. These data may indicate
that IL-17A has pleiotropic roles in GVHD. Autocrine IL-17A may promote CD4+ T cell
activation and differentiation, leading to increased Th1 responses whilst systemic IL-17A
protects against tissue damage (Wu and Yu, 2018).
1.4.2.4 Tregs
Tregs were first identified by Gershon and Kondo (1970) as suppressor T cells important
for the induction of tolerance. However, Sakaguchi et al. (1995) was the first to
demonstrate that they were a separate subset of CD4+ T cells due to their constitutively
high expression of the IL-2 receptor α-chain, CD25. It is now known that Tregs are also
characterised by expression of the transcription factor forkhead box P3 (FoxP3) (Hori et
al., 2003) (Fig. 1.2), providing a way to separate Tregs from activated CD4+ Tcons, which
also up-regulate CD25 (Caruso et al., 1997). More recently, FoxP3 expression on Tregs
was shown to be controlled by DNA methylation (Polansky et al., 2008) and in humans,
inversely correlate with CD127 expression (Fazekas de St Groth et al., 2011, Liu et al.,
2006). Therefore, human Tregs can also be identified as having high CD25 and low
CD127, alleviating the need for intracellular FoxP3 staining to detect them using flow
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cytometry (Fazekas de St Groth et al., 2011). Whilst Tregs are mainly referred to as a
subset of CD4+ T cells, studies have demonstrated the presence of suppressive CD8+ T
cells (termed CD8+ Tregs) in human peripheral blood (Kiniwa et al., 2007). However,
CD8+ Tregs are an extremely rare population (Yu et al., 2018b) and there is currently no
well-established marker for them. CD8+ Tregs will not be discussed further in this thesis.
Tregs can be produced in the thymus (nTregs) and naturally express FoxP3 (Jordan et al.,
2001), or can be induced in the periphery (iTregs), where FoxP3 expression is initiated
by long-term antigen exposure and exogenous cytokines, such as IL-2 (D'Cruz and Klein,
2005). Despite different origins, both nTregs and iTregs have similar suppressive
mechanisms. High expression of CD25 allows Tregs to directly consume IL-2 and
prevent the activation and proliferation of Tcons (Levine et al., 2014). Tregs also highly
express the ectoenzymes ectonucleoside triphosphate diphosphorylase-1 (CD39) and
ecto-5’-nucleotidase (CD73). CD39 and CD73 are involved in purinergic signalling, an
important signalling network implicated in GVHD (Apostolova and Zeiser, 2016), and
are responsible for the hydrolysis of extracellular ATP and the generation adenosine,
respectively (Antonioli et al., 2013). Adenosine has suppressive roles in GVHD (Lappas
et al., 2010, Whitehill et al., 2016). Tregs also release anti-inflammatory cytokines, such
as IL-10 and transforming growth factor (TGF)-β that oppose the pro-inflammatory
cytokines released by Tcons, which are hallmarks of GVHD. Further, Tregs can also
express inhibitory molecules such as cytotoxic T lymphocyte associated protein 4
(CTLA-4) that reduces expression of co-stimulatory receptors and inhibiting T cell
activation (Qureshi et al., 2011).
The role of Tregs in GVHD has been thoroughly explored in mouse and human studies
and it is universally accepted that Tregs reduce GVHD (Di Ianni et al., 2011, Ruggeri et
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al., 2014, Zorn et al., 2005). In mice, the hydrolysis of ATP and generation of adenosine
by Tregs can limit GVHD by activating A2A receptors on neutrophils and lymphocytes to
promote anti-inflammatory functions (Wang et al., 2013, Lappas et al., 2010). In other
mouse studies co-infusions of Tregs alongside Tcons at a 1:1 ratio prevent lethal GVHD
(Nguyen et al., 2007, Nguyen et al., 2008, Taylor et al., 2002). It has also been suggested
that this effect is due, in part, to the release of IL-10 (Tawara et al., 2012). Additionally,
at this ratio Tregs do not impact the GVT effect (Edinger et al., 2003, Nguyen et al.,
2007). However, for Tregs to maximally reduce GVHD they must be reconstituted before
Tcons to allow early suppression of alloreactive donor T cells (Nguyen et al., 2007, Pierini
et al., 2015, Bolton et al., 2015). In humanised mouse models, that more accurately
replicate the human system than allogeneic mouse models, the transplantation of ex vivo
expanded Tregs can reduce GVHD development (Cao et al., 2009, Hannon et al., 2014).
Consistent with this, in clinical studies, the adoptive transfer of Tregs reduces GVHD in
allo-HSCT recipients (Di Ianni et al., 2011, Gaidot et al., 2011). Higher proportions of
FoxP3+ Tregs in the peripheral blood (Miura et al., 2004) and skin (Fondi et al., 2009) of
allo-HSCT recipients are associated with less severe GVHD and may be a viable
biomarker to predict disease onset. As a result of their importance in GVHD, targeting
human Tregs are at the forefront of many novel GVHD therapeutic strategies (discussed
in section 1.9.1).
1.4.2.5 CD8+ T cells
CD8+ T cells are characterised by their expression of CD8, which recognises MHC class
I molecules on APCs (Fig. 1.2). CD8+ T cell differentiation is aided by CD4+ Th cells
which promote APCs to provide signalling to activate naive CD8+ T cells. These cells
then release potent cytokines such as IFNγ to exert their pro-inflammatory roles (Szabo
et al., 2002). Both CD4+ and CD8+ T cells can initiate GVHD, as mice deficient in either
16

MHC class I or class II, still develop GVHD following allo-HSCT (Matte et al., 2004,
King et al., 2009). However, in these studies CD4+ T cells triggered earlier GVHD onset.
Therefore, it is accepted that GVHD is initiated by CD4+ T cells but exacerbated by CD8+
T cells. IL-17 releasing CD8+ T cells (Tc17 cells) have also been identified that are
functionally distinct from IFNγ releasing CD8+ T cells (Yen et al., 2009). Tc17 cells have
been implicated in the induction of GVHD (Zhao et al., 2016, Lai et al., 2012). CD8+ T
cells also release perforin and granzymes following activation. Notably granzyme B is
pivotal for CD8+ T cells to propagate GVHD (Graubert et al., 1997). CD8+ T cells are
also able to infiltrate the skin and initiate apoptosis (Klimczak and Lange, 2000). CD8+
T cell infiltration has also been observed in the gut epithelia, driven by the expression of
CD103 (Klimczak and Lange, 2000). Finally, CD8+ T cells can also form
memory T cell subsets which may propagate GVHD (Zhang et al., 2005b). The
expression of the activation marker CD38 on CD8+ EM cells may be a viable
biomarker for predicting GVHD severity in allo-HSCT recipients (Khandelwal et al.,
2015, Khandelwal et al., 2020) (Fig. 1.2).
1.4.2.6 Memory T cells
Memory T cells are a subset of long-lived antigen-experienced T cells generated in
response to a prior pathogen. This ensures a rapid immunological response if reinfection
occurs (Ratajczak et al., 2018). Memory T cells can become activated and respond to
pathogens quicker than naive T cells (Sallusto et al., 1999, Croft et al., 1994), and may
be beneficial for anti-tumour responses in allo-HSCT recipients (Zheng et al., 2008).
Since humans do not live in a pathogen free environment, all donors for allo-HSCT have
been exposed to a multitude of pathogens and are likely to have increased memory T
cells. Therefore, many studies have investigated the role of donor memory T cells in
GVHD, both within the donor graft and post-HSCT.
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CD4+ and CD8+ T cells can be divided into four main memory T cell subsets depending
on the expression of CCR7 and the naive cell marker CD45RA; naive memory (NM)
(CCR7+CD45RA+), CM (CCR7+CD45RA-), EM (CCR7-CD45RA-) and terminally
differentiated effector memory (TEMRA) (CCR7-CD45RA+) (Mahnke et al., 2013).
These subsets can also be defined by the expression of the memory marker CD45-RO, an
isoform of CD45, which inversely correlates with CD45-RA expression (Faint et al.,
2001). In humans, EM and TEMRA cells are found in circulation and home to peripheral
inflamed tissue to exert cytotoxic effects. However, they display limited proliferative
capacity (Martin and Badovinac, 2018). Conversely, CM cells are found in secondary
lymphoid tissue, have little effector function but readily differentiate into effector subsets
in response to antigenic stimulation (Willinger et al., 2005).
The exact role of memory T cells in GVHD is still unclear due to much conflicting data.
Many studies in mice have shown that CD4+ and CD8+ CM and EM T cells have a reduced
capacity to induce GVHD compared to naive T cells, but still may propagate the disease
(Zheng et al., 2008, Chen et al., 2007, Anderson et al., 2003). However, it is whether these
cells mediate GVT immunity that is contentious. Studies have demonstrated that CD4+
EM cells mediate the GVT effect in allogeneic mice with GVHD (Zheng et al., 2008),
however other studies have shown that CD8+ EM and CM cells, but not CD4+ EM and
CM cells, could invoke the GVT effect in a similar model (Dutt et al., 2011). Moreover,
despite not inducing GVHD in mice, studies indicate that CD8+ EM cells may be a
biomarker for GVHD onset in human patients (Khandelwal et al., 2020, Khandelwal et
al., 2015). In these recent studies, CD38 on CD8+ EM cells was associated with more
severe GVHD (Khandelwal et al., 2015). Additionally, CD38+CD8+ EM cells were found
to have cytotoxic capabilities and may be able to propagate GVHD (Khandelwal et al.,
2020). Furthermore, CD38 on CD8 EM cells may increase expression of the trafficking
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marker CXCR6 (Khandelwal et al., 2020), which may direct these cells to the liver in
GVHD. Whilst EM and CM cells are believed to be involved in acute GVHD, TEMRA
cells are mainly investigated in the context of chronic GVHD (D'Asaro et al., 2006, M et
al., 2009).
1.4.2.7 NK cells
NK cells are a lymphocyte subset that are amongst the first to reconstitute following alloHSCT (Ullah et al., 2016). NK cells are characterised by their expression of CD56 and
CD16 and their lack of CD3. NK cells can form three main subsets: those expressing high
CD56 with high CD16; those expressing high CD56 and low CD16; and those with low
CD56 and high CD16 (Stabile et al., 2017). NK cells expressing low CD56 exhibit high
levels of perforin and enhanced killing, whereas those expressing high CD56 and
high/low CD16 NK cells have low perforin and are specialized for cytokine production
(Stabile et al., 2017). It is still unclear if these subsets are functionally distinct or represent
different states of maturation.
A role for NK cells in GVHD was first suggested by Lopez et al. (1979) who associated
increased GVHD severity with higher levels of NK cell activity in allo-HSCT recipients
prior to transplantation. The notion that NK cells could induce GVHD was enforced by
other early studies that demonstrated that donor NK cells could infiltrate target organs
during GVHD (Roy et al., 1993, Tanaka et al., 1989). However, these early studies were
restricted by the heterogeneity of donors and the methods employed to detect NK cells.
Similarly, in a humanised mouse model, IL-2 activated NK cells could release IFNγ and
TNFα to induce GVHD (Xun et al., 1993). This is supported by more recent data
demonstrating that higher proportions of IFNγ releasing NK cells are found in patients
with more severe GVHD (Cooley et al., 2005). However, NK cells may also protect
19

against GVHD. In mice, transplantation of NK cells alone does not cause GVHD, and
activated NK cells can lower GVHD when co-transplanted with splenocytes (Huber et
al., 2015, Murphy et al., 1992). This protective role has also been seen in humans, where
higher numbers of NK cells, and NK cell alloreactivity are associated with reduced
GVHD (Kim et al., 2016b, Tanaka et al., 2012). Evidence suggests that this may occur
because activated donor T cells up-regulate stress molecules that behave as ligands for
the NK cell activating receptor NKG2D (Cerboni et al., 2007).
1.5

Mouse models of GVHD

Mouse models are the primary pre-clinical models used to investigate GVHD and have
provided vast insight into the pathophysiology of the disease. The murine immune system
is similar to humans, and GVHD development in mice mirrors clinical disease in humans
(Schroeder and DiPersio, 2011). Additionally, mice are much cheaper to breed and
maintain compared to other animal models of GVHD, such as canines (Boieri et al.,
2016). The common use of mouse models has resulted in a number of well-established
transgenic and inbred strains that allow tight control over MHC, known as H2 in mice,
and immune cell subsets that are not possible in clinical studies. The use of these strains
has demonstrated the importance of a number of factors such as MHC mismatch and the
role of specific immune cell subsets in GVHD pathogenesis. Both allogeneic and
humanised mouse models are used to investigate GVHD and are discussed below.
1.5.1

Allogeneic mouse models

Allogeneic mouse models of GVHD involve the transfer of T cell depleted bone marrow
and different lymphocyte subsets, usually splenocytes or T cells, from one mouse strain
into a recipient from another mouse strain that has been lethally irradiated (Schroeder and
DiPersio, 2011). Donor and recipient mice may have completely different H2 (MHC20

mismatch), partial H2 mismatch (haploidentical) or differences only in MiHAgs
(MiHAg-mismatch).
The transfer of bone marrow promotes hematopoietic reconstitution whilst T cell
depletion allows specific control over the donor immune cells that are transplanted. The
numbers and subset of transplanted T cells (Korngold and Sprent, 1978, Edinger et al.,
2003), and the degree of irradiation (Hill et al., 1997) and genetic disparity allow control
over the severity of GVHD that develops in these models.
Early work in MHC-mismatch models demonstrated that alloreactive donor T cells are
the main mediators of GVHD (Korngold and Sprent, 1978). The most commonly used
MHC-mismatch model is transplantation of cells from C57BL/6 (H2b) donors into
BALB/c (H2d) recipients (Schroeder and DiPersio, 2011). The use of transgenic mice
with mutant MHC class I and MHC class II in MHC-mismatch models have elucidated
the role of CD8+ and CD4+ T cells in GVHD, respectively (Sprent et al., 1988). Using
these mice, it was found that only host APCs are necessary for CD8+ T cell mediated
GVHD (Shlomchik et al., 1999) and that both host and donor APCs can stimulate CD4+
T cell mediated GVHD (Anderson et al., 2005). However, MHC-mismatched allo-HSCT
do not commonly occur in humans, therefore MiHAgs-mismatch models more closely
resemble clinical settings. Similar to the clinic, GVHD in these models is generally less
severe than MHC-mismatch models (Bauerlein et al., 2013). The T cells that propagate
GVHD in these models depends on the MiHAgs differences. For example, in transplants
from B10.D2 mice to BALB/c mice (B10.D2 → BALB/C; both expressing H2d ) GVHD
is mediated by CD4+ T cells and not CD8+ T cells (Sprent et al., 1988). Conversely, CD8+
T cells are more dominant in GVHD in C3H.SW → Bl6 (H2d) and DBA/2 → B10.D2
(H2d) models (Schroeder and DiPersio, 2011).
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Allogeneic mouse models have been integral in identifying potential therapeutic
strategies against GVHD. For example, targeting alloreactive donor T cells with agents
such as Cy reduces GVHD in allogeneic mouse models (Kanakry et al., 2013a, Ganguly
et al., 2014). Subsequently, post-transplant cyclophosphamide (PTCy) is now commonly
used to reduce GVHD in clinical settings (Kanakry et al., 2016). Other studies have
targeted the production of pro-inflammatory cytokines such as IL-11 (Hill et al., 1998,
Teshima et al., 1999), IL-6 (Tawara et al., 2011, Chen et al., 2009) and TNFα (Cooke et
al., 1998). However, these therapies do not always translate to clinical settings. For
example, following positive results in preclinical allogeneic mouse models, recombinant
human IL-11 was tested as GVHD prophylaxis in a phase1/2 double blinded clinical trial
(Antin et al., 2002). However, this treatment resulted in high mortality rates in patients
due to severe fluid retention resulting in pulmonary oedema. Similarly, therapies targeting
TNFα (Antin et al., 2002) and IL-6 (NCT01475162) have not been successful in clinical
trials despite reducing GVHD in allogeneic mouse models (Tawara et al., 2011, Schmaltz
et al., 2003).
The inability to fully replicate human settings is a major limitation of allogeneic mouse
models of GVHD. Further, allogeneic mouse models are all reliant on the exclusive use
of lethal irradiation as conditioning which does not necessarily occur in human alloHSCT. More recently, reduced intensity conditioning regimens have been examined
(Turner et al., 2008, Shahin et al., 2017). Another major limitation is the difference
between the mouse and human immune systems which further restricts the translation of
GVHD therapeutics from mouse models to human clinical studies.
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1.5.2

Humanised mouse models

An alternative to allogeneic mouse models is to use humanised mouse models of GVHD.
These involve the use of mice with genetic deficiencies to their immune system, allowing
them to engraft human immune cells which then mediate GVHD. This is useful for
discerning the impact of donor (human) or host (murine) cells on GVHD. The first
attempts at generating humanised mice for GVHD were performed by injecting
non-obese diabetic severe combined immunodeficient (NOD-SCID) mice with human
peripheral blood mononuclear cells (hPBMCs) (Hoffmann-Fezer et al., 1993,
Christianson et al., 1997). Whilst these mice lacked functional B and T cells, the presence
of functional NK cells restricted the engraftment rate to 20% (Hoffmann-Fezer et al.,
1993, Christianson et al., 1997). The major breakthrough in the development of
humanised mice came in the early 2000’s when immunodeficient mice were generated
with mutations in the IL-2 receptor common gamma chain (IL2rgnull) (Brehm et al., 2010).
This chain forms part of a number of receptors for the binding and signalling of a number
of important cytokines, including IL-2 and IL-4 (Roifman, 2019). When combined with
the SCID mutation in either the protein kinase DNA activated catalytic polypeptide
(Prkdcscid), or the recombination activating gene (Rag) 1 or 2 (Rag1null or Rag2null)
mutations, the resultant mice lack functional T, B and NK cells and partly defective
macrophages and DCs (Shultz et al., 1995). This allows much higher engraftment rates
than earlier mouse strains.
Currently, there are two main strains of mice used for humanised mouse
models of GVHD, the NOD.Cg-PrkdcscidIl2rgnull (NSG) and the NODShi.CgPrkdcscidIl2rgnull (NOG). These strains are almost identical, only differing because NSG
mice have a complete lack of the IL-2 receptor common gamma chain whilst NOG mice
have a truncated form, which is unable to signal (Walsh et al., 2017).
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1.5.2.1 Humanised NSG mouse model of GVHD
The injection of hPBMCs into NSG mice was established as a humanised mouse model
of GVHD by King et al. (2009) and has since been well-established in our laboratory
(Geraghty et al., 2019a, Geraghty et al., 2019b, Geraghty et al., 2017, Geraghty et al.,
2019c, Geraghty et al., 2019d, Cuthbertson et al., 2020) (Fig. 1.3). When injected
intra-peritoneally (i.p) NSG mice engraft hPBMCs within three weeks. Engraftment can
be achieved with as few as 5 x 106 hPBMCs (King et al., 2008). Notably, 100%
engraftment is observed with the injection of 10-50 x 106 hPBMCs (King et al., 2008).
The engraftment of hPBMCs and the severity of GVHD in this model can be influenced
by the injection route of the hPBMCs. NSG mice have been reported to engraft as few as
1 x 106 hPBMCs when injected intra-venously (i.v.), two weeks following injection (Ehx
et al., 2018). Moreover, i.v injections can result in more severe GVHD than i.p. injections
(Ehx et al., 2018), presumably due to the cells being directly injected into circulation.
However, i.v. injections require a higher level of expertise than i.p. injections, and thus
the latter are more commonly used in GVHD models.
Humanised NSG mice typically begin showing clinical signs of GVHD between three
and four weeks post-hPBMC injection (King et al., 2008, Geraghty et al., 2017, Ehx et
al., 2018). Clinical GVHD development in these mice is similar to allogeneic mouse
models and can be assessed by monitoring weight loss, hunched posture, fur ruffling, skin
denudation and reduced activity (Cooke et al., 1996).
As in humans, GVHD development in humanised NSG mice is dependent on human
donor T cells becoming reactive against the host. Both hCD4+ (Ito et al., 2017, TaryLehmann et al., 1994) and hCD8+ T cells (King et al., 2009) can recognise murine MHC
and become xenoreactive. Despite murine MHC class I and class II molecules being
24

responsible for the majority of T cell activation in this model, how exactly murine MHC
leads to human donor T cell xenoreactivity remains unknown. For example, murine MHC
might directly present antigens (direct activation) to human donor T cells or behave as an
antigen for human donor DCs (indirect activation). However, in in vitro mixed
lymphocyte cultures (MLCs), splenocytes from BALB/c mice are unable to directly
trigger human T cell activation without the presence of autologous human APCs
(Benfield et al., 1993, Lindahl and Bach, 1976). Supporting this, preliminary data from
our laboratory has shown that BALB/C splenocytes can stimulate human T cells in
hPBMCs in vitro (Adhikary, unpublished). Although human APCs were not specifically
added to these cultures, the human cells were freshly isolated hPBMCs which would have
contained low amounts of DCs and higher amounts of B cells.

Figure 1.3 The humanised NSG mouse model of GVHD. Immunodeficient NSG mice are injected i.p.
with freshly isolated hPBMCs. Mice are assessed for the development of GVHD thrice weekly until ethical
endpoint, or day 70 by monitoring clinical symptoms of GVHD, as indicated. Mice are checked for the
engraftment of human immune cells by immunophenotyping tail blood by flow cytometry at week 3.
hPBMC engraftment can be checked in NSG mouse spleens at endpoint and GVHD damage assessed in
the liver, small intestines and skin.

Human (h) CD4+ and hCD8+ T cells are the main mediators of GVHD in humanised NSG
mice since MHC class I- and class II-deficient NSG mice demonstrate delayed GVHD
onset following hPBMC injection (King et al., 2009, Brehm et al., 2010). However, MHC
class I deficient mice demonstrate slower disease onset compared to MHC class II
deficient mice, suggesting that CD8+ T cells are the more potent effectors of GVHD in
this model (Pino et al., 2010, King et al., 2009). However, CD4+ T cells alone are still
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able to induce GVHD in humanised NSG mice (Covassin et al., 2011), and increased
hCD4+:hCD8+ T cell ratios are associated with more severe GVHD in this model
(Geraghty et al., 2019b).
Our laboratory has shown that human leukocytes make up 40-80% of the total leukocyte
population in humanised NSG mice injected (i.p) with hPBMCs (Cuthbertson et al., 2020,
Geraghty et al., 2019b, Geraghty et al., 2017, Geraghty et al., 2019c). However, this
population is not entirely composed of GVHD effector T cell subsets. Studies have found
that human Tregs engraft in humanised NSG mice (Geraghty et al., 2019a, Geraghty et
al., 2019b, Geraghty et al., 2019d), which can prevent GVHD in these mice (Del Papa et
al., 2016). Moreover, the numbers of human Tregs inversely correlates to GVHD severity
in this model (Bruck et al., 2013, Achita et al., 2018). Other human immune cell subsets
observed in humanised NSG mice include NK cells (Ono et al., 2019), B cells
(Cuthbertson, unpublished), monocytes and DCs (Geraghty et al., 2019d) but they are
rare.
GVHD development in humanised NSG mice accurately reflects that in humans, with the
main target organs being the liver, gastro-intestinal tract and skin (Fig. 1.3). GVHD
causes severe damage to the livers of humanised NSG mice (King et al., 2009), including
hepatic apoptosis (Geraghty et al., 2019c). Leukocyte infiltration in the liver is focussed
around bile ducts and portal veins (Geraghty et al., 2017, Cuthbertson et al., 2020, Ehx et
al., 2018). It has been suggested that the majority of liver infiltrating cells are hCD3+ T
cells (Geraghty et al., 2019c, Ehx et al., 2018). This was recently confirmed by our
laboratory using flow cytometry (Cuthbertson et al., 2020). Human leukocytes also
infiltrate the small intestines (King et al., 2009) to cause blunting of villi (Tobin et al.,
2013) and apoptosis (Nakauchi et al., 2015). In contrast, studies by our laboratory show
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minimal histological damage to the duodenum, jejunum, ileum or colon (Cuthbertson et
al., 2020). Since mice were not irradiated in our previous studies, this may indicate that
GVHD involvement of the gastrointestinal tract in this model requires prior damage
caused by irradiation. GVHD also impacts the flank skin, resulting in separation of the
dermal layers and detachment of the dermis from the epidermis (Cuthbertson et al., 2020,
Geraghty et al., 2017, Ali et al., 2012). hCD4+ T cells can infiltrate flank skin (Ito et al.,
2017). Further, our laboratory has demonstrated that GVHD causes thickening of the ear
skin, which may be a viable indicator for GVHD severity in humanised NSG mice
(Cuthbertson et al., 2020).
Human cells in humanised NSG mice are responsive to regulation by therapeutic agents,
or adoptive transfer of other immune cell subsets. Therefore, this model is useful for preclinical investigations into novel therapeutic strategies for GVHD. For example, this
model has been used to investigate the efficacy of using mesenchymal stem cells (Bruck
et al., 2013, Huang et al., 2017), the adoptive transfer of Tregs (Hannon et al., 2014,
Achita et al., 2018), targeting chemokines (Burger et al., 2018) and DCs (Wilson et al.,
2009) as well as T cell depletion strategies (Kanakry et al., 2013a) for GVHD prophylaxis.
Our laboratory has used this humanised mouse model to investigate the efficacy of P2X7
(Geraghty et al., 2017, Geraghty et al., 2019c) blockade in GVHD. Importantly, since
donor and host cells can be easily identified in this model, this model may also be useful
for determining potential GVHD biomarkers.
1.6

GVHD biomarkers

The identification of reliable GVHD biomarkers to identify those at risk of developing
GVHD following allo-HSCT, could negate the need to even treat for the disease.
Currently, there are few validated biomarkers to predict GVHD onset. Therefore, the
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treatment and diagnosis of GVHD is predominantly reliant on the development of clinical
symptoms, which are often life-threatening.
Potential GVHD biomarkers are classed into three groups: prediction, prognosis and
response evaluation biomarkers (Zhao and Huang, 2019). These classes are based on if
biomarkers can be used to predict GVHD onset, GVHD severity or patient response to
treatments. The ideal GVHD biomarker should have sensitivity and specificity for GVHD
and should be able to be tested in a simple and non-invasive manner that is quick and
economically viable (Ahmed et al., 2016, Zhao and Huang, 2019). Biomarkers may
include unique cellular markers, such as increased T cell ratios in the donor graft (Luo et
al., 2009), or cytokine profiles, such as heightened Th1 cytokines in the donor or host
(Miyamoto et al., 1996), or may even have a genetic basis, such as mutations in genes
important in inflammation (Zhao and Huang, 2019).
Studies indicate that the composition of immune cells in the donor graft may predict
GVHD following allo-HSCT. Lower frequencies of donor CD8+ T cells (Watz et al.,
2015) and donor grafts with CD4+:CD8+ T cell ratios > 1.16 are associated with more
severe GVHD (Luo et al., 2009). Similarly, lower numbers of Tregs in the peripheral
blood of allo-HSCT recipients may indicate a greater susceptibility for GVHD (Rezvani
et al., 2006). Other studies have investigated the potential of key cytokines in GVHD
pathogenesis, such as IL-2, IL-6 and IFNγ, as valid prognosis biomarkers (Zhao and
Huang, 2019). Detection of soluble IL-2 receptor (sIL-2R) at day 3 post allo-HSCT
(Miyamoto et al., 1996), and sustained high levels of sIL2-R in the serum at 1-2 weeks
post allo-HSCT has been observed before the onset of severe GVHD (Mathias et al.,
2000). Similarly, the levels of suppressor of tumerogenicity 2 (ST2), the receptor for IL33, in allo-HSCT recipients is associated with resistance to GVHD therapies (Vander
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Lugt et al., 2013, Ponce et al., 2015) and may be a viable response evaluation biomarker.
ST2 is currently considered the most valid biomarker for GVHD, but it does not predict
GVHD onset. Finally, the concentrations of plasma REG3α predicts response to therapy
and non-relapse mortality in human allo-HSCT recipients (Ferrara et al., 2011).
Increasing REG3α signalling also promotes intestinal stem cell survival and may be a
novel strategy for GVHD (Zhao et al., 2018).
Over the past 10 years single nucleotide polymorphisms (SNPs) in genes involved in the
adaptive and innate immune responses have been marked as potential GVHD biomarkers.
Donors with SNPs in the IFNG (rs2069727) and IL6 (rs1800797) genes may have a higher
risk of causing steroid refractory GVHD (Alam et al., 2015). Recently a study involving
25 donor SNPs in 12 cytokine genes, including IL2, IFNG and TGFB, in 509 patients
successfully and accurately predicted severe GVHD following allo-HSCT (MartínezLaperche et al., 2018). This may indicate that SNPs in other donor genes in inflammation
could have potential as GVHD biomarkers, but this requires more research.
The purinergic signalling system is an important signalling network in the inflammatory
immune response and is implicated in the development of GVHD (Zeiser et al., 2011,
Apostolova and Zeiser, 2016). SNPs in purinergic signalling molecules are associated
with a number of inflammatory diseases including rheumatoid arthritis (Al-Shukaili et
al., 2011), neonatal sepsis (Timperi et al., 2016a) and multiple sclerosis (Gu et al., 2015).
Therefore, purinergic signalling donor SNPs may be involved in GVHD and be potential
GVHD biomarkers, however this has not been previously assessed.
1.7

Purinergic signalling

The purinergic signalling system is an extracellular signalling network involving purine
nucleotides and nucleosides, such as ATP, behaving as extracellular signalling molecules.
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Purinergic signalling was first conceptualized by (Burnstock, 1972) and is an important
mediator of the inflammatory immune response (Eltzschig et al., 2012). Consequently,
purinergic signalling is implicated in numerous inflammatory disorders (reviewed by
Arulkumaran et al. (2011), Di Virgilio et al. (2017)), including the development of GVHD
(Zeiser et al., 2011, Apostolova and Zeiser, 2016).
ATP is found at high concentrations intracellularly, as such stress or damage to cells can
cause the release of extracellular ATP via specific (hemichannels and exocytosis) or
nonspecific (cell death) pathways (Dosch et al., 2018). Extracellular ATP behaves as a
DAMP by activating the purinergic P2 receptors, triggering a number downstream
pathways that promote inflammation (Di Virgilio and Vuerich, 2015). The concentration
of extracellular ATP is tightly regulated by the ecto-enzymes CD39 and CD73. CD39 is
responsible for the hydrolysis of ATP to adenosine diphosphate (ADP) and adenosine
monophosphate (AMP). CD73 then hydrolyses AMP to adenosine (Zimmermann, 2000).
Adenosine can activate P1 receptors to impair inflammation (Antonioli et al., 2013) (Fig.
1.4).
1.7.1

Purinergic receptors

Purinergic receptors are classified as either P1 or P2 receptors based on their structure
and mechanism of activation. P1 receptors are G-protein coupled receptors (GPCRs) that
are activated by adenosine and comprise of four sub-types; A1, A2A, A2B and A3 (Olah
and Stiles, 1995). P2 receptors are activated by ATP and are composed of two families,
P2X and P2Y. P2X receptors are ligand-gated ion channels whilst P2Y receptors are
GPCRs (Burnstock, 2006). P1 and P2Y receptors will not be discussed further in this
chapter; for a detailed review of P1 and P2Y receptors see (Jacobson et al., 2012).
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Figure 1.4 The purinergic signalling cascade. Stress or damage to tissue causes the release of
extracellular ATP via hemichannels such as pannexin-1 (or exocytosis or cell lysis; not shown).
Extracellular ATP can activate P2X receptors, including the P2X7 receptor, or be hydrolysed to ADP and
subsequently AMP by the ecto-enzyme CD39. Both ATP and ADP can activate P2Y receptors. AMP is
hydrolysed to adenosine by CD73. Adenosine activates P1 receptors. Activation of P2X and P2Y or P1
receptors leads to a number of downstream responses that promote or impair inflammatory immune
responses, respectively.

1.7.1.1 P2X receptors
P2X receptors assemble as homotrimers or heterotrimers from seven potential subunits,
denoted P2X1-7 and range between 379 (P2X4) to 595 (P2X7) amino acids in length
(Valera et al., 1994) with 35-54% sequence similarity (Khakh and Alan North 2006). In
humans, P2X receptors demonstrate particularly high expression in immune cells,
including mast cells (Tatham and Lindau, 1990), macrophages (Surprenant et al., 1996,
Greenberg et al., 1988), monocytes (Gu et al., 2000, Wiley et al., 2001) and lymphocytes
(Gu et al., 2000). Within the P2X family, the P2X7 receptor is the most extensively
studied and is found on a number of immune cell subsets in humans. P2X7 activation on
these cells triggers unique downstream signalling events that are involved in the
inflammatory immune response (Burnstock 2007).
1.7.1.2 The human P2X7 receptor
The human P2X7 receptor is encoded by the P2RX7 gene and is a trimer composed of
three P2X7 monomers (Nicke, 2008). Each P2X7 subunit contains an intracellular amino
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and carboxyl terminus, with two hydrophobic transmembrane domains, separated by a
glycosylated extracellular loop containing ATP-binding sites (Jiang et al., 2013). This
computational structure was originally based on the crystal structure of the zebrafish
P2X4 receptor (Jiang et al., 2013), with the first P2X7 receptor structure obtained in
pandas in 2016 (Karasawa and Kawate, 2016). Recently, cryoelectron microscopy was
used to show the full structure of rat P2X7 in the ATP bound state (McCarthy et al., 2019).
Overall, recombinant P2X7 has been characterised in 12 different species (seven
mammalian and five non-mammalian) (Sluyter, 2017a).
P2X7 is predominantly expressed on mononuclear leukocytes with highest expression on
macrophages (De Torre-Minguela et al., 2016) followed by DCs (Saez et al., 2017),
monocytes, NK cells, B cells and T cells (Wiley et al., 2011, Wiley et al., 2001, Sluyter
and Wiley, 2002, Gu et al., 2000). Moreover, P2X7 is also found on neutrophils
(Karmakar et al., 2016). On leukocytes, P2X7 mediates various roles such as cell
activation, cell migration and cell death. For example, P2X7 activation on macrophages
triggers the formation of the NLRP3 inflammasome and stimulates the release of IL-1β
(Pelegrin and Surprenant, 2006) which is required for the polarization of IFNγ releasing
CD8+ T cells (Aymeric et al., 2010). P2X7 on Tregs can inhibit stability and suppressive
functions, and trigger their conversion into Th17 cells (Schenk et al., 2011). Furthermore,
P2X7 activation can trigger up-regulation of CD80 and CD86 on DCs to stimulate T cell
activation (Wilhelm et al., 2010).
P2X7 is less sensitive to ATP than other P2X receptors, requiring ATP concentrations >
100 µM ATP to become activated (Bianchi et al., 1999). Upon activation, P2X7
rearranges its subunits to form a channel to allow rapid cationic flux across the plasma
membrane (Surprenant et al., 1996). Prolonged activation with ATP (> 30 s) causes P2X7
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to form a pore that mediates the influx of large organic cations, including fluorescent dyes
such as ethidium2+ (Wiley et al., 1993) and YO-PRO-12+ (Surprenant et al., 1996). This
principle provides a standardized method for quantifying P2X7 activity on human cells
with minimal variation (Korpi-Steiner et al., 2008, Jursik et al., 2007). ATP is the
physiological agonist of human P2X7, but other agonists exist. The ATP analogue 2',3'(4-benzoyl)-benzoyl-adenosine triphosphate is a more potent P2X7 agonist than ATP and
is often used in quantification studies (Bianchi et al., 1999). Similarly, a number of P2X7
antagonists are commercially available, including Brilliant Blue G (BBG) (Jiang et al.,
2000) and pyridoxal phosphate-6-azophenyl-2-4-disulfonic acid (PPADS) (Gargett and
Wiley, 1997).
In humans, there are a number of factors that influence the expression, activity and
downstream effects of P2X7 on immune cells. Amongst these, the presence of missense
single nucleotide polymorphisms (SNPs) in the human P2RX7 gene can strongly
influence P2X7 activity (Sluyter and Stokes, 2010, Wiley et al., 2011).
1.7.1.3 The human P2RX7 gene
The human P2RX7 gene is comprised of 13 exons, spanning 53 kb, and has been mapped
to the 12q24.31 chromosomal region (Buell et al., 1998). Early quantification studies
demonstrated that P2X7 activity on human macrophages (Lammas et al., 1997), T and B
cells and monocytes (Gu et al., 2000) varied between human donors. However, on
leukocytes, this variation was not due to differences in cell surface expression (Gu et al.,
2000). Since these initial studies, the P2RX7 gene has been found to be highly
polymorphic, giving rise to 16 missense SNPs (Table 1.1) across the 13 exons (Fig. 1.5)
which strongly influence P2X7 activity (Sluyter and Stokes, 2010). The functional effects
of these SNPs are well-established, and they can increase (gain-of-function; GOF) or
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decrease (loss-of-function; LOF) P2X7 activity (Sluyter and Stokes, 2010) (Table 1.1).
Of these 16 SNPs, 12 are classed as LOF, two as GOF SNPs and two neutral. Although
the phenotypic effects of these SNPs have been established, their impact on P2X7 activity
has only been studied on a small number of human monocyte and T cell subsets (Gu et
al., 2004, Gu et al., 2001, Stokes et al., 2010). As a result, how these SNPs impact P2X7
activity on other important lymphocyte subsets, such as NK cells and Tregs remains
unknown.

Figure 1.5 Location of functionally characterised non-synonymous SNPs in the human P2RX7 gene.
Solid lines and numbered boxes represent introns (not to scale) and exons, respectively. SNPs correspond
to Table 1.3 and are listed based on their amino acid residue substitutions. SNPs are coloured based on their
phenotypic effect on P2X7 activity; GOF (green), LOF (red) and neutral (blue).
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Table 1.1 Characterized non-synonymous SNPs of the human P2RX7 gene
SNP ID⁰

Base
Change

Amino Acid
Change

Minor Allelic
Frequency*

rs17525809

253T>C

V76A

0.062

rs28360445

375C>T

R117W

ND

Loss-of-function

rs28360447

474G>A

G150R

0.018

Loss-of-function

rs208294

489C>T

H155Y

0.439

Gain-of-function associated
with onset of gouty arthritis

Effect
Partial loss-of-function

Loss-of-function; associated
with heterotrophic
cardiomyopathy
rs28360452
598T>C
L191P
ND
Partial loss-of-function
Partial loss-of-function;
rs7958311
835A>G
R270H
0.255
increased pain sensitivity
rs7958316
853G>A
R276H
0.020
Loss-of-function
Loss-of-function; associated
with accelerated lumbar bone
rs28360457
946G>A
R307Q
0.013
loss and protection against
inflammation in multiple
sclerosis
Gain-of-function; associated
with anxiety disorder,
rs1718119
1068G>A
A348T
0.400
protection against symptomatic
toxoplasmosis and reduced
susceptibility to hypertension
Partial loss-of-function;
decreased in vitro killing by
human macrophages and
rs2230911
1096C>G
T357S
0.083
increased susceptibility to
tuberculosis in Brazilian
populations
Partial loss or unchanged
rs2230912
1405A>G
Q460R
0.170
function; association with mood
disorders
Loss-of-function; associated
with increased risk of
reactivation of tuberculosis
rs3751143
1513A>C
E496A
0.175
infection and associated with
risk of bone fracture and
potential biomarker for bipolar
disorder
rs2230913
1589C>G
H521Q
0.020
No effect on function
Loss-of-function; associated
with osteoporosis in postrs1653624
1729T>A
I568N
0.029
menopausal women and
increased bone loss
Increased molecular weight
28360460
1753G>A
R578Q
ND
receptor and possible loss-offunction
⁰ ID based on nomenclature from National Centre for Biotechnology Information (NCBI)
* Minor allele frequency data obtained from an Australian cohort of 3430 subjects by sequencing
methods by Fuller et al. (2009) and Stokes et al (2010).
ND, Not determined
rs28360451

582G>A

E186K

ND

Reference
Roger et al. (2010),
Stokes et al. (2010)
Roger et al. (2010)
Roger et al. (2010),
Stokes et al. (2010)
Cabrini et al. (2005),
Stokes et al. (2010),
Tao et al. (2017), Roger
et al. (2010)
Biswas et al. (2019),
Roger et al. (2010)
Roger et al. (2010)
Stokes et al. (2010),
Kambur et al. (2018)
Stokes et al. (2010)
Gu et al. (2004),
Gartland et al. (2012),
Gu et al. (2015)
Jamieson et al. (2010),
Roger et al. (2010),
Stokes et al. (2010),
Sun et al. (2010)

Shemon et al. (2006),
Souza de Lima et al.
(2016)
Barden et al. (2006),
Lucae et al. (2006),
Stokes et al. (2010)

Gu et al. (2001),
Fernando et al. (2007),
Gubert et al. (2019)

Roger et al. (2010)
Wiley et al. (2003),
Jørgensen et al. (2012)

Wickert et al. (2013)

and/or high throughput
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Notably, in Caucasian cohorts there are high levels of linkage disequilibrium between a
group of fours P2RX7 SNPs leading to the identification of five major P2RX7 haplotype
variants (denoted P2X7 1-5) which give rise to altered P2X7 activity on human
lymphocytes (Stokes et al., 2010). These haplotypes have also been observed in other
studies (Husted et al., 2013). Subsequent analysis revealed that these five haplotypes
could be subdivided into a further 17 haplotypes (denoted H1-H17), encompassing a total
of 11 missense P2RX7 SNPs (Jørgensen et al., 2012) (Table 1.2). Whilst the functional
effect of these 17 haplotypes have been predicted, they have not all been confirmed.
Since P2RX7 genotype greatly influences P2X7 activity, human and animal studies have
implicated P2RX7 SNPs in a number of diseases such as osteoporosis (Husted et al., 2013,
Xu et al., 2017), Alzheimer’s (Sanz et al., 2014) and tuberculosis (Fernando et al., 2007).
Three large studies, with a total of 2,500 human patients demonstrated a significant
disease association between the presence of the Q460R SNP and the onset of either
bipolar or major depressive disorder (Barden et al., 2006, Lucae et al., 2006, McQuillin
et al., 2009). Similarly, the GOF A348T SNP is associated with an increased risk of
anxiety (Roger et al., 2010) and protection against symptomatic toxoplasmosis (Jamieson
et al., 2010). Given the importance of P2X7 in inflammation, P2RX7 SNPs have also been
implicated in a number of inflammatory disorders. Studies have found that the LOF V76A
SNP is found more frequently in patients suffering from multiple sclerosis (OyangurenDesez et al., 2011). Similarly, P2RX7 SNPs have been associated in the pathogenesis of
rheumatoid arthritis (Al-Shukaili et al., 2011) and bacterial sepsis (Geistlinger et al.,
2012). P2RX7 SNPs may also play a role in allo-HSCT and GVHD, which is discussed
below.
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Table 1.2 Haplotype variants of the human P2RX7 gene
V76A

G150R

H155Y

R270H

R276H

R307Q

A348T

T357S

Q460R

E496A

I568N

Frequency (%)

Activity

H1

V

G

H

R

R

A

T

Q

E

I

16.2

Wild-type

H2

V

G

H

H
R

R

R

A

T

Q

E

I

5.3

Wild-type

H3

V

G

R

A

T

Q

E

I

4.4

Wild-type

V

G

H
R

R

H4

Y
H

R

R

A

T

Q

E

2.6

Loss

H5

V

G

Y

R

R

R

A

T

Q

E

N
I

2.3

Wild-type

H6

V

G

V

G

Y
H

H

H7

H
R

H8

V

G

H

H
R

H9

G

H

H10

A
V

G

H11

V

G

H12

V

G

H13

V

H14

V

R
G

H15

V

H16

V

H17

V

R

A

T

Q

E

I

1.4

Loss

A

T

Q

E

I

1.1

Loss

R

Q
R

T

T

Q

E

I

15.3

Gain

R

R

R

T

T

Q

E

I

4.5

Gain

Y

R

R

R

Q

E

I

2.4

Gain

R

R

R

T
A

T

Y
H

T

Q

A

I

11.8

Loss

R

R

R

A

T

Q

A

I

2.6

Loss

Y

R

R

R

A

T

Q

I

1

Loss

R

R

R

T

T

R

I

14

Gain

G

Y
H

A
E

R

R

R

T

I

1.2

Gain

G

R

R

R

S

R
Q

E

H

T
A

E

I

5

Loss

G

Y

R

R

R

A

S

Q

E

I

3.4

Loss

Table adapted from Sluyter (2017b)
Haplotypes H1-H17 encompass the five haplotypes (P2X7-1 to 5) described by Sluyter and Stokes (2010) and are shaded: P2X7-1 (H1-H7), P2X7-2 (H8-H10),
P2X7-3 (H11-H13), P2X7-4 (H14 and H15) and P2X7-5 (H16-H17)
Amino acid variations caused by SNPs in the human P2RX7 gene are coloured based on effect on P2X7 activity based on previous studies (Table 1.2); GOF(green),
LOF (red), neutral (Blue) and wild-type (black).
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1.7.2

P2X7 and GVHD

Experimental evidence for the role of P2X7 in GVHD comes mainly from allogeneic
mouse models of GVHD and a small number of clinical studies. The role of P2X7 in
GVHD was directly investigated by Wilhelm et al. (2010) who showed that P2X7 is upregulated in the peripheral blood and small intestines of human GVHD patients, and in
GVHD target organs in mice with GVHD. In this study GVHD was exacerbated by
increased amounts of extracellular ATP. Increased extracellular ATP resulted in P2X7
activation on host APCs and up-regulation of CD80 and CD86. This resulted in increased
donor T cell activation and pro-inflammatory cytokine release. In line with this, deletion
of host P2X7 reduced the concentration of IFNγ, TNFα and IL-6 and prolonged survival
in mice with GVHD (Wilhelm et al., 2010). Supporting this, our laboratory has shown
that P2X7 expression is increased in the gastro-intestinal tract and skin of humanised mice
with GVHD (Cuthbertson et al., 2020). Other studies have provided indirect evidence for
P2X7 in GVHD. P2X7 activation leads to formation of the NLRP3 inflammasome
(Jankovic et al., 2013) and mice deficient in NLRP3 are protected from GVHD.
Additionally, micro-RNA-155, which regulates P2X7 mediated NLRP3 inflammasome
activation, and IL-6 and TNF-α production (Faraoni et al., 2009), is upregulated in
activated T cells in mice with acute GVHD (Ranganathan et al., 2012). Consistent with
this, deletion of micro-RNA-155 reduced the proportions of activated T cells and reduced
damage to GVHD target organs in mice (Ranganathan et al., 2012). Moreover, the
deletion of micro-RNA 155 corresponded to reduced P2X7 expression in DCs, impairing
their activation by ATP (Chen et al., 2015).
Pharmacological blockade of P2X7 has beneficial effects against GVHD in a number of
studies. In allogeneic mouse models P2X7 blockade using KN-62 and PPADS led to a
reduction in serum IFNγ and inflammatory damage to GVHD target organs (Wilhelm et
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al., 2010). Similarly, P2X7 blockade with stavudine has been reported to lower GVHD
severity and the concentrations of serum IFNγ in an allogeneic mouse model (Fowler et
al., 2014). P2X7 blockade with BBG also reduces GVHD in an allogeneic mouse
model (Zhong et al., 2016). In humanised NSG mice, the use of BBG
(50 mg.kg-1 on day 0, 2, 4, 6 and 8) led to reduced serum IFNγ in humanised mice with
GVHD (Geraghty et al., 2017). Moreover, an altered injection regime of BBG (50 mg.kg1

thrice weekly for up to 10 weeks) led to reduced liver inflammation in humanised NSG

mice with GVHD (Geraghty et al., 2019c). However, in both of these studies BBG did
not impact mouse survival or the severity of GVHD. Given that NSG mice express
functional P2X7 (Geraghty et al., 2017), and it is thought that P2X7 on host APCs
exacerbates GVHD in allogeneic mice (Wilhelm et al., 2010), BBG may have been
blocking mouse (recipient) P2X7 in these prior studies to protect against GVHD.
Nevertheless, the relative roles of P2X7 activity on recipient and donor cells in GVHD
development in humanised mice is still unclear and warrants further investigation.
Experimental evidence has led to the proposition of a model of GVHD pathogenesis
involving P2X7 (Fig. 1.6). In this model damage to host tissue caused by the conditioning
regime or the underlying malignancy, triggers the release of extracellular ATP which
engages P2X7 on host APCs (Wilhelm et al., 2010, Zeiser et al., 2011). P2X7 activation
on host APCs promotes the expression of CD80 and CD86 and the activation and priming
of reactive donor T cells. Reactive donor T cells then differentiate into numerous subsets
that proliferate and migrate to GVHD target organs and promote inflammatory tissue
damage and extracellular ATP release (Wilhelm et al., 2010). Importantly extracellular
ATP may also be able to activate P2X7 on donor Tregs, to impair their activity and
prevent Treg conversion into Th17 cells (Schenk et al., 2011). Similarly, P2X7 could be
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activated on CD4+ and CD8+ effctor T cell subsets to promote IL-2 production and
proliferation (Yip et al., 2009), contributing to GVHD.

Figure 1.6 The role of purinergic signalling in GVHD. Tissue damage caused by the underlying
malignancy or conditioning regime triggers the release of extracellular ATP. Extracellular ATP can
promote the maturation of host APCs and cause donor T cell activation and differentiation. Donor T cells
can then migrate to GVHD target organs and cause inflammatory tissue damage and extracellular ATP
release. P2X7 is also found on activated donor T cells, therefore extracellular ATP may also activate P2X7
on these cells to further promote inflammation. CD39, predominantly found on Tregs, can regulate P2X7
activation by hydrolysing extracellular ATP to ADP and AMP. AMP is then hydrolysed to adenosine by
CD73 which is also expressed on Tregs. Adenosine can reduce GVHD by activating A2A receptors on Tregs.

Since GVHD is mediated by donor T cells, and P2X7 activity on these cells is strongly
influenced by P2RX7 genotype, donor P2RX7 genotype may influence the development
of GVHD. However, this has not been thoroughly investigated. A role for P2RX7
genotype in allo-HSCT was suggested by Lee et al. (2007b) who showed that the E496A
SNP in recipients was associated with reduced survival following allo-HSCT. Whilst this
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was not supported by a second, more highly powered study (Karaesmen et al., 2017),
neither study reported the incidence of GVHD. Consequently, whether P2RX7 genotype
influences GVHD is still unclear. Recently, donor and recipient’s P2RX7 SNPs were
shown to have minimal impact on GVHD in a clinical study, however this has only been
performed in one study (Koldej et al., 2020). As a result, further investigation into how
donor P2RX7 genotype influences GVHD and if it has potential to be a predictive
biomarker is warranted.
1.7.3

Ecto-nucleotidases

P2X7 is the primary purinergic receptor implicated in GVHD, however other components
of purinergic signalling can impact GVHD. For example, activation of A2A receptors by
extracellular adenosine can reduce GVHD (Lappas et al., 2010). In purinergic signalling
ecto-nucleotidases mediate the availability of extracellular nucleotides for the activation
of P1 and P2 receptors (Zimmermann et al., 2012). There are four main classes of ectonucleotidases; ecto-nucleoside triphosphate di-phosphohydrolases (ENTPDases), which
includes CD39; ecto-nucleotide pyrophosphatase/phosphodiesterases (E-NPPs); alkaline
phosphatases (APPs); and ecto-5’-nucleotidases (Zimmermann, 2000, Zimmermann et
al., 2012). This chapter will only discuss CD39, for a detailed review on the role of the
other ecto-nuceleotidases in purinergic signalling and inflammation see (Zimmermann et
al., 2012).
1.7.3.1 CD39
CD39 is one of eight ENTPDases and was the first of this family to be cloned and
sequenced (Maliszewski et al., 1994, Chadwick and Frischauf, 1997). CD39 is
responsible for the hydrolysis of ATP to ADP and ADP to AMP, which can occur without
leaving the active site (Zebisch et al., 2012, Zebisch et al., 2013) (Fig. 1.4). Human CD39
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is a 510 amino acid protein, encoded by the human ENTPD1 gene, anchored to the plasma
membrane by two transmembrane domains with a large extracellular hydrophobic domain
(Heine et al., 2001) .
CD39 is constitutively expressed in a number of tissues, including the spleen and thymus
(Enjyoji et al., 1999). Therefore, CD39 is found on a large number of leukocytes including
B cells (Figueiro et al., 2016), CD4+ Tcons (Zhou et al., 2009), CD8+ T cells (Gupta et
al., 2015) and NK cells (Morandi et al., 2015). CD39 can behave as an activation
(Raczkowski et al., 2018) or exhaustion marker (Gupta et al., 2015, Canale et al., 2018)
on these cells, or denote regulatory subsets (Parodi et al., 2013, Dwyer et al., 2010,
Figueiro et al., 2016). Notably, high expression of CD39 is a characteristic feature of
human Tregs and mediates the immunosuppressive capacities of these cells (Rissiek et
al., 2015). Consequently, CD39 has been more extensively studied on Tregs than on any
other immune cell subset.
1.7.3.1.1

CD39 on Tregs

The hydrolysis of ATP by CD39 is central for the immunoregulatory functions of Tregs
(Deaglio et al., 2007, Zhou et al., 2009, Gu et al., 2017, Rissiek et al., 2015, Borsellino et
al., 2007). Consistent with this, studies have shown that around 90% of FoxP3+ Tregs in
humans are also CD39+ (Dwyer et al., 2010, Mandapathil et al., 2009). CD39 also
promotes Treg stability by minimising the loss of FoxP3 in inflammatory environments,
preventing Tregs reverting into Tcons (Gu et al., 2017, Komatsu et al., 2014). Further,
extracellular ATP impairs Treg survival (Schenk et al., 2011), therefore CD39 promotes
Treg longevity. Extracellular ATP hydrolysis by CD39 also prevents expression of the
transcription factor hypoxic inducible factor 1 (HIF-1) in Tregs, which initiates FoxP3
ubiquitination and degradation (Dang et al., 2011). Additionally, CD39 may also drive
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Treg migration to inflamed regions with high extracellular ATP so they can exert
suppressive functions (Borsellino et al., 2007). Finally, the presence of CD39 is required
for Tregs to suppress potent pro-inflammatory cytokines, such as IL-17 and IFNγ (Rissiek
et al., 2015).
Since CD39 is extremely important for human Treg function and stability, it has been
investigated in many inflammatory diseases. In multiple sclerosis CD39+FoxP3+ Tregs
are able to suppress pathogenic Th17 cells and impair disease development (Fletcher et
al., 2009). Similarly, in rheumatoid arthritis low expression of CD39 on Tregs is
associated with poor responses to methotrexate (MTX) therapy (Peres et al., 2015). The
genetic ablation of CD39 has been reported to enhance inflammatory bowel disease in
mice (Friedman et al., 2009a) and reduce the capacity of Tregs to suppress Tcons in mice
with contact hypersensitivity (Ring et al., 2009). Therefore, CD39 may also be involved
in the development of GVHD following allo-HSCT (discussed further in section 1.7.2.2).
Notably, CD39 expression on Tregs is independent of FoxP3 and the transcription factor
Helios, which are critical for the maintenance of human Tregs (Gerner et al., 2020).
However, CD39 expression on Tregs can be influenced by the rs10748643 SNP in the
human ENTPD1 gene (Rissiek et al., 2015). This SNP strongly alters CD39 expression
and Treg functionality, and may be a viable biomarker for inflammatory disease,
including GVHD.
1.7.3.1.2

The human ENTPD1 gene

The human ENTPD1 gene has been mapped to the 10q24.1 chromosomal position
(Maliszewski et al., 1994). Like the human P2X7 gene, the human ENTPD1 gene gives
rise to a number of SNPs which can strongly influence CD39 expression on human
immune cells and tissues (Rissiek et al., 2015, Friedman et al., 2009b, Maloney et al.,
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2017). For example, the rs3814159 SNP in the human ENTPD1 promoter can impact
CD39 activity and surface expression on platelets (Maloney et al., 2017). One of the most
thoroughly studied SNPs in the human ENTPD1 gene is the rs10748643 (AG) SNP in
intron 1. In healthy donors of German (Rissiek et al., 2015) and Italian (Timperi et al.,
2016a) descent, individuals encoding the G allele demonstrate higher proportions of
Tregs, and CD39+ Tregs, in peripheral blood than individuals possessing the A allele.
Subsequently, Tregs encoding the A allele demonstrate reduced suppressive capacities,
including suppression of IFNγ and IL-17 from Tcons, compared to Tregs encoding the G
allele (Rissiek et al., 2015). This effect may also be present in other ethnic cohorts since
the rs10748643 SNP also influences CD39 mRNA expression in lymphocytes from
donors of Chinese, Japenese and Yoruba ancestry (Friedman et al., 2009a). The
rs10748643 SNP is also believed to have high linkage disequilibrium with the rs3814159
SNP, which may further influence CD39 expression (Maloney et al., 2017) and may
explain how the rs10748643 SNP influences CD39 expression on Tregs despite being an
intronic SNP.
Due to its role in influencing CD39 expression on Tregs the rs10748643 SNP is thought
to be associated with a number of inflammatory diseases. For example, donors encoding
the A allele demonstrate a higher susceptibility for Crohns disease (Friedman et al.,
2009a) and slower progression of autoimmunity deficiency syndrome (Nikolova et al.,
2011). Conversely, the G allele has been associated with protection against neonatal
sepsis (Timperi et al., 2016a). A recent study identified a three SNP haplotype in the
ENTPD1 gene, encompassing rs11188513, rs7071836 and rs10748643 in German
individuals (Maloney et al., 2017). Notably, this study implicated the G allele of the
rs10748643 SNP in acute organ rejection following liver transplantation. Importantly,
these phenotypic effects remain consistent in donors with chronic inflammatory diseases
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(Rissiek et al., 2015). Therefore, the rs10748643 may have a role in the development of
other inflammatory diseases, including GVHD, but this has not been previously
investigated.
1.7.3.2 CD39 and GVHD
CD39 may have a role in the development of GVHD, primarily because of its importance
for the suppressive capacities of human Tregs. However, there are limited studies
investigating this. In humans CD39 on Tregs is responsible for the downregulation of
Notch signalling on Tcons (Caridade et al., 2013). Notch signalling is an important signal
transduction pathway that regulates T cell differentiation and may be involved in GVHD
(Di Ianni et al., 2018). In line with this, CD39 blockade with the selective CD39 inhibitor
polyoxometalate-1 (POM-1) can increase GVHD by promoting Notch signalling on
Tcons in allogeneic mouse models (Del Papa et al., 2016).
A role for CD39 in GVHD has also been suggested in humanised mouse models, where
adoptive transfer of human Tregs with high CD39 expression, but not those with low
CD39, can protect against GVHD and prolong mouse survival when co-transferred with
hPBMCs (Gu et al., 2017). In this same study high CD39 expression was required to
prevent Tregs from differentiating into Th1 and Th17 cells during GVHD pathogenesis.
CD39hi Tregs are also required for AJI-100 (aurora kinase A and JAK 2 antagonist) to
reduce GVHD in humanised mice by reducing the expansion of CD4+ T cells, Th17 cells
and CD8+ T cells (Betts et al., 2017b). Humanised mice have been previously used in our
lab to suggest a role for CD39 in GVHD (Geraghty et al., 2019d). Here, co-blockade of
CD39 and CD73 using αβ-methylene-ADP increased weight loss and histological damage
to the livers of humanised NSG mice with GVHD. This suggests that CD39 may act to
minimise extracellular ATP to limit P2X7 activation.
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Direct evidence suggesting a role for CD39 in GVHD from human studies is extremely
limited and mainly comes from in vitro studies. High CD39 expression on Tregs,
conferred by the G allele of the rs10748643 SNP increases the ability of human Tregs to
suppress IFNγ and IL-17 from activated Tcons in MLCs (Rissiek et al., 2015). Moreover,
MLCs performed by Huang et al. (2017) demonstrated that CD39 is required for gingivaderived mesenchymal stem cells to suppress alloreactive T cells. Mesenchymal stem cells
can prevent GVHD in humanised mouse models (Tobin et al., 2013, Bruck et al., 2013)
and are a promising novel strategy for GVHD, however they are unable to do so if treated
with POM1 before transplantation (Huang et al., 2017). As a result of these findings,
CD39 may have potential as a novel therapeutic strategy in GVHD, or as a predictive
GVHD biomarker, but this has not been thoroughly investigated.
1.8

Current therapeutic strategies for GVHD

While biomarkers are key to predicting GVHD development, understanding the disease
mechanisms and developing novel therapeutic strategies are vital to improving outcomes
for allo-HSCT recipients. The complex pathophysiology of GVHD makes the
management and treatment of the disease difficult. As a result, there are many limitations
to current GVHD treatments, including exposing the patient to opportunistic infection
and increasing rates of cancer relapse (Villa et al., 2016).
Systemic corticosteroids are the current first-line treatment for GVHD and have
consistently improved outcomes for GVHD patients in many studies (Weisdorf et al.,
1990, MacMillan et al., 2002). However, the use of corticosteroids often leads to steroid
refractory GVHD, where the patient no longer responds to steroidal therapies.
Consequently, the outcomes of steroid refractory GVHD patients are dismal, with
morbidity and mortality figures approaching 90% (MacMillan et al., 2002, Van Lint et
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al., 2006). Second line treatment is generally used if GVHD worsens in any organ over 3
days of first-line treatment, or there is no response to steroid therapy in 5–14 days (Dignan
et al., 2012). Numerous therapeutic agents have been studied in this context, but none
have demonstrated convincing long-term benefit (Malard et al., 2020).
Aside from corticosteroids, the most common treatments for GVHD has involved
strategies targeting alloreactive donor T cells since they are central to GVHD
pathogenesis (Vadakekolathu and Rutella, 2017). Historically, this has been achieved
using calcineurin inhibitors such as cyclosporine A (CYA) and tacrolimus (TAC) (Villa
et al., 2016, Hamilton, 2018). Calcineurin inhibitors block the nuclear factor of activated
T cells (Powles et al., 1980), thereby impeding T cell proliferation. These drugs also
attenuate IL-2 expression in activated T cells, restricting T cell differentiation (Chao and
Chen, 2006). Calcineurin inhibitors are often combined with short course MTX which
suppresses T cell proliferation through inhibition of dihydrofolate reductase and
disrupting the production of thymidylate (Johnston et al., 2005, Chhabra et al., 2019).
Whilst MTX can reduce GVHD on its own, combination of MTX with CYA or TAC
results in far more effective abrogation of GVHD (Storb et al., 1993, Storb et al., 1986,
Hamilton et al., 2019).
Mycophenolate mofetil (MMF) is also currently used to treat GVHD (Penack et al.,
2020). MMF is an ester prodrug of the immunosuppressant mycophenolic acid that
reduces T cell proliferation by inhibiting de novo purine metabolism (Kiehl et al., 2002).
MMF successfully prevents GVHD after non-myeloablative conditioning in canine
models (Yu et al., 1998) and is mainly used following reduced intensity conditioning
(Ghosh et al., 2016). A regimen of CYA and MMF has shown similar ability in preventing
GVHD as high dose MTX alone (Kiehl et al., 2002, Perkins et al., 2010). However, the
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efficacy of MMF following high intensity conditioning allo-HSCT is not well established.
A recent study involving 3979 matched sibling donors and 4163 unrelated donors
suggested that MTX combined with CYA is more effective than MMF with CYA at
reducing GVHD following high-intensity conditioning (Hamilton et al., 2015). However,
the reduced use of high-intensity conditioning for allo-HSCT may increase the usage of
MMF in clinical allo-HSCT.
Rapamycin (Battaglia et al., 2005) has been used for the prophylaxis and treatment of
several immune diseases, including GVHD (Antin et al., 2003, Couriel et al., 2005,
Ruggeri, 2019). Rapamycin causes immunosuppression of alloreactive T cells by
expanding Tregs (Battaglia et al., 2005, Geissler, 2009). Preclinical mouse studies
demonstrated that a combination of rapamycin and exogenous IL-2 is effective in
preventing GVHD-induced lethality due to a robust expansion of human Tregs, more so
than either compound alone (Blazar et al., 1993, Blazar et al., 1996). Human studies have
demonstrated that rapamycin can reduce the incidence of acute GVHD in HLA
mismatched allo-HSCT patients following high intensity conditioning (Antin et al., 2003,
Al Malki et al., 2020). Other findings have been mixed. For example, a trial investigating
a dosage regime of rapamycin and MTX in GVHD prophylaxis found high incidences of
acute GVHD in HLA-mismatched allo-HSCT patients (Furlong et al., 2008).
While the above therapies are still used currently to treat GVHD, they do not prevent the
disease. Importantly, these therapies are also associated with a risk of cancer relapse
which negates any benefit of the allo-HSCT (Villa et al., 2016). More recently the direct
depletion of alloreactive T cells has become a mainstay for GVHD prophylaxis. Of the
many methods to deplete alloreactive donor T cells (Table 1.3), PTCy is most commonly
used to treat GVHD in clinical settings, with increasing use following HLA-mismatched
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and haploidentical allo-HSCT. PTCy demonstrates great efficacy in reducing GVHD and
is discussed in detail below (section 1.8.1).
1.8.1

PTCy

Cy is an alkylating agent initially developed as a chemotherapeutic treatment. In
allo-HSCT, high-dose Cy given post-transplant (PTCy) (> 50 mg/kg) effectively reduces
GVHD (Luznik et al., 2010, Munchel et al., 2011). Therefore, PTCy has become a
mainstay in current GVHD prophylaxis regimes. Cy is typically given at 10-50 mg.kg-1
on day 3 and 4 post allo-HSCT (Kanakry et al., 2016) and can be given alone or in
combination with other treatments, including those described above (section 1.6.2). The
dose, timing and exposure time for PTCy is crucial for GVHD prophylaxis. Cy treatment
on days 3 and 4 post-transplant provides optimal GVHD abrogation with maximal
immune reconstitution in allogeneic mouse models (Wachsmuth et al., 2020).
Clinical data suggests that PTCy reduces GVHD following haploidentical allo-HSCT to
a greater extent than other standard treatments after HLA-matched allo-HSCT (Kanate et
al., 2016, Ciurea et al., 2015, Ghosh et al., 2016). Haploidentical allo-HSCT is typically
a greater risk factor for GVHD than HLA-matched allo-HSCT (Bertaina and Andreani,
2018). Moreover, Cy has an excellent toxicity profile (Whirl-Carrillo et al., 2012), is not
associated with increased rates of relapse and is inexpensive (Kanakry et al., 2016). This
highlights why the use of PTCy as a treatment for GVHD is growing worldwide.
However, in contrast to its common use clinically, there is little confirmed mechanistic
data regarding how Cy reduces GVHD.
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Table 1.3 Commonly used T cell depletion strategies to reduce GVHD
Depletion strategy/drug

Mechanism of action

Reference

Alemtuzumab

Anti-CD52 monoclonal antibody that depletes mature alloreactive T
cells

Gómez-Almaguer et al. (2008)

Antigthymocyte globulin

Recognises markers expressed by alloreactive T cells (CD3, CD4
and CD8) and induces apoptosis and lysis of these cells. Also
promotes generation of Tregs

Kekre and Antin (2017)

PTCy

Metabolised to toxic metabolites that intercalate with DNA and
disrupts replication of alloreative donor T cells. May also induce
alloreactive T cell dysfunction

Kanakry et al. (2016), Kanakry et al.
(2014)

CD34 Sorting

Positive selection of CD34+ stem cells from the donor graft and
infused into the host. Reduces the rates of severe GVHD in alloHSCT recipients

Butt et al. (2003), Larocca et al.
(2006)

CD3/CD19 depletion

Negative selection using anti-CD3/Cd19 monoclonal antibodies to
simultaneously deplete CD3+ T cells that propagate GVHD and
CD19+ B cells that initiate post-transplant lymphoproliferative
disease.

Bethge et al. (2006), Federmann et al.
(2012)

αβ depletion

Anti‐αβ antibodies bind to αβ T cells, which drive GVHD
pathogenesis, and initiates their lysis. Preserves other T cell subsets
that mediate GVT responses.

Rådestad et al. (2019)

In vivo

+

Ex vivo
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In mice and humans Cy is metabolised in the liver by cytochrome P450, resulting in the
production of phosphoramide mustard and acrolein (Al-Homsi et al., 2015). These
products intercalate with DNA and cause crosslinking, disrupting cell division.
Subsequently, the effects of Cy are most pronounced during the G1 and S phases of the
cell cycle (Emadi et al., 2009). Therefore, cells undergoing rapid proliferation, such as
alloreactive donor T cells, are more susceptible to Cy. Notably, high expression of
aldehyde dehydrogenase on certain hematopoietic cell subsets, such as Tregs, makes them
resistant to Cy by breaking down phosphoramide mustard (Brodsky et al., 1998). Early
preclinical studies in skin allograft models demonstrated that PTCy could reduce allograft
rejection due to MHC mismatch (Berenbaum and Brown, 1964, Berenbaum and Brown,
1963) and induce tolerance of MiHAgs (Nirmul et al., 1973, Nirmul et al., 1971). Based
on these studies, Eto et al. (1991) used the Vβ TCR as a marker for proliferation and
demonstrated that PTCy decreases the proportions of alloreactive Vβ+CD4+ T cells. These
results led to a long-accepted paradigm that PTCy prevents GVHD by depleting
alloreactive donor T cells.
Whilst Eto et al. (1991) observed direct destruction of Vβ+CD4+ T cells in the thymus of
mice treated with PTCy, other studies have suggested that Cy induces clonal deletion of
T cell precursors (Eto et al., 1990a, Eto et al., 1990b). It has also been suggested that Cy
preferentially depletes T cells undergoing antigen-driven proliferation in MHC-matched
murine HSCT (Ross et al., 2013). However, not only were these studies performed in
allogeneic mouse models, but they were not assessed in clinical settings or humanised
mouse models. Therefore, how closely these skin allograft models reflect models of
GVHD is unclear.
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The paradigm that Cy depletes alloreactive T cells in GVHD is based on decades old data
and has been recently challenged by new studies. Tregs are essential for Cy to reduce
GVHD since their depletion from donor graft prevents Cy from reducing GVHD in
humanised (Kanakry et al., 2013a) and allogeneic mouse models (Ganguly et al., 2014,
Ikegawa et al., 2019). In HLA-haploidentical MLCs, Tregs were found to be resistant to
Cy due to high expression of aldehyde dehydrogenase (Kanakry et al., 2013a, Ganguly et
al., 2014). Moreover, Tregs are known to recover rapidly following PTCy treatment
(Kanakry et al., 2013a).
Recently, Wachsmuth et al. (2019) used five allogeneic mouse models of GVHD to
convincingly demonstrate that alloreactive donor T cells are not eliminated after PTCy
treatment, irrespective of PTCy dose, MHC-matching or alloreactive T cell specificity.
Whilst they were not eliminated, alloreactive CD4+ and CD8+ T cells showed reduced
proliferation in PTCy treated mice and became functionally impaired in terms of their
ability to cause clinical GVHD. Further, these conclusions are supported by clinical
observations that severe GVHD still frequently develops in allo-HSCT recipients
receiving single-agent PTCy (Holtick et al., 2016, Bradstock et al., 2015, Kanakry et al.,
2014). This indicates that allo-HSCT recipients in these studies still had a large proportion
of alloreactive donor T cells that drove GVHD. Since dosing regimens of PTCy that do
not reduce reactive donor CD4+ effector T cells are ineffective at reducing GVHD
(Wachsmuth et al., 2020), it has been proposed that CD8+ effector T cells are not the
primary target of PTCy (Nunes and Kanakry, 2019). Surviving reactive donor CD4+
effector T cells show diminished activity, which steadily returns over time, starting at 5
days following PTCy. However, this can be augmented by the quick reconstitution of
donor Tregs (Nunes and Kanakry, 2019).

52

This new mechanism is based solely on allogeneic mouse models (Wachsmuth et al.,
2019, Wachsmuth et al., 2020, Ganguly et al., 2014). As a result, it is unclear if this is the
case in humanised mice or clinical settings. Moreover, this mechanism does not take into
account that PTCy is rarely given as a single treatment to allo-HSCT recipients which
may alter the action of PTCy.
The majority of studies involving PTCy in GVHD are performed in allogeneic mouse
models, but studies in humanised mice are limited. A single dose of PTCy (100 mg.kg-1)
on day 3 reduces GVHD in humanised NSG mice (Kanakry et al., 2013a), but there are
no other studies investigating PTCy in this model. Moreover, this study did not report
histological damage to GVHD target organs or the impact of PTCy on human cell
engraftment. Regardless, PTCy alone does not prevent GVHD in mice or humans. This
suggests that PTCy must be combined with other strategies to prevent GVHD. Therefore,
there is a need for more established humanised mouse models of GVHD using PTCy.
This would allow more effective study on how PTCy can be combined with novel
therapeutic strategies against GVHD in humans.
1.9

Novel therapeutic strategies for GVHD

The success of allo-HSCT is not based solely on preventing GVHD, but also on the GVT
effect and the prevention of cancer relapse. Many current therapies increase
immunosuppression or directly manipulate the donor graft, and whilst this reduces
GVHD, these strategies can impact the other important outcomes in allo-HSCT. As a
result, several novel GVHD therapeutic strategies are being investigated in clinical and
pre-clinical studies which may be more effective at preventing GVHD without impacting
the GVT effect or cancer relapse. A number of novel strategies for GVHD are outlined in
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Table 1.4, however amongst the most promising strategies is targeting donor Tregs to
suppress GVHD.
1.9.1

Targeting donor Tregs

As discussed above, the immunosuppressive functions of Tregs makes them essential for
the prevention of GVHD and the centre of many novel GVHD treatment strategies. Both
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Table 1.4 Promising novel therapeutic strategies to reduce GVHD currently in clinical trials
Therapy

Monoclonal
antibodies

Strategy/Drug

Mechanism of action

Reference

Clinical trial(s)

Clinical trial design

Clinical trial status

Tocilizumab

Blockade of IL6 receptor
signalling

Ganetsky et al. (2019),
Drobyski et al. (2011)

NCT03434730

Phase II

Active, Recruiting

NCT04070781

Phase I

Not yet recruiting

Inhibits TNFα

Nygaard et al. (2018)

NCT00201799

Phase II

Completed

De Jong et al. (2017)

NCT00726375

Phase III

Completed

Gómez-Almaguer et al.
(2008)

NCT00775632

Phase II

Completed

NCT02867800

Phase I

Active, recruiting

NCT00539695

Phase II

Completed

NCT01937468

Phase I

Active, recruiting

NCT01366092

Phase II

Active, not recruiting

NCT02340676

Phase II

Active, not recruiting

NCT01903473

Phase II

Active, recruiting

NCT00803010

Phase II

Completed

NCT01903473

Phase II

Recruiting

NCT02342613

Phase I

Recruiting

NCT01660607

Phase II

Active, recruiting

NCT00602693

Phase I

Completed

NCT01818479

Phase I

Terminated

Infliximab
Etanercept
Alemtuzumab

Anti-CD52 monoclonal
antibody that depletes
alloreactive T cells

Low-dose IL-2
In vivo expansion of host
Tregs following alloHSCT
Rapamycin
Tregs
Anti-CD3 and antiCD28 antibodies

Expansion from
umbilical cord blood

Kennedy-Nasser et al.
(2014), Zhao et al. (2014)
Koreth et al. (2016)
Abraham et al. (2017)
Palmer et al.
(2010) Battaglia et al.
(2005), Geissler (2009),
Hippen et al. (2011a)
Zhao et al. (2014), He et al.
(2017)

Tregs expanded ex vivo are
co-transfused alongside
allo-HSCT

Brunstein et al. (2011),
Kellner et al. (2018)

* According to clinicaltrials.gov last accessed 22/06/2020
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Table 1.4 Promising novel therapeutic strategies to reduce GVHD currently in clinical trials, continued
Therapy

Strategy/Drug

Mechanism of action

Reference

Clinical trial

Clinical trial
design

Clinical trial status

Itacitinib

Selective JAK 1 inhibitor
with potential
antineoplastic activity

Schroeder et al. (2018)

NCT03139604

Phase III

Active, not recruiting

NCT02953678

Phase II

Active, not recruiting

Ruxolutinib

JAK 1/2 inhibitor that
reduces IFNG receptor
signalling and can reduce
GVHD

Escamilla Gómez et al.
(2020), Jagasia et al. (2020)

NCT02913261

Phase III

Active, not recruiting

NCT02997280

Phase II

Completed

Kakihana (2017)

NCT03359980

Phase II

Active, recruiting

NCT03847844

Phase I and II

Active, recruiting

NCT03631589

Phase II and III

Active, not recruiting

NCT00366145

Phase III

Completed

NCT02406651

Phase I and II

Active, not recruiting

NCT02956122

(phase II/III)

Terminated

NCT03172455

(phase II/III)

Complete

Kinase
inhibition

Microbiome
manipulation

Faecal microbiota
transplants

Loss of microbiome is
associated with increased
GVHD severity

Mesenchymal
stem cells

Expanded ex vivo and
transplanted into alloHSCT recipients

Inhibit proliferation and
cytotoxic activity of
alloreactive donor T cells

Acts on intestinal stem
cells to strengthen
IL-22
epithelial barrier function;
Cytokine
tissue repair
manipulation
Serum protease inhibitor
α-1 antitrypsin
that inhibits action of
elastase
* According to clinicaltrials.gov last accessed 22/06/2020

Elgaz et al. (2019), Zoehler et
al. (2020)

Hanash et al. (2012), Sabat et
al. (2014)

Magenau et al. (2018)
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nTregs and iTregs are able to prevent GVHD in mice and humans (Ramlal and
Hildebrandt, 2017, Heinrichs et al., 2016). However, whilst nTregs consistently reduce
GVHD across numerous studies, the efficacy of iTreg therapy for GVHD is controversial
in the literature (Heinrichs et al., 2016). Therefore, this chapter will focus on the
expansion of nTregs as a novel strategy against GVHD. For a review on the use of iTregs
as a novel treatment for GVHD see Heinrichs et al. (2016).
The adoptive transfer of nTregs can prevent GVHD in HLA-haploidentical
transplantation without increasing rates of cancer relapse (Di Ianni et al., 2011, Martelli
et al., 2014). However, nTregs need to be transferred prior or close to the same time as
donor T cells to maximally reduce GVHD (Nguyen et al., 2007, Pierini et al., 2015,
Bolton et al., 2015). The major problem with nTreg therapy is that nTregs only comprise
1-2 % of CD4+ T cells in humans, but are required at a 1:1 Tcon:Treg ratio to attenuate
GVHD (Hoffmann et al., 2002). Taylor et al. (2002) demonstrated that nTregs could be
expanded ex vivo 67-fold to numbers high enough to be used for GVHD prophylaxis,
highlighting the promise of nTreg expansion as a therapeutic strategy against GVHD.
One-hundred-fold expansion of nTregs was achieved by Godfrey et al. (2004) using antiCD3 and anti-CD28 antibodies alongside exogenous IL-2. Moreover, in this study these
nTregs were capable of completely suppressing pro-inflammatory cytokines in MLCs.
nTregs can also be effectively expanded from cord blood, which contains higher
proportions of CD25bright cells than adult peripheral blood (Heinrichs et al., 2016), using
anti-CD3 and anti-CD28 monoclonal antibodies attached to beads and rapamycin
(MacDonald et al., 2019). nTregs expanded in this manner demonstrate stable FoxP3
expression, have similar suppressive capacity to peripheral nTregs and can reduce GVHD
in clinical trials (Hippen et al., 2011b, Brunstein et al., 2011, Brunstein et al., 2016).
However, ex vivo nTreg expansion can also lead to the expansion of CD4+ Tcons which
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have pathogenic roles in GVHD. This problem can be averted by expanding nTregs using
K562 cells, expressing CD64 and CD86 for co-stimulation of APCs instead of anti-CD3
and anti-CD28 monoclonal antibodies (Brunstein et al., 2016).
Although ex vivo isolation and expansion of nTregs is effective at reducing GVHD, this
process is expensive and requires specialized cell sorting and cell culture facilities.
Therefore, studies determining other methods to expand nTregs are required. The addition
of TGFβ can induce Treg formation from CD4+ Tcon precursors (Fu et al., 2004). Treg
expansion can also be induced in vivo using low-dose IL-2, a critical cytokine for human
Treg and Tcon development. nTregs constitutively express high levels of CD25, therefore
they can be preferentially expanded by low-dose of IL-2, which does not expand Tcon
subsets that mediate GVHD (Barron et al., 2010, Kennedy-Nasser et al., 2014). IL-2 (0.2
MIU.m-2.day-1) was first used clinically to prevent relapse in allo-HSCT recipients to
increase the numbers of NK cells, which also express CD25 (Soiffer et al., 1994). In this
study, NK cells were expanded and Tcons remained stable, however there were no reports
on Tregs because of the lack of knowledge of these cells at the time. The first major
GVHD study with low-dose IL-2 was performed by Kennedy-Nasser et al. (2014). Here,
low-dose IL-2 (0.1 – 0.2 MIU.m-2 three times per week for up to twelve weeks, starting
from day 7) was used in 16 paediatric allo-HSCT recipients who also received standard
GVHD prophylaxis. Patients receiving low-dose IL-2 demonstrated increased
CD4+CD25+FoxP3+ Tregs compared to baseline (Day 0) and these Tregs maintained
suppressive functionality, resulting in no incidences of severe GVHD. Similarly, (Betts
et al., 2017a) used low-dose IL-2 (0.2 MIU.m-2, thrice weekly from day 0 to day 90) in
combination with TAC. However, this did not translate to reduced GVHD because Tregs,
despite initially increased at day 30, steadily declined until day 90. This reflects a major
roadblock to the success of Treg therapy for GVHD, in that Tregs show poor long term
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longevity following transplantation (Tang and Vincenti, 2017). Moreover, in
inflammatory conditions, such as in GVHD, Tregs can revert to Tcons (Kim et al., 2009,
Hanidziar and Koulmanda, 2010). Other clinical studies using low-dose IL-2 to treat acute
GVHD are limited, however there are a small number that have investigated low-dose
IL-2 as a treatment for chronic GVHD (Koreth et al., 2016). Notably, in all the above
studies, low-dose IL-2 alone does not prevent GVHD. This may due to IL-2 causing Tcon
activation, which can express CD25 following activation. In humanised NSG mice, IL-2
at a dose of 0.25 MIU/m2 increased both Tregs and GVHD effector Tcons and did not
reduce disease (Pérol et al., 2014). Since IL-2 is necessary for human Tregs in humanised
NSG mice (Abraham et al., 2017), it may be viable to combine low dose IL-2 with
strategies such as PTCy to target Tcons and potentially prevent GVHD onset. Although
the combination of low-dose IL-2 and rapamycin increases human Tregs in humanised
NSG mice (Hu et al., 2020), combinational therapy of PTCy with low-dose IL-2 has not
been investigated in clinical studies or pre-clinical models (Fig. 1.7).
1.10

Summary

Allo-HSCT is one of the only curative therapies for blood cancers, however 50% of
allo-HSCT recipients develop deadly GVHD. Therefore, blood cancer patients are faced
with the harsh reality of potentially having to overcome two life-threatening diseases in
close succession. Currently, there are no effective biomarkers to predict disease onset or
therapies that prevent GVHD in clinical settings.
The release of extracellular ATP from damaged tissue drives GVHD by activating P2X7
on host APCs, but a role for donor P2X7 in GVHD cannot be excluded at present time.
Since P2X7 activity is strongly influenced by P2RX7 genotype, it is plausible that donor
P2RX7 genotype influences GVHD and may be a viable biomarker to predict disease
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onset (Fig. 1.6). Moreover, SNPs in other purinergic signalling genes, such as the
ENTPD1 gene which encodes CD39 and regulates the availability of extracellular ATP
and Treg immunosuppression, may also influence GVHD development (Fig. 1.6). This
has not been previously investigated.

Figure 1.7 The roles of PTCy and low-dose IL-2 in GVHD. Tissue damage caused by the underlying
malignancy or conditioning regime triggers the release of extracellular ATP. Extracellular ATP can
promote the maturation of host APCs and cause reactive donor T cell activation and differentiation.
However, extracellular ATP can also impair the survival and stability of Tregs. Reactive donor T cells can
then proliferate and migrate to host tissue to illicit further inflammatory damage. PTCy targets proliferating
reactive donor T cells and can reduce GVHD. Tregs are required for PTCy to reduce GVHD and can be
expanded by low-dose IL-2. Tregs can reduce GVHD by hydrolysing extracellular ATP and suppressing
the proliferation of reactive donor T cells.
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Current first-line treatment for GVHD relies on immunosuppression, but this is
unfavourable since it increases the rates of cancer relapse and infection. Therefore,
strategies that deplete alloreactive donor T cells and maintain Tregs whilst also
maintaining other cells involved in GVT responses are currently being investigated. Other
treatments, such as PTCy, reduce GVHD clinically but do not prevent the disease and
have a misunderstood mechanism of action. This could be elucidated using
well-established pre-clinical humanised mouse models of GVHD that closely resemble
clinical settings. Whilst PTCy has been thoroughly investigated in allogeneic models of
GVHD, there are no established humanised mouse models of GVHD using PTCy. It may
also be viable to combine PTCy with novel therapeutic strategists, such as expanding
Tregs with low-dose IL-2, to further reduce GVHD development (Fig. 1.7).
1.11

Aims

1.11.1 General aims
This thesis aims to determine novel therapeutic strategies for the prediction or prevention
of GVHD development by specifically manipulating the donor T cells.
1.11.2 Specific aims
The specific aims of this PhD thesis are:
i.

To investigate the impact of donor P2RX7 genotype on P2X7 activity on
donor immune cell subsets important in GVHD, and on the development of
disease in a humanised mouse model of GVHD (Chapter 3);

ii.

To determine the influence of the rs10748643 SNP in the ENTPD1 (CD39)
gene on human donor immune cells and on the development of GVHD
(Chapter 4);

61

iii.

To investigate the mechanism of PTCy on human donor cells and the
therapeutic effect development of GVHD in a humanised mouse model
(Chapter 5);

iv.

To determine the therapeutic effect of combinational therapy of PTCy and
low-dose IL-2 on the development of GVHD in a humanised mouse model
(Chapter 6).

Chapter 2:
2.1

Materials and Methods

Materials

RPMI-1640 medium, L-glutamine, GlutaMAX, penicillin and streptomycin, Dulbecco’s
phosphate buffered saline (D-PBS), YO-PRO-1 iodide, RNAlater, TRIzol reagent,
BlueJuice Gel Loading Buffer, mouse GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) primer, TaqMan Universal Master Mix II, Taqman primer/probes for
qPCR and carboxyfluorescein succinimidyl ester (CFSE) were from Thermo Fisher
Scientific (Waltham, USA). Agarose, adenosine-5’-triphosphate (ATP), neutral buffered
(10%) formalin, citrate solution (4% w/v), collagenase type 1, DNase type 1, ethanol,
cyclophosphamide monohydrate and hydrochloric acid (HCl) were from Sigma-Aldrich
(St Louis, USA). Mango Taq DNA polymerase and MangoTaq colourless reaction buffer,
TRIsure reagent and Hyperladder I molecular weight markers were from Bioline
(London, UK). Primers for amplifying and sequencing human P2RX7 and ENTPD1
genes, 100 base pair DNA ladder, 100 mM deoxyribonucleotide triphosphate (dNTP) mix
and ExoSAP-IT enzyme were from Invitrogen (Carlsbad, USA). qScript cDNA supermix
and GelRed agarose staining dye were from Gene Target Solutions (Gaithersburg, USA).
Foetal bovine serum (FBS) was from Bovogen Biologicals (Keilor East, Australia) and
heat-inactivated (56 °C for 30 mn) before use. Sodium chloride (NaCl), potassium
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chloride

(KCl),

D-glucose,

4-(2-hydroxyethyl)-1-piperazineethanesulfonic

acid

(HEPES), calcium chloride, bovine serum albumin (BSA) and Tween-20 were from
Amresco (Solon, USA). Magnesium chloride (MgCl2) and magnesium sulphate (MgSO4)
were from Chem-Supply (Gillman, Australia). Hematoxylin, eosin and citrolene were
from POCD scientific (Artarmon, Australia). Ficoll-Paque PLUS was from GE
Healthcare (Uppsala, Sweden). SPHERO rainbow fluorescent particles were from
Spherotech

(Lake

Forest,

piperazinyl)-2H-pyran-4-yl]

USA).
methyl-3

2-(Phenylthio)-N-[[tetrahydro-4-(4-phenyl-1pyridinecarboxamide

(JNJ-47965567),

ammonium chloride (NH4Cl), potassium hydrogen carbonate (KHCO3) and sodium
carbonate (Na2CO3) were from Tocris Bioscience (Bristol, UK). Zombie NIR dye and
precision count beads were from BioLegend (San Diego, USA). Interleukin (IL)-2
(Proleukin) was from Prometheus Therapeutics and Diagnostics (San Diego, USA).
Fluorochrome conjugated monoclonal antibodies were used for flow cytometric analysis
of freshly isolated human peripheral blood mononuclear cells (hPBMCs) and leukocytes
from humanised mice (Table 2.1).
Table 2.1. Fluorochrome conjugated monoclonal antibodies for flow cytometry
Fluorochrome

Allophycocyanin (APC)

Brilliant Violet 421 (BV421)

Brilliant Violet 711 (BV711)

R-Phycoerythrin (PE)

Phycoerythrin-cyanine 7 (PE-Cy7)

Target

Clone

Human (h) CD3

UCHT1

hCD45

H130

hCD38

HIT2

hCD19

HIB19

hCD127

HL-7R-M21

hCD197 (CCR7)

HBF-719

hCD14

MΦPg

hCD3

UCHT1

hCD4

RPA-T4

hCD45RA

HI100

hCD25

M-A251

hCD8

RPA-T8

hCD56

B159
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Peridinin chlorophyll protein-cyanine 5.5
(PerCP-Cy5.5)
Fluorescein isothiocyanate (FITC)

hCD3

SK7

hCD4

SK3

hCD16

3G8

Mouse (m) CD45

30-F11

hFoxP3

PCH101

All monoclonal antibodies were from Becton Dickinson (BD) Bioscience (San Jose,
USA) except hFoxP3 (eBioscience, San Diego, USA)
All monoclonal antibodies were mouse except mCD45 (rat)
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2.2

Mice

All mouse experiments were approved by the University of Wollongong Animal Ethics
Committee (protocol numbers AE16/03 and AE16/23; Wollongong, Australia). Female
NOD-SCID-IL-2Rγnull (NSG) mice (aged 6-8 weeks) were obtained from Australian
BioResources (Moss Vale, Australia) and housed in individually ventilated cages
(Techniplast; Buggugiate, Italy). Mice were exposed to a 12h light/12h dark cycle and
provided with autoclaved food and water, ad libitum. Mice were acclimatised for at least
one week prior to use.
2.3

DNA sequencing

2.3.1

Isolation of human genomic DNA

Experiments using human blood were approved by the University of Wollongong Human
Ethics Committee (protocol number HE12/210; Wollongong, Australia) with the
informed, written consent of donors. Genomic DNA was isolated from donor peripheral
blood, collected by venepuncture into VACUETTE lithium heparin tubes (Greiner BioOne; Frickenhausen, Germany), using a Wizard® Genomic DNA Isolation Kit (Promega;
Madison, USA) as per the manufacturer’s instructions and stored at -20°C.
2.3.2

DNA amplification

All 13 exons of the human P2RX7 gene and part of intron 1 of the human ENTPD1 gene
were amplified and sequenced from donor genomic DNA by PCR. Amplification was
performed in a total volume of 20 µL using donor genomic DNA, 5 X MangoTaq
colourless reaction buffer, 1 X dNTP mix, 50 mM MgCl2, 5 mM of respective forward
and reverse primers, Mango Taq DNA polymerase (5 units.μL-1) and sterile H2O. Sterile
H2O was used as the negative control for all PCRs.

65

PCR for exons 1-13 of the human P2RX7 gene was performed in 23 healthy human donors
using 12 primer pairs (Table 2.2) (Gu et al., 2015). PCR consisted of an initial
denaturation step of 94°C for 1 min followed by 35 cycles of denaturation at 94°C for 30
s, annealing at 60°C (for P2RX7 exons 1, 2 and exons 4-13) or 55°C (for P2RX7 exon 3)
for 30 s, and extension at 72°C for 1 min, before a final extension for 5 min at 72°C.
Table 2.2 Forward and reverse primer sequences for exons 1-13 of the human P2RX7 gene with
expected product sizes.
Exon

Forward Primer (5’ to 3’)1

Reverse Primer (5’ to 3’)1

1
TCAGAATGTGCACCTGAAGC
CCAGTACGTTTCATTTTGCAG
2
GGCTGTAGATCCTAGGGGAAG
AGTCACACGGAAGCAAGTCA
3
GTCCGCATTTCTGCTTCTTC
CCCAGCAAGCTGGATTATTA
4
TGACCTGGGCATCACAAAT
GTGTGCACATTCTGGTGGAT
5
TAGGACCCAGGACTTTGCAG
CGGGTTGAGTTAATGATGTCC
6
TTCAGGCTTCTGAGGTTTGG
AGAAGCCTCTGGTCCCACTG
7
GCCTCTTGGCTGTTTGACAT
TGGAACCTCTCCACCACACT
8
GTTGCCTTGGAAACCAAAAT
CTATGCAGGGAGATGTCTGG
9
GCCCCACAGCAGTAATTAGG
GCTGCAGTGAGTGGTAATCCT
10-11
TAGAACCCAGCGACGTATCC
CCAACAATTGCACGTTGAAG
12
GGGGCATAAAAGGGACTCCT
TGAGCCAGCTTGTTCAATAGTC
13
CAGACGTGAGCCACGGTGC
GAACCTAGAACCTGAGGGCT
1
Primer sequences were obtained from Gu et al. (2015).

Product Size
(base pairs)
315
379
230
241
299
239
300
300
279
499
399
579

Amplification of intron 1 of the ENTPD1 gene was performed in 15 healthy human
donors using one primer pair (forward: 5’-GTAGAGGGAGGAAATAG-3’; reverse: 5’TGGCTACTCATGCTAT-3’) and touchdown PCR as described by Rissiek et al. (2015).
Touchdown PCR consisted of an initial denaturation step of 95°C for 1 min, followed by
10 touchdown cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s (lowered
by 1 °C per cycle) and extension at 72°C for 1 min. This was followed by 25 stable cycles
of denaturation at 95°C for 30 s, annealing at 50°C for 30 s and extension at 72 °C for 1
min. Amplification was performed using a GeneAmp PCR System 9700 (Applied Bio
Systems; Carlsbad, USA).
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2.3.3

Agarose gel electrophoresis

DNA amplicons were confirmed on a 1.5 % v/v Tris acetate EDTA (TAE) (20 mM acetic
acid, 1 mM EDTA, 40 mM Tris, pH 8) agarose gel with GelRed using a PowerPac 3000
(Bio-Rad Laboratories; Hercules, USA). Gels were visualized under UV light using a
UVP Imaging System (John Morris Scientific; Sydney, Australia) and Safe-Image
Transluminator (Life Technologies; Carlsbad, USA).
2.3.4

Sequencing

DNA amplicons were purified using ExoSAP-IT enzyme in a total volume of 7 µL
followed by incubation at 37°C for 15 min and the 80°C for 15 min. Purified amplicons
were sequenced with the respective forward primer and the ABI PRISM BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). PCR cycling conditions
for sequencing were 95°C for 2 min followed by 25 cycles of 96°C for 30 s, 55°C for 15
s and 60°C for 4 min. Sequences were acquired on an Applied Biosystems 2130xl Genetic
Analyzer by Margaret Phillips (University of Wollongong). For two donors, amplicons
for exons 1-12 of the human P2RX7 gene were purified using the QIAquick® Purification
Kit (Qiagen; Venlo, Netherlands) as per the manufacturer’s instruction and sequenced
using the above primers (Table 2.2) by the Australian Genome Research Facility (AGRF)
(Melbourne, Australia). Exon 13 of the human P2RX7 gene for all donors was sequenced
by the AGRF using amplicons excised from TAE agarose gels using a QIAquick ® Gel
Extraction Kit (Qiagen) as per the manufacturer’s instructions. For five donors, amplicons
for intron 1 of the ENTPD1 gene were sequenced by the AGRF. Sequences were analysed
using Chromas Pro software (Technelysium; Brisbane, Australia) by comparing to the
NCBI wild type reference sequence for the human P2RX7 gene (NG_011471.2), or the
human ENTPD1 gene (NG0_42803.1). The presence of detected SNPs was confirmed by
sequencing as above but using the reverse primer.
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2.4

Isolation of human peripheral blood mononuclear cells

Human peripheral blood mononuclear (hPBMCs) were isolated from the peripheral blood
of healthy human donors. Blood was diluted in an equal volume of sterile D-PBS,
underlayed with Ficoll-Paque PLUS and centrifuged (560 x g for 30 min, brake
disengaged). hPBMCs were isolated from the Ficoll-Paque/plasma interface and washed
twice in two volumes of D-PBS (440 x g for 10 min, followed by 300 x g for 10 min),
resuspended in D-PBS at twice the original volume of blood and counted using an
improved bright line haemocytometer (Boeco Neubauer; Hamburg, Germany) and a
Leica (Wetzlar, Germany) DM750 inverted light microscope.
2.5

ATP-induced YO-PRO-12+ uptake assay

P2X7 activity on human leukocyte subsets was quantified using an ATP-induced
YO-PRO-12+ uptake assay, adapted from Spildrejorde et al. (2014), on freshly isolated
hPBMCs. Cells were resuspended at 1 x 106 cells.mL-1 in NaCl medium (145 mM NaCl,
5 mM KCl, 5 mM glucose and 10 mM HEPES, pH 7.5) and pre-incubated at 37°C for 5
min before incubation with 1 μM YO-PRO-1 iodide in the absence or presence of 1 mM
ATP for 5 min. YO-PRO-12+ uptake was stopped with 1 mL ice-cold NaCl medium
containing 20 mM MgCl2 and centrifugation (300 x g for 3 min). Cells were washed in
PBS (300 x g for 3 min), incubated with fluorochrome-conjugated mAb (as indicated) at
RT for 15 min and washed in PBS (300 x g for 3 min). In some experiments, hPBMCs
were incubated in the absence or presence of 60 μM JNJ-47965567 at 37°C for 15 min
prior to the addition of YO-PRO-12+. Data was collected using SPHERO™ rainbow
fluorescent particles and a BD Bioscience LSR Fortessa X-20 flow cytometer (using the
band pass filters 450/50 for BV421, 710/50 for BV711, 515/20 for YO-PRO-12+, 586/15
for PE, 780/60 for PE-Cy7, 670/30 for APC and 695/40 for PerCP) and BD Biosciences
FACSDiva software v8.0. Geometric mean fluorescence intensity of YO-PRO-12+ uptake
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was analysed with FlowJo software v8.7.1 (TreeStar Inc.; Ashland, USA). ATP-induced
YO-PRO-12+ uptake (P2X7 activity) was determined as the difference in YO-PRO-12+ in
the presence and absence of ATP from duplicate samples. P2X7 activity was determined
prior to P2RX7 genotyping.
2.6

Humanised mouse model of GVHD

NSG mice were weighed on day 0 (starting weight) and injected (i.p) with either 10 x 106
or 20 x 106 freshly isolated hPBMCs from one donor that same day (King et al., 2008).
In some models, mice were subsequently injected i.p. with 33 mg.kg-1 cyclophosphamide
(or saline) on days 3 and 4 post hPBMC injection. In other models, mice were injected
i.p. with 33 mg.kg-1 cyclophosphamide (or saline) on days 3 and 4 post hPBMC injection
as well as 0.3 mega international units (MIU) of Proleukin (or saline) from day 0 – 4 and
then thrice weekly until endpoint. In experiments requiring multiple donors and treatment
groups, each treatment group contained mice injected from cells of either donor(s) to
minimise the effect of donor differences.
For each mouse model, mice from different experimental groups were caged together.
Mice were assessed for clinical GVHD symptoms, in a blinded fashion, three times per
week for up to 10 weeks post-hPBMC injection using a monitoring system that scored
five criteria (weight loss, hunched posture, decreased activity, fur ruffling and skin
scaling) out of 3 (total score out of 15) (Table 2.3). Mice were checked for
the engraftment of human immune cells at 3 weeks post-hPBMC injection by
immunophenotyping tail blood using flow cytometry (see section 2.6.1).
Mice were euthanised if: they demonstrated a score of 3 in any category (excluding fur
ruffling); exhibited a total score ≥ 10; displayed ≥ 10% weight loss over a 7-day period;
or survived 10 weeks post-injection, as mandated by the approved animal ethics protocol.
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In some experiments, mice were euthanised at 6-days post hPBMC injection.
Immediately following euthanasia mouse blood was collected by cardiac puncture and
serum isolated following incubation at RT for 1 h and centrifugation (1700 x g for 10
min) (Geraghty et al., 2017). Sera was stored at -80°C before cytokine analysis. Samples
of spleens were collected into D-PBS for immunophenotyping by flow cytometry.
Samples of spleen, liver, skin and small intestine were stored in either RNA later (SigmaAldrich) at -20°C for quantitative real-time PCR (qPCR) analysis or fixed overnight in
neutral buffered formalin for histological analysis.
Table 2.3 Clinical scoring criteria for the assessment of GVHD in humanised NSG mice.1
SCORE2
Weight loss 3, 4

1
2
3
5 to 9.9%
10 to 15%
>15%
Hunching noted
Hunching noted at rest
Severe hunching
Normal
Hunched Posture
at rest only
and movement
Mild to
Stationary unless
moderately
Normal
Permanently stationary
Activity
stimulated
decreased
Mild to
Severe ruffling and hair
Areas of hair loss
moderate
Normal
Fur Loss
loss (thinning)
(balding)
ruffling
Scaling of paws
Scaling at additional
Areas of denuded skin
Normal
Skin Integrity
and/or tail
areas
(loss of surface layers)
1
NSG mice, injected i.p. with 10 x 106 hPBMCs, were monitored for GVHD development by scoring for
weight loss, posture, activity, fur loss and skin integrity for up to 10 weeks post-PBMC injection.
2
Mice were euthanised if they scored 3 in any category (excluding fur) or at a total score ≥ 10
3
Weight loss determined as percentage loss from starting weight (weight on Day 0).
4
Acute weight loss determined as >10% weight loss over any 7-day period and assigned a score of 3 for
weight

2.6.1

0
<5%

Immunophenotyping

Immunophenotyping was performed on freshly isolated hPBMCs and cells isolated from
mouse tail blood and spleens. Cells were isolated from mouse tail blood and spleens as
previously described (Geraghty et al., 2017). Briefly, tail blood was collected by tail snip
or tail prick into citrate solution, diluted in D-PBS and centrifuged (300 x g for 5 min).
Mouse spleens were homogenised in D-PBS through a 70 µm nylon filter (Falcon
Biosciences; New York City, USA) and centrifuged (300 x g for 5 min). In some models
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immunophenotyping was also performed on mouse livers, which were processed as
previously described (Alanio et al., 2018, Yu et al., 2016). Briefly, livers were sectioned
and incubated in RPMI-1640 medium supplemented with 1.4 mg.mL-1 collagenase and
0.4 mg.mL-1 DNaseI for 45 min at 37°C. Cell suspensions were mixed with D-PBS and
passed through a 70 µm nylon filter before centrifugation (300 x g for 5 min, RT).
Cells isolated from mouse blood, spleen and liver were incubated in ammonium chloride
potassium lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2CO3, pH 7.3) for 5
min at RT, washed twice in D-PBS containing 2% FBS (300 x g for 5 min) and incubated
with fluorochrome conjugated mAb (as indicated) for 15 min at RT. In some experiments,
cells were incubated with zombie NIR dye for 15 min on ice and washed with PBS
containing 2% FBS (300 x g for 5 min, RT) prior to staining with fluorochrome
conjugated mAb. Cells were washed in PBS (300 x g for 3 min) and data collected using
a BD LSR Fortessa X-20 flow cytometer (using the band pass filters 450/50 for BV421,
710/50 for BV711, 586/15 for PE, 780/60 for Zombie NIR and PE-Cy7, 670/30 for APC
and 695/40 for PerCP) and FACSDiva software v8.0. Cell populations were analysed
using FlowJo software v8.7.1.
2.6.2

RNA isolation and cDNA synthesis

RNA was isolated from mouse tissue stored in RNAlater using TRIzol or TRIsure reagent
as per the manufacturers’ instructions. RNA was immediately converted to
complementary DNA (cDNA) using a qScript cDNA Synthesis Kit (Quanta Biosciences,
Beverly, MA, USA) and diluted 10X in H2O, as per the manufacturer’s instructions. RNA
was stored at -80°C and cDNA was stored at -20°C. cDNA quality was checked by PCR
and amplicons visualised as described in section 2.4.2, using primers to the house keeping
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gene GAPDH (forward primer 5’-TGCACCACCAACTGCTTAGC-3’; reverse primer
5’–GGAAGGCCATGCCAGTGA-3’). Sterile H2O was used as the negative control.
2.6.3

qPCR

qPCR was performed on cDNA in a total volume of 10 µL. qPCR consisted of Taqman
Universal Master Mix II (1 X), fluorescent primer/probes (1 X), cDNA and sterile H2O,
as per the manufacturer’s instructions. Primers/probes for qPCR were FAM-labelled
human IFNG (Hs00989291_m1) primers, human P2X7B (AIOIXC2) primers, human
IL17A (Hs00174383_m1) primers, human FOXP3 (Hs01085834_m1) primers, human
IL17A (Hs00174383_m1), human ENTPD1 (Hs00969556_m1) primers or VIC-labelled
human P2X7B (AIOIXC2) with human HPRT-1 (Hs99999909_m1) fluorescent primers
as a housekeeping gene. qPCR cycles consisted of an initial step of 50°C for 2 min, a
subsequent 50°C step for 10 min, and 50 cycles of 95°C for 15 s, and 60°C for 1 min.
Reactions were conducted in triplicate using a Roche Diagnostics (Indianapolis, USA)
LightCycler 480 with LightCycler480 software v1.5.1 or an Applied Biosystems
Quantstudio 5 real time PCR System (Thermo Fisher Scientific) with Quantstudio Design
and Analysis Software v1.4.3. Gene expression was quantified using the ΔΔCt method
(Livak and Schmittgen, 2001) and calculated relative to the gene expression in cDNA
generated from freshly isolated hPBMCs from one randomly selected individual.
2.6.4

Haematoxylin and eosin staining

Formalin-fixed tissue was processed in a Leica Biosystems tissue processor and
embedded in paraffin for histological analysis. Embedded tissue was sectioned (5 µm)
using a Leica Biosystems RM2255 microtome and stained with hematoxylin and eosin
(Table 2.4). Histological changes were assessed using a Leica DM750 inverted light
microscope at 20X objective and Leica application suite software version 4.7. Infiltrating
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cells in liver tissue sections were quantified using FIJI is Just ImageJ software (Schindelin
et al., 2012).
Table 2.4 Protocol for haemotoxylin and eosin staining of tissue sections
Step
1

Reagent
Citrolene

2

100% Ethanol

3

H2O

4

Haematoxylin

5

H2O

6

Acid alcohol
(1M HCl, 100% ethanol)

7
8

H2O
Scott’s bluing reagent
(45 mM NaHCO3, 166 mM MgSO4)

9
10
11
12

H2O
Eosin
100% Ethanol
Citrolene

Incubation time
2 min 30 s
1 min 40 s
1 min
2 min
2 min
0.01 s*
1 min
1 min
1 min
20 s
1 min 45 s
1 min 10 s

* Tissue sections were dipped once in acid alcohol

2.6.5

Apoptosis staining

Apoptosis staining was performed on paraffin embedded liver tissues (section 2.7.4)
using terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL). Livers
were sectioned (5 µm) using a Leica Biosystems RM2255 microtome and TUNEL
performed using an in situ apoptosis detection kit (Abcam, Melbourne, Australia) to
detect apoptotic cells, as per the manufacturer’s instructions. Tissue sections were
visualised using a Leica DM750 inverted light microscope at 20X objective and Leica
application suite software version 4.7. Apoptotic cells were quantified using FIJI is Just
ImageJ software (Schindelin et al., 2012).
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2.6.6

Cytokine measurements

The concentration of circulating human interferon (IFN)-γ in mouse sera was measured
using an IFNγ Human Uncoated ELISA Kit (Thermo Fisher Scientific) as per the
manufacturer’s instructions, with serum diluted 1:100 in assay buffer. Absorbances (570
nm and 450 nm) were measured using a SpectraMax Plus 384 (Molecular Devices;
Sunnyvale, USA).
In some experiments, the concentrations of hIFNγ, hIL-2, hIL-6, hIL-10 and hTNFα were
measured in mouse sera using a BioLegend LEGENDplex Human Th1 Panel (5-plex) kit
as per the manufacturer’s instructions. In some experiments, hIL-17 was added to the
LEGENDplex panel. Serum was diluted 1:50 in assay buffer. Data was collected using a
BD LSR Fortessa X-20 flow cytometer and FACSDiva software version 8.0 and analysed
using LEGENDplexTM data analysis software version 8.0.
2.7

Statistical analysis

Data is given as mean ± standard error of the mean (SEM). Statistical differences between
means were calculated using a Student’s t-test for single comparisons or a one-way
analysis of variance (ANOVA) with Tukey’s post-hoc test for multiple comparisons.
Comparisons of mouse weight and clinical score over time were completed using a twoway ANOVA. Mouse survival was analysed using a log-rank (Mantel-Cox) test.
Normality was tested using chi-squared tests. Correlations were analysed using
Spearman’s rank correlation coefficient. All statistical analysis and graphs were
generated using GraphPad Prism software version 8.0 (GraphPad Software, La Jolla,
USA). For all analysis, differences were considered significant if P < 0.05.
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Chapter 3:

Altered Donor P2X7 Activity in Human Leukocytes Correlates with

P2RX7 Genotype but does not affect the Development of Graft-Versus-Host Disease
in a Humanised Mouse Model
3.1

Introduction

The purinergic signalling cascade is a key mediator of the inflammatory immune response
and has an emerging role in the development of graft-versus-host disease (GVHD)
through activation of the P2X7 receptor (Castillo-Leon et al., 2018, Wilhelm et al., 2010).
In allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, the
myeloablative regime used to treat the initial haematological malignancy often leads to
inflammatory tissue damage and the release of extracellular adenosine-5’-triphosphate
(ATP). This can result in P2X7 activation on GVHD effector leukocytes and the release
of pro-inflammatory cytokines, such as interferon (IFN)-γ and interleukin (IL)-17, which
promote GVHD progression (Coghill et al., 2011, Wilhelm et al., 2010). P2X7 is
upregulated in mice and humans with GVHD (Wilhelm et al., 2010), and P2X7 blockade
can reduce GVHD severity in allogeneic mouse models (Wilhelm et al., 2010, Fowler et
al., 2014, Zhong et al., 2016). Furthermore, our laboratory has previously shown that
P2X7 blockade can reduce the concentration of serum human (h) IFNγ and reduce liver
inflammation in humanised mice with GVHD (Geraghty et al., 2017, Geraghty et al.,
2019c). This indicates an important role for P2X7 in mouse models of GVHD, but there
are limited studies investigating the role of P2X7 in human GVHD development.
In humans, P2X7 is predominantly expressed on leukocytes, with highest expression on
monocytes followed by natural killer (NK) cells, B cells and T cells (Gu et al., 2000,
Stevenson et al., 2009). Prolonged P2X7 activation on these cells causes the formation of
a pore that allows the flux of organic cations and fluorescent dyes, such as YO-PRO-12+
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iodide, providing a method to reliably quantify P2X7 activity on human immune cells
(Jursik et al., 2007, Korpi-Steiner et al., 2008). P2X7 activity can be influenced by single
nucleotide polymorphisms (SNPs) in the human P2RX7 gene and to date, 16 missense
P2RX7 SNPs have been identified (Fig. 1.5) which cause a gain-of-function (GOF) or
loss-of-function (LOF) effect on human P2X7 (Sluyter, 2017b). Notably, four of these
SNPs originally defined five haplotype variants (denoted P2X7-1 to 5) which give rise to
altered P2X7 activity (Stokes et al., 2010, Fuller et al., 2009) (Table 1.2). Subsequent
analysis of another seven SNPs revealed that these haplotypes can be further segregated
into seventeen haplotypes (H1 to H17) (Jørgensen et al., 2012) (Table 1.2). Whilst the
functional effect of these SNPs have been described in monocyte (Stokes et al., 2010,
Sluyter et al., 2004) and T cell (Cabrini et al., 2005, Di Virgilio et al., 2017, Wiley et al.,
2003) subsets, how P2RX7 genotype influences P2X7 activity on other immune cell
subsets important in GVHD, including Tregs, natural killer (NK) cells and invariant NK
(iNK) T cells, is unclear.
Human P2RX7 SNPs have been associated with chronic inflammatory conditions such as
multiple sclerosis (Gu et al., 2015) and rheumatoid arthritis (Al-Shukaili et al., 2011).
Moreover, P2RX7 SNPs in either donors or recipients are known to influence clinical
outcomes in allo-HSCT patients (Lee et al., 2007a). As a result, donor P2RX7 genotype
may influence the development of GVHD following allo-HSCT, but this has not been
previously investigated. Therefore, this chapter aimed to determine the effect of donor
P2RX7 genotype on P2X7 activity on human leukocyte subsets important in GVHD, and
on the development of GVHD in a preclinical humanised mouse model.
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The data in this chapter formed a research article published in the journal Purinergic
Signalling (Adhikary et al., 2019), with some data obtained previously (Adhikary, 2015)
or by Dr. Nicholas Geraghty (University of Wollongong, Australia), as indicated.
3.2

Results

3.2.1

PCR amplification of the P2RX7 gene in human donors

The human P2RX7 gene gives rise to a number of missense SNPs that influence P2X7
activity on human immune cells. To determine the P2RX7 genotype of human donors,
exons 1-13 of the human P2RX7 gene were amplified from the genomic DNA of 25
healthy human donors by PCR. For nine donors, exons had already been previously
amplified (Adhikary, 2015). Correct sized amplicons (Table 2.2) for exons 1, 2 and 4-13
were obtained at an annealing temperature of 60°C. The correct sized amplicon for exon
3 was obtained using an annealing temperature of 55°C.
3.2.2

P2RX7 genotype varies between donors

Following amplification, all P2RX7 exons were sequenced in 25 donors. Sequences for
nine donors were previously assessed (Adhikary, 2015). From the 25 human donors
sequenced, seven different missense P2RX7 SNPs were identified. Donors were assigned
to P2RX7 genotypes and haplotypes, as described by Stokes et al. (2010) (P2X7-1 to 5)
and Jørgensen et al. (2012) (H1 to H17), based on their SNPs (Table 3.1). Donor P2X7
activity was predicted based on haplotypes described by Jørgensen et al. (2012). P2RX7
haplotype varied between donors and all five haplotypes described by Stokes et al. (2010)
were identified. In relation to haplotypes H1 to H17, four donors were homozygous for
H8 and another three homozygous for H14. Exact haplotypes could be assigned to 22 of
the 25 donors, but not for the remaining three donors (Table 3.1). Donors with one wildtype allele were defined as GOF or LOF based on their mutant allele. Although some
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donors possessed both GOF and LOF SNPs, such as R270H and H155Y SNPs, no donors
demonstrated mixed GOF or LOF haplotypes. Nineteen donors were predicted to have
GOF P2X7 activity and six predicted to have LOF P2X7 activity (Table 3.1).
Table 3.1 P2RX7 genotype and predicted P2X7 activity of healthy human donors. Genomic DNA
was isolated from peripheral blood of 25 human donors.
P2RX7 Genotype1
Donor2 H155Y

R270H

R307Q

A348T

T357S

Q460R

E496A

Haplotype

rs208294 rs7958311 rs28360457 rs1718119 rs2230911 rs2230912 rs3751143 (P2X7-1 to 5)
GOF
Y/Y
Y/Y
WT
WT
WT
WT
H/Y
Y/Y
WT
WT
H/Y
Y/Y
Y/Y
Y/Y
Y/Y
WT
Y/Y
WT
Y/Y
Y/Y
WT
Y/Y
WT
WT
WT

LOF
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT

LOF
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT

GOF
T/T
T/T
A/T
T/T
T/T
A/T
A/T
T/T
T/T
T/T
A/T
T/T
T/T
A/T

LOF
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT

Neutral
R/R
WT
WT
WT
WT
WT
WT
R/R
WT
Q/R
WT
WT
R/R
WT

LOF
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT
WT

P2X7-4/4
P2X7-2/2
P2X7-1/2
P2X7-2/2
P2X7-2/2
P2X7-1/2
P2X7-1/2
P2X7-4/4
P2X7-2/2
P2X7-2/4
P2X7-1/2
P2X7-2/2
P2X7-4/4
P2X7-1/2

Haplotype

Predicte

(H1to H17)

activity3

H14/H14
H10/H10
H2/H8
H8/H8
H8/H8
H2/H8
H2/H5/H8/H10
H14/H14
H8/H8
H8/H15
H2/H8/H5/H10
H10/H10
H14/H14
H5/H10

GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF
GOF

WT
WT
WT
WT
WT
P2X7-1/2
H5/H10
A/T
WT
WT
WT
WT
WT
P2X7-1/2
H8/H8
T/T
WT
WT
WT
WT
P2X7-2/4
H10/H14
T/T
Q/R
WT
WT
WT
WT
WT
P2X7-1/2
H2/H8
A/T
WT
WT
WT
WT
WT
P2X7-2/2
H10/H10
T/T
WT
WT
WT
WT
P2X7-1/3
H3/H5/H11
R/H
E/A
WT
WT
WT
WT
WT
P2X7-1/5
H2/H16
T/S
WT
WT
WT
WT
WT
P2X7-1/3
H5/H11
E/A
WT
WT
WT
WT
P2X7-1/1
H1/H7
H/H
R/Q
WT
WT
WT
WT
WT
P2X7-1/3
H2/H12
E/A
WT
WT
WT
WT
WT
P2X7-1/3
H2/H12
E/A
1
Donor P2RX7 genotype was determined by sequencing the 13 exons in the human P2RX7 gene using
exon specific primers. Donors were classed into P2RX7 haplotypes based on the presence or absence of
different P2RX7 SNPs according to Stokes et al. (2010) (P2X7-1 to 5) and Jørgensen et al. (2010) (H1H17).
2
Symbols represent individual donors in Figures 3.1-3.6
3
Predicted activity based on the presence of P2RX7 SNPs in each donor
GOF; Gain-of-function, LOF; Loss-of-function
Colours represent P2X7 activity: Green; GOF, Red; LOF
All donors were wild type for unlisted missense P2RX7 SNPs
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GOF
GOF
GOF
GOF
GOF
LOF
LOF
LOF
LOF
LOF
LOF

3.2.3

Donor P2RX7 genotype correlates with P2X7 activity on human T cell subsets

Functional P2X7 has been previously found on human CD3+ T cells (Gu et al., 2000),
CD4+ and CD8+ T cells (Sluyter and Wiley, 2014a), however there are limited studies
investigating P2X7 activity on human Tregs (Schenk et al., 2011), which have protective
roles in GVHD (Di Ianni et al., 2011). Furthermore, the impact of various P2RX7
genotypes on P2X7 activity on these T cell subsets in humans is lacking. Therefore, P2X7
activity was determined in the above donors by flow cytometric measurements of ATPinduced YO-PRO-12+ uptake (Spildrejorde et al., 2014) in CD3+ T cells, CD3+CD4+ and
CD3+CD8+ T cells and CD3+CD4+CD25+CD127lo Tregs (Fazekas de St Groth et al.,
2011) using a defined gating strategy (Fig. 3.1a-f). P2X7 activity was similar between all
T cell subsets in each donor (P > 0.05) (Fig. 3.1g). Moreover, donor P2RX7 genotype
correlated with P2X7 activity in each T cell subset investigated as ATP-induced YOPRO-12+ uptake in GOF donors was significantly greater than in corresponding LOF
donors in each subset (P < 0.001) (Fig. 3.1g).
To determine if YO-PRO-12+ uptake on these cells was mediated by P2X7, hPBMCs from
three randomly selected genotyped donors were incubated with the P2X7 specific
antagonist JNJ-47965567 (Bhattacharya et al., 2013) (Fig. 3.1h). P2X7 blockade with
JNJ-47965567 caused a significant reduction in ATP-induced YO-PRO-12+ uptake in
CD3+ T cells (98.7% inhibition), CD3+CD4+ T cells (99.4% inhibition), CD3+CD8+ T
cells (98.4% inhibition) and CD3+CD4+CD25+CD127lo Tregs (94.69% inhibition) (P <
0.0001 for all T cell subsets) (Fig. 3.1h).
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Figure 3.1 Donor P2X7 activity correlates with P2RX7 genotype on human T cell subsets. hPBMCs,
from donors of either GOF or LOF P2RX7 genotype were resuspended in NaCl medium and incubated with
1 µM YO-PRO-12+ in the absence or presence of 1 mM ATP for 5 minutes at 37°C. YO-PRO-12+ uptake
into human T cell subsets was analysed by flow cytometry using (a-f) a consistent gating strategy. (a) Single
cells were gated by forward scatter area (FSC-A) and height (FSC-H). (b) Lymphocytes were gated using
FSC-A and side scatter (SSC-A) which were then used to identify (c) CD3+ T cells, (d) CD3+CD4+ and
CD3+CD8+ T cells and (e) CD3+CD4+CD25+CD127lo Tregs. (f) P2X7 activity was determined by
comparing YO-PRO-12+ uptake in the absence (blue histograms) and presence (orange histogram) of ATP.
Representative histogram for CD3+ T cells from one donor is shown. (g) P2X7 activity in CD3+, CD3+CD4+
and CD3+CD8+ T cells and Tregs was determined in multiple donors. (h) hPBMCs from three donors were
pre-incubated with 60 µM JNJ-47965567 (JNJ) at 37°C for 15 min to block P2X7 before incubation in the
absence or presence of 1 mM ATP. Symbols correlate to Table 3.1 and represent (g) mean values of
duplicate ATP-induced YO-PRO-12+ uptake measurements into CD3+, CD3+CD4+, CD3+CD8+ (GOF, n =
19; LOF, n = 6 for all) and Tregs (GOF, n = 11; LOF, n = 3); *** P < 0.001 compared to corresponding
LOF donors. (h) Data represents group means ± SEM (n = 3), **** P < 0.0001 compared to hPBMCs
incubated with ATP+JNJ.
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3.2.4

Donor P2RX7 genotype correlates with P2X7 activity on human iNKT cells

Low numbers of iNKT cells are associated with worsened GVHD in human allo-HSCT
patients (Crough et al., 2004, Haraguchi et al., 2004). Moreover, functional P2X7 has not
been identified on human iNKT cells. Therefore, in the current study P2X7 activity was
quantified on donor CD3+CD19-Vα24-Jα18+ iNKT cells (Exley et al., 2017) using flow
cytometry with a defined gating strategy (Fig. 3.2a-e) and compared to the P2X7 activity
in CD3+ T cells.All uptake experiments were performed by Dr. Nicholas Geraghty. Donor
P2RX7 genotype correlated with P2X7 activity on iNKT cells as GOF donors showed
significantly higher ATP-induced YO-PRO-12+ uptake than LOF donors (P < 0.05) (Fig.
3.2f). Notably, P2X7 activity on iNKT cells was significantly higher than on CD3+ T cells
in each corresponding donor analysed, regardless of P2RX7 genotype (P < 0.01 for all)
(Fig. 3.2f).
3.2.5

Donor P2RX7 genotype correlates with P2X7 activity on human NK cell

subsets
NK cells can either protect against (Ruggeri et al., 2002) or exacerbate (Xun et al., 1993)
GVHD following allo-HSCT. Furthermore, the impact of donor P2RX7 genotype on
P2X7 activity on human NK cell subsets has not been previously investigated. In the
current study P2X7 activity was measured on donor CD3-CD56+CD16-, CD3-CD56CD16+ and CD3-CD56+CD16+ NK cell subsets (Stabile et al., 2017) using flow cytometry
with a defined gating strategy (Fig. 3.3a-e). All NK cell subsets demonstrated comparable
P2X7 activity in each donor (P > 0.05 for all) (Fig. 3.3f). P2X7 activity also correlated
with donor P2RX7 genotype in all NK cell subsets, with GOF donors demonstrating
significantly higher ATP-induced YO-PRO-12+ uptake than corresponding NK cell
subsets from LOF donors (P < 0.001 for all) (Fig. 3.3f).
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Figure 3.2 Donor P2X7 activity correlates with P2RX7 genotype on human iNKT cells. hPBMCs from
donors of either GOF or LOF P2RX7 genotype were resuspended in NaCl medium and incubated with 1
µM YO-PRO-12+ in the absence or presence of 1 mM ATP for 5 minutes at 37°C. YO-PRO-12+ uptake into
human iNKT cells was analysed by flow cytometry using a (a-e) consistent gating strategy. (a) Single cells
were gated by forward scatter area (FSC-A) and height (FSC-H). (b) Lymphocytes were gated using FSCA and side scatter (SSC-A) which were then used to identify (c) CD3+CD19- cells to subsequently identify
(d) CD3+Vα24-Jα18+ iNKT cells. (e) P2X7 activity was determined by comparing YO-PRO-12+ uptake in
the absence (blue histograms) and presence (orange histogram) of ATP. Representative histogram from
one donor is shown. (f) P2X7 activity in iNKT cells and corresponding CD3+ T cells (Fig. 3.3) was
determined in multiple donors (GOF, n = 5; LOF, n = 3). Lines represent mean ± SEM. Symbols correlate
to Table 3.1 and represent mean values of duplicate ATP-induced YO-PRO-12+ uptake measurements into
iNKT cells; * P < 0.05 compared to corresponding LOF T cells, †† P < 0.01, ††† P < 0.001 compared to
corresponding CD3+ T cells compared to corresponding LOF donors.

3.2.6

Donor P2RX7 genotype correlates with P2X7 activity on human monocyte

subsets
P2X7 is highly expressed on human monocytes (Gu et al., 2000); however the impact of
various P2RX7 genotypes on P2X7 activity on human monocyte subsets has not been
thoroughly investigated. In the current study, P2X7 activity was measured on donor
classical (CD14+CD16-), non-classical (CD14-CD16+) and intermediate (CD14+CD16+)
monocytes (Passlick et al., 1989) using a defined gating strategy (Fig. 3.4a-d). In each
donor, all monocyte subsets demonstrated similar P2X7 activity (P > 0.05 for all). P2X7
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activity also correlated to donor P2RX7 genotype, with GOF donors demonstrating
significantly greater ATP-induced YO-PRO-12+ uptake than corresponding monocyte
subsets from LOF donors (P <0.0001) (Fig. 3.4e).

Figure 3.3 Donor P2X7 activity correlates with P2RX7 genotype on human NK cell subsets. hPBMCs
from donors of either GOF or LOF P2RX7 genotype were resuspended in NaCl medium and
incubated with 1 µM YO-PRO-12+ in the absence or presence of 1 mM ATP for 5 minutes at 37°C.
YO-PRO-12+ uptake into human NK cell subsets was analysed by flow cytometry using a (a-e) consistent
gating strategy. (a) Single cells were gated by forward scatter area (FSC-A) and height (FSC-H). (b)
Lymphocytes were gated using FSC-A and side scatter (SSC-A) which were then used to identify (c) CD3cells and (d) CD16+CD56-, CD16+CD56+ or CD16-CD56+ NK cell subsets. (e) P2X7 activity was
determined by comparing YO-PRO-12+ uptake in the absence (blue histograms) and presence (orange
histogram) of ATP. Representative histogram for CD16-CD56+ NK cells from one donor is shown. (f) P2X7
activity in NK cell subsets was determined in multiple donors (GOF, n = 7; LOF, n = 3). Lines represent
mean ± SEM. Symbols correlate to Table 3.1 and represent mean values of duplicate ATP-induced YOPRO-12+ uptake measurements into NK cell subsets; *** P < 0.001 compared to corresponding LOF donors.
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Figure 3.4 Donor P2X7 activity correlates with P2RX7 genotype on human monocyte subsets.
hPBMCs, from donors of either GOF or LOF P2RX7 genotype, in NaCl medium were incubated with 1
µM YO-PRO-12+ in the absence or presence of 1 mM ATP for 5 minutes at 37°C. YO-PRO-12+ uptake into
human monocyte subsets was analysed by flow cytometry using a (a-d) consistent gating strategy. (a)
Single cells were gated by forward scatter area (FSC-A) and height (FSC-H) and (b) monocytes gated using
FSC-A and side scatter (SSC-A). (c) CD14+CD16-, CD14+CD16+ or CD14-CD16+ monocyte subsets were
then identified within the monocyte population (indicated by arrow). (d) P2X7 activity on monocyte subsets
was determined by comparing YO-PRO-12+ uptake in the absence (blue histograms) and presence (orange
histogram) of ATP. Representative histograms for CD14+CD16- monocytes from one donor is shown. (e)
P2X7 activity in monocyte subsets was determined in multiple donors (GOF, n = 7; LOF, n = 3). Lines
represent mean ± SEM. Symbols correlate to Table 3.1 and represent mean values of duplicate ATP-induced
YO-PRO-12+ uptake tests from different donors (GOF, n = 7; LOF, n = 3); *** P < 0.001 compared to
corresponding LOF donors.

3.2.7

Donor P2RX7 genotype does not influence human T cell engraftment in the

blood of NSG mice at 3 weeks post-hPBMC injection
The injection of hPBMCs into NSG mice is a well-established preclinical humanised
mouse model of GVHD (King et al., 2009, Geraghty et al., 2017). To determine the effect
of human donor P2RX7 genotype on the development of GVHD, NSG mice were injected
with hPBMCs, isolated from donors of either GOF (hP2X7GOF mice) or LOF (hP2X7LOF
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mice) P2RX7 genotype (n = 4 donors per genotype) (Table 3.2), and monitored for signs
of clinical GVHD (Table 2.3) for up to 10 weeks (Fig. 3.5).
Table 3.2 P2RX7 genotype and P2X7 activity of paired human donors for a humanised mouse model
of GVHD.1
P2RX7 Genotype
H155Y
1

Donor

Study 2
Study 3
Study 4

R307Q

A348T

T357S

Q460R

E496A

Haplotype

rs208294 rs7958311 rs28360457 rs1718119 rs2230911 rs2230912 rs3751143 (P2X7-1 to
GOF

Study 1

R270H
LOF

LOF

GOF

LOF

Neutral

LOF

5)

Haplotype

P2X7

(H1to H17)

activity3

Y/Y

WT

WT

T/T

WT

R/R

WT

P2X7-4/4

H14/H14

GOF

WT

H/H

R/Q

WT

WT

WT

WT

P2X7-1/1

H1/H7

LOF

WT

WT

WT

T/T

WT

WT

WT

P2X7-2/2

H8/H8

GOF

Y/Y

WT

WT

WT

WT

WT

E/A

P2X7-1/3

H5/H11

LOF

Y/Y

WT

WT

T/T

WT

WT

WT

P2X7-2/2

H10/H10

GOF

WT

WT

WT

WT

WT

WT

E/A

P2X7-1/3

H2/H12

LOF

H/Y

WT

WT

A/T

WT

WT

WT

P2X7-1/2

H2/H8/H5/H10

GOF

WT

WT

WT

WT

WT

WT

E/A

P2X7-1/3

H2/H12

LOF

1

Each human donor pair, with opposing P2RX7 genotypes, were matched for age and sex. Donor P2RX7
genotype was sequenced from genomic DNA by sequencing 13 exons in the human P2RX7 gene. Donors
were classed into P2RX7 haplotypes based on the presence or absence of different P2RX7 SNPs according
to Stokes et al. (2010) (P2X7-1 to 5) and Jørgensen et al. (2012) (H1-H17). GOF or LOF of P2X7 activity
in CD3+, CD4+ and CD8+ T cells was confirmed by flow cytometric measurements of ATP-induced YOPRO-12+ uptake prior to mouse studies.
2
Symbols represent individual donors in Table 3.1
3
P2X7 activity was confirmed in T cells by flow cytometry of ATP-induced YO-PRO-12+ uptake
GOF; Gain-of-function, LOF; Loss-of-function
Colours represent P2X7 activity: Green; GOF, Red; LOF
All donors were wildtype for unlisted non-synonymous P2RX7 SNPs

Figure 3.5 Humanised mouse model to investigate the effect of donor P2RX7 genotype on the
development of GVHD. NSG mice were injected (intra-peritoneal) with 10 x 106 hPBMCs isolated from
donors of either GOF (hP2X7GOF mice) or LOF (hP2X7LOF mice) P2RX7 genotype (hP2X7GOF: n = 30
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mice, n = 4 donors; hP2X7LOF: n = 37 mice, n = 4 donors). Mice were monitored for clinical GVHD by
scoring GVHD clinical symptoms (Table 2.3) for up to 10 weeks post-hPBMC injection. Mice were
checked for the engraftment of human cells at 3 weeks post-hPBMC injection by immunophenotyping tail
blood using flow cytometry. At endpoint human cell engraftment was checked by immunophenotyping
mouse spleens using flow cytometry. Histological damage to GVHD target organs (liver, small intestines
and skin) were assessed by haematoxylin and eosin staining of tissue. The relative expression of
inflammatory cytokines in spleens and GVHD target organs were assessed by qPCR. The concentration of
hIFNγ in mouse sera was assessed by ELISA.

Human T cells are the main mediators of GVHD in this humanised mouse model
(Geraghty et al., 2017). Therefore, human T cell engraftment was assessed in mouse tail
blood at 3 weeks post-hPBMC injection by flow cytometry using a consistent gating
strategy (Fig. 3.6a-e). Donor P2RX7 genotype did not influence the engraftment of human
leukocytes in tail blood, with comparable proportions hCD45+ leukocytes in hP2X7GOF
(28.67 ± 2.30% hCD45+mCD45- cells, n = 30) and hP2X7LOF mice (24.49 ± 1.78%
hCD45+ mCD45- cells, n = 37) (P = 0.1495) (Fig. 3.6f).
The majority of hCD45+ leukocytes were hCD3+ T cells in both groups (hP2X7GOF: 92.31
± 0.73% hCD3+hCD19- cells, n = 30; hP2X7LOF: 94.6 ± 0.90% hCD3+ hCD19- cells, n =
37) (P = 0.0776) (Fig. 3.6g). Similar proportions of hCD3+hCD4+ and hCD3+hCD8+ T
cells were observed in hP2X7GOF (40.71 ± 2.14%, n = 30 vs. 43.43 ± 2.20%, n = 30,
respectively) (P = 0.3803) and hP2X7LOF mice (41.36 ± 1.68%, n = 37 vs. 45.83 ± 1.67%,
n = 37, respectively) (P = 0.0625) (Fig. 3.6h). Furthermore, both groups demonstrated
similar percentages of hCD3+hCD4+ (P = 0.8102) and hCD3+hCD8+ (P = 0.3792) T cells.
This resulted in comparable hCD4+:hCD8+ T cell ratios (hP2X7GOF: 1.06 ± 0.10, n = 30;
hP2X7LOF: 0.91 ± 0.90, n = 37), (P = 0.7801) (Fig. 3.6i).
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Figure 3.6 Donor P2RX7 genotype does not influence the engraftment of human T cell subsets in
NSG mice at 3 weeks post-hPBMC injection. hP2X7GOF and hP2X7LOF mice were checked for the
engraftment of human T cell subsets at 3 weeks post-hPBMC injection by immunophenotyping tail blood
using flow cytometry with (a-e) a consistent gating strategy. (a) Single cells were gated by forward scatter
area (FSC-A) and height (FSC-H), and (b) lymphocytes gated within this population using FSC-A and side
scatter (SSC-A). (c) hCD45+mCD45- leukocytes were gated and (d) hCD45+hCD3+ T cells, (e) CD3+CD4+
and CD3+CD8+ T cells were identified. (f) hCD45+ leukocytes are expressed as a percentage of total
mCD45+ and hCD45+ leukocytes. (g) hCD3+ T cells are expressed as a percentage of total hCD45+
leukocytes. (h) hCD4+ and hCD8+ T cells are expressed as a percentage of hCD3+ cells. (i) hCD4+:hCD8+
T cell ratios were calculated. (f-i) Lines represent group mean ± SEM (hP2X7GOF: n = 30 mice; hP2X7LOF:
n = 37 mice); symbols represent individual mice.
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3.2.8

Donor P2RX7 genotype does not influence human T cell engraftment in the

spleen of NSG mice at endpoint
Human T cell engraftment was also assessed at endpoint in mouse spleens using flow
cytometry with a consistent gating strategy (Fig. 3.7a-f). Splenic hCD45+ leukocyte
engraftment was similar in hP2X7GOF (69.73 ± 2.59%, hCD45+mCD45- cells, n = 30) and
hP2X7LOF mice (71.36 ± 2.51%, hCD45+ mCD45- cells, n = 37) (P = 0.6550) (Fig. 3.7g).
hCD3+ T cells constituted the bulk of the splenic leukocyte population in both groups.
(hP2X7GOF: 83.32 ± 2.22% hCD3+hCD19- cells, n = 30; hP2X7LOF 82.82 ± 1.97% hCD3+
hCD19- cells, n = 37) (P = 0.8654) (Fig. 3.7h).
Splenic hCD3+hCD4+ and hCD3+hCD8+ T cells were observed at endpoint, with
significantly higher frequencies of hCD3+hCD4+ T cells than hCD3+hCD8+ T cells in
both hP2X7GOF (62.77 ± 3.35% vs 28.47 ± 2.33%, respectively, n = 30) (P < 0.0001) and
hP2X7LOF mice (64.98 ± 2.76% vs. 28.93 ± 2.22%, respectively, n = 37) (P < 0.0001)
(Fig. 3.7i). However, the proportions of splenic hCD3+hCD4+ and hCD3+hCD8+ T cells
were similar between hP2X7GOF and hP2X7LOF mice (hCD3+hCD4+ T cells, P = 0.6093;
hCD3+hCD8+ T cells, P = 0.8894), leading to similar hCD4+:hCD8+ T cell ratios
(hP2X7GOF: 2.21± 0.80, n = 30; hP2X7LOF: 2.98 ± 0.76, n = 37) (P = 0.6513) (Fig. 3.7j).
Finally, both hP2X7GOF and hP2X7LOF mice displayed similar proportions of
hCD3+hCD4+hCD25+hCD127lo Tregs (1.68 ± 0.27%, n = 30 vs. 1.40 ± 0.16%, n = 37,
respectively) (P = 0.3490) (Fig. 3.7k).
3.2.9

Donor P2RX7 genotype does not affect the engraftment of human NK cells in

NSG mice at endpoint
Small proportions of human NK cells, identified as hCD3-hCD19-hCD16-hCD56+ cells,
were present in NSG mouse spleens at endpoint using flow cytometry with a consistent
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Figure 3.7 Donor P2RX7 genotype does not influence the engraftment of human T cell subsets in NSG
mice at endpoint. hP2X7GOF and hP2X7LOF mice were checked for the engraftment of human T cell subsets
at endpoint by immunophenotyping spleens using flow cytometry with (a-e) a consistent gating strategy.
(a) Single cells were gated by forward scatter area (FSC-A) and height (FSC-H), and (b) lymphocytes gated
within this population using FSC-A and side scatter (SSC-A). (c) hCD45+mCD45- leukocytes were
identified and (d) hCD3+ T cells were gated and (e) hCD3+hCD4+ and hCD3+hCD8+ T cells and (f)
hCD3+hCD4+hCD25+hCD127lo (hCD4+)Tregs were then identified. (g) hCD45+ leukocytes are expressed
as a percentage of total mCD45+ and hCD45+ leukocytes. (h) hCD3+ T cells are expressed as a percentage
of total hCD45+ leukocytes. (i) hCD4+ and hCD8+ T cells are expressed as a percentage of hCD3+ T cells.
(j) hCD4+:hCD8+ T cell ratios were calculated. (k) hCD4+ Tregs are expressed as a percentage of hCD4+ T
cells. (g-k) Lines group mean ± SEM (hP2X7GOF: n = 30 mice; hP2X7LOF: n = 37 mice); symbols represent
individual mice; (j) **** P < 0.0001 compared to hCD8+ T cells.
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gating strategy (Fig. 3.8a-d). Donor P2RX7 genotype did not impact the engraftment of
these cells in hP2X7GOF (1.50 ± 0.12%, n = 30) or hP2X7LOF (1.36 ± 0.13% cells, n = 37)
mice (P = 0.5524) (Fig. 3.8e). Other NK cell subsets (hCD3-hCD19-hCD16+hCD56- and
hCD3-hCD19-hCD16+hCD56+ NK cells) were not identified at endpoint.

Figure 3.8 Donor P2RX7 genotype does not impact the engraftment of human NK cells in humanised
mice at endpoint. hP2X7GOF and hP2X7LOF mice were checked for the engraftment of human T cell subsets
at endpoint by immunophenotyping spleens using flow cytometry with (a-d) a consistent gating strategy.
(a) Single cells were gated by forward scatter area (FSC-A) and height (FSC-H), and (b) lymphocytes gated
within this population using FSC-A and side scatter (SSC-A). (c) hCD3-hCD19- cells were gated and (d)
hCD3-hCD19-hCD16-hCD56+ NK cells were subsequently identified. (e) hCD3-hCD19-hCD16-hCD56+
NK cells are expressed as a percentage of total hCD3-hCD19- cells. Lines represent group mean ± SEM
(hP2X7GOF: n = 30 mice; hP2X7LOF: n = 37 mice); symbols represent individual mice.

3.2.10 GVHD development in humanised NSG mice is not affected by donor P2RX7
genotype
GVHD development in humanised NSG mice was analysed by monitoring weight loss
and scoring clinical GVHD symptoms (Table 2.3) over 10 weeks, as described (Geraghty
et al., 2017). Donor P2RX7 genotype did not affect GVHD development in humanised
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mice (Fig. 3.9a-c). Weight loss was similar between hP2X7GOF and hP2X7LOF mice (P =
0.3398), which was first observed from day 25 in both groups (Fig. 3.9a). Both hP2X7GOF
and hP2X7LOF mice started scoring for clinical symptoms from day 16, with comparable
mean clinical scores over 10 weeks (P = 0.6093) and at end point (7.26 ± 0.35, n = 30 vs.
7.53 ± 0.26, n = 37, respectively) (P = 0.6512) (Fig. 3.9b). Finally, all mice succumbed
to the ethical endpoint (clinical score > 10 or 10 % acute weight loss) by 10 weeks, with
no significant difference in median survival time (MST) between hP2X7GOF (MST, 34
days, n = 30) or hP2X7LOF mice (MST, 36 days, n = 37) (P = 0.8107) (Fig. 3.9c).

Figure 3.9 Donor P2RX7 genotype does not influence the severity of GVHD in a humanised mouse
model. hP2X7GOF and hP2X7LOF mice were monitored for clinical GVHD for 10 weeks post-hPBMC
injection by assessing (a) weight loss, (b) GVHD clinical score and (c) survival. Data represents (a, b)
group means ± SEM or (c) percentage survival (a-c) hP2X7GOF, n = 30; hP2X7LOF, n = 37.
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3.2.11 Damage to GVHD target organs is not influenced by donor P2RX7 genotype
in humanised NSG mice
NSG mice injected with hPBMCs demonstrate histological damage to GVHD target
organs, including the liver, small intestine and skin (Geraghty et al., 2017, King et al.,
2009, Geraghty et al., 2019b). Therefore, in the current study, histological damage to
these tissues was assessed in humanised mice at endpoint (Fig. 3.10a-c). Tissue fibrosis
and leukocyte infiltration was similar in the livers of hP2X7GOF and hP2X7LOF mice (Fig.
3.10a). Both groups also demonstrated comparable leukocyte infiltration in the small
intestine, with similar crypt damage and rounding of villi (Fig. 3.10b). hP2X7GOF and
hP2X7LOF mice also showed signs of skin GVHD with comparable dermal thickening and
epidermal detachment (Fig. 3.10c).

Figure 3.10 Donor P2RX7 genotype does not impact histological damage to GVHD target organs in
humanised mice with GVHD. At endpoint, 5 μm sections of (a) liver, (b) small intestine and (c) skin
tissue from hP2X7GOF (top panel) and hP2X7LOF (bottom panel) were cut and stained with haematoxylin
and eosin and imaged by microscopy. Representative images from four mice per group are shown; bars
represent 100 µm. Red arrows indicate infiltrating leukocytes.

3.2.12 Donor P2RX7 genotype does not alter relative hP2RX7 expression in the
spleen or GVHD target organs in humanised NSG mice
P2X7 expression is increased in human GVHD patients (Wilhelm et al., 2010) and in
humanised mice with GVHD (Cuthbertson et al., 2020). In the current study, qPCR was
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used to measure relative hP2RX7 expression in spleens, livers and small intestines of
humanised mice with GVHD (Fig. 3.11a-c). hP2RX7 expression was expressed in all
organs in humanised mice, however relative hP2RX7 expression was unaffected by donor
P2RX7 genotype in the spleen (hP2X7GOF: 4.87 ± 0.38, n = 18; hP2X7LOF: 4.19 ± 0.33, n
=18) (P = 0.1912) (Fig. 3.11a), liver (hP2X7GOF: 2.16 ± 0.19, n = 18; hP2X7LOF 2.29 ±
0.16, n =18, respectively) (P = 0.6005) (Fig. 3.11b) or small intestine (hP2X7GOF: 17.62
± 0.37, n = 18; hP2X7LOF: 16.77 ± 0.42, n = 18) (P = 0.1444) (Fig. 3.11c).

Figure 3.11 Donor P2RX7 genotype does not influence the relative expression of hP2X7 in spleens
and GVHD target organs in humanised mice with GVHD. RNA was extracted and cDNA synthesized
from the (a) spleen, (b) liver and (c) small intestines of hP2X7GOF and hP2X7LOF mice at endpoint. The
relative expression of hP2RX7 was measured in mouse tissue by qPCR. Lines represent group mean ± SEM
(n = 12-18 per group); symbols represent individual mice.

3.2.13 Relative liver hIFNG expression is increased in humanised NSG mice from a
GOF donor P2RX7 genotype than a LOF donor P2RX7 genotype
IFNγ is a key pro-inflammatory cytokine in GVHD pathogenesis that enhances disease
development (Yi et al., 2009). Therefore, in this chapter, qPCR was used to measure
relative hIFNγ expression the spleen, liver and small intestine (Fig. 3.12a-c). Relative
splenic hIFNγ expression was similar in hP2X7GOF (12.46 ± 0.52, n = 18) and hP2X7LOF
mice (13.11 ± 0.27, n = 18) (P = 0.3363) (Fig. 3.12a). However, hP2X7GOF mice
demonstrated significantly higher (1.3-fold) hepatic hIFNγ expression compared to
hP2X7LOF mice (3.82 ± 0.24, n = 18 vs. 3.12 ± 0.14, n = 18, respectively) (P = 0.0154)
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(Fig. 3.12b). The opposite was observed in the small intestine, with a slight reduction in
relative hIFNγ expression in hP2X7GOF than hP2X7LOF mice (3.66 ± 0.15, n = 18 vs. 3.25
± 0.15, n = 18, respectively), but this was not significant (P = 0.0625) (Fig. 3.12c).

Figure 3.12 GOF donor P2RX7 genotype increases relative hepatic hP2X7 expression in humanised
mice with GVHD. RNA was extracted and cDNA synthesized from the (a) spleen, (b) liver and (c) small
intestines of hP2X7GOF and hP2X7LOF mice at endpoint. The relative expression of hIFNG was measured
in mouse tissue by qPCR. Lines represent group mean ± SEM (n = 12-18 per group); symbols represent
individual mice; * P < 0.05 compared to hP2X7LOF mice.

3.2.14 Donor P2RX7 genotype does not alter the concentration of serum hIFNγ in
humanised NSG mice
Serum hIFNγ is increased in humanised mice with GVHD (Geraghty et al., 2019b), and
can be reduced by P2X7 blockade in both allogeneic (Wilhelm et al., 2010, Fowler et al.,
2014) and humanised mouse models of GVHD (Geraghty et al., 2017). In the current
study, the concentration of serum hIFNγ in hP2X7GOF and hP2X7LOF mice was analysed
by ELISA (Fig. 3.13). Serum hIFNγ was present in the majority of mice, but there was
no difference in the serum hIFNγ concentration between hP2X7GOF mice (8.68 ± 1.26
pg.mL-1, n = 30) and hP2X7LOF mice (9.67 ± 1.20 pg.mL-1, n = 37) (P =0.6662) Fig.3.13).
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Figure 3.13 Donor P2RX7 genotype does not alter the concentration of serum hIFNγ in humanised
mice with GVHD. At endpoint blood was collected from hP2X7GOF and hP2X7LOF mice by cardiac
puncture and serum isolated. The concentration of serum hIFNγ was analysed by ELISA. Lines represent
group mean ± SEM (hP2X7GOF: n = 30 mice; hP2X7LOF: n = 37 mice); symbols represent individual mice.

3.3

Discussion

This study aimed to determine the effect of human donor P2RX7 genotype on P2X7
activity on human leukocyte subsets important in GVHD and on disease development in
a humanised mouse model of GVHD. The current study demonstrates that P2X7 activity
correlates with GOF and LOF P2RX7 genotypes on human T cell, NK cell and monocyte
subsets,

and

showed

this

correlation

for

the

first

time

on

human

CD3+CD4+CD25+CD127lo Tregs, and iNKT cells. However, donor P2RX7 genotype did
not alter the development of clinical or histological disease in a pre-clinical humanised
mouse model of GVHD. These results in humanised mice are consistent with a recent
clinical study indicating that donor P2RX7 SNPs have minimal effect on GVHD
development following clinical allo-HSCT (Koldej et al., 2020). However, the current
study contrasts previous studies in allogeneic mouse models where genetic ablation of
P2X7 (Wilhelm et al., 2010), or P2X7 blockade with PPADS or KN-62 (Wilhelm et al.,
2010), BBG (Zhong et al., 2016) or stavudine (Fowler et al., 2014) significantly reduced
GVHD severity. However, it must be noted, that these previous results were obtained
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from allogeneic, not humanised, mice. Furthermore, whilst P2X7 is implicated in GVHD
it is P2X7 activation on host, not donor, antigen presenting cells that is thought to
exacerbate the disease (Wilhelm et al., 2010).
The role of donor P2X7 activation on GVHD has not been thoroughly investigated and
the current study suggests that altered donor P2X7 activity does not affect GVHD in this
humanised mouse model. Despite the current results, the effect of individual P2RX7 SNPs
on GVHD development cannot be discounted. The effect of individual donor P2RX7
SNPs on GVHD could not be assessed in this Chapter since all donors displayed multiple
P2RX7 SNPs, which could be assessed by expanding the donor cohort to identify
individuals with individual P2RX7 SNPs. Moreover, donor and recipient P2RX7 SNPs
are also reported to influence survival outcomes in allo-HSCT patients (Lee et al., 2007a).
Whilst this second study was not supported by a larger molecular study (Karaesmen et
al., 2017), the lack of clarity warrants further investigation into the role of host P2RX7
genotype on the development of GVHD. This seems plausible given that P2RX7
genotypes are associated with a number of inflammatory diseases such as multiple
sclerosis (Oyanguren-Desez et al., 2011) and rheumatoid arthritis (Al-Shukaili et al.,
2011), and due to the importance of host P2X7 activity on GVHD development (Wilhelm
et al., 2010, Geraghty et al., 2017).
Donor P2RX7 genotype did not affect the engraftment of human leukocytes in this
humanised mouse model of GVHD. In the current study the vast majority of human
leukocytes were T cells, and the engraftment levels of hCD3+, hCD3+hCD4+ and
hCD3+hCD8+ T cells parallels that observed in previous studies with this humanised
mouse model in our laboratory (Cuthbertson et al., 2020, Geraghty et al., 2017, Geraghty
et al., 2019b, Geraghty et al., 2019c). Furthermore, given that human monocytes and B
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cells were not detected in humanised mice, this chapter confirms that hCD4+ and hCD8+
T cells are the main effectors of GVHD in this model (King et al., 2009, Covassin et al.,
2013, Abraham et al., 2015). As well as the closely related NOG model (Kawasaki et al.,
2018). Consequently, the comparable engraftment of hCD3+hCD4+ and hCD3+hCD8+ T
cells between hP2X7GOF and hP2X7LOF may account for the similarities in clinical and
histological GVHD between the two groups.
Donor P2RX7 genotype also did not influence the engraftment of human Tregs in this
humanised mouse model of GVHD. Tregs have a protective role against GVHD in
humanised mouse models (Ruggeri et al., 2014, Hannon et al., 2014) and in allo-HSCT
patients (Rezvani et al., 2006, Kennedy-Nasser et al., 2014) and their detection in
humanised NSG mice in this study aligns with previous reports (Abraham et al., 2012,
Geraghty et al., 2019a, Geraghty et al., 2017). Since P2X7 is present on human Tregs
(Cortes-Garcia et al., 2016) and its activation can influence Treg proliferation and their
suppressive capacities in vitro (Trabanelli et al., 2012), it is possible that GOF and LOF
P2RX7 genotypes may influence GVHD development by enhancing and reducing Treg
numbers and function, respectively. However, the similar engraftment of Tregs, and
severity of GVHD in both mouse groups implies that this is not the case in this study.
The current study demonstrates that donor P2RX7 genotype does not alter the relative
expression of hP2X7 in the spleen, liver or small intestine in this humanised mouse
model. Although P2X7 is up-regulated in the small-intestines and livers of allogeneic
mice with GVHD, and on PBMCs from human GVHD patients (Wilhelm et al., 2010), in
the current study P2X7 expression indirectly reflected human leukocyte engraftment and
supports it being similar between donor P2RX7 genotypes. In contrast, hIFNγ RNA was
differentially expressed between hP2X7GOF and hP2X7LOF mice in the liver and small
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intestine. Although these differences were small and assuming IFNγ expression correlates
with GVHD severity (Yi et al., 2009), the possibility exists that molecular GVHD is worse
in the livers and small intestine of mice injected with GOF and LOF P2RX7 genotype
donors, respectively. Nonetheless, such differences were not readily observed by
histological assessment of GVHD mediated tissue damage in hP2X7GOF and hP2X7LOF
mice. In line with this, the concentration of serum hIFNγ in humanised mice was similar
for both donor P2RX7 genotypes. This latter finding contrasts previous data in allogeneic
mouse models of GVHD where genetic deficiency of P2RX7 reduced serum IFNγ
(Wilhelm et al., 2010), and in previous studies with this humanised mouse model where
short-term P2X7 blockade with BBG reduced serum hIFNγ and tissue leukocyte
infiltration and damage (Geraghty et al., 2017). Thus, the data in this chapter may imply
that P2X7 blockade with BBG is acting on host (murine) rather than donor (human) P2X7
to reduce GVHD development in humanised mice in this previous study.
The detection of functional P2X7 on human Tregs in the current study supports previous
work suggesting that P2X7 activation on these cells reduces their suppressive potential
and increases their susceptibility to apoptosis (Schenk et al., 2011, Cortes-Garcia et al.,
2016). Moreover, since P2X7 activity on human Tregs is influenced by donor P2RX7
genotype, Tregs from LOF donors may have increased suppressive capabilities. Likewise,
investigations into the role of P2X7 on iNKT cells are lacking, however functional P2X7
has been described on mouse iNKT cells, where it is important in cell regulation
(Kawamura et al., 2006, Liu and Kim, 2019). The detection of functional P2X7 on donor
iNKT cells in the current study supports recent work showing that P2X7 expression on
human iNKT cells is increased following their stimulation in vitro (Yu et al., 2018a).
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The current results indicate that P2X7 activity on human CD3+, CD3+CD4+ and
CD3+CD8+ T cells and Tregs is similar to one another, and comparable to the three main
monocyte subsets. In contrast, other findings show that monocytes demonstrate four to
five-fold greater P2X7 activity compared to lymphocytes (Gu et al., 2004, Gu et al., 2000)
and that P2X7 expression is much higher on monocytes than on T cells (Sluyter and
Wiley, 2014b, Gu et al., 2000). Therefore, the possibility remains that some P2RX7
haplotypes may increase or decrease cell-surface P2X7 expression; however previous
attempts using an anti-P2X7 mAb to determine this in primary leukocytes have repeatedly
been unsuccessful (Stokes et al., 2010, Gu et al., 2001, Wiley et al., 2003, Gu et al., 2004,
Shemon et al., 2006). Consequently, the significantly higher P2X7 activity in iNKT cells
compared to other leukocyte subsets may also reflect differences in cell-surface P2X7
expression, but this remains to be determined in any study to date. The reasons for the
differences between the current and past studies remain unclear, but most likely reflect
the assessment of dye uptake in real-time and fixed-time measurements, respectively.
Although the identity of the P2X7 pore remains unknown (Di Virgilio et al., 2018),
ethidium+ is thought to pass through the same pore as YO-PRO-12+ iodide (CankurtaranSayar et al., 2009). Thus, differences between studies due to the use of different dyes are
unlikely.
ATP-induced dye uptake is well known to be mediated by P2X7 activity (Korpi-Steiner
et al., 2008, Gu et al., 2000), and this was confirmed for YO-PRO-12+ iodide using the
P2X7 antagonist JNJ-47965567. Therefore, the variations in dye uptake between GOF
and LOF P2RX7 genotype donors in each immune cell subset can be largely attributed to
donor P2RX7 genotype. Additionally, P2X7 activity was successfully predicted for all
donors based on P2RX7 genotype, with the exception of one LOF donor of H2/H16
haplotype. The vast majority of LOF P2RX7 genotype donors contained the strong LOF
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E496A or R307Q SNPs and constantly demonstrated significantly reduced P2X7 activity
in all immune cell subsets investigated, consistent with previous studies (Gu et al., 2004,
Gu et al., 2001, Jiang et al., 2013). Notably, the donor of H2/H16 haplotype demonstrated
P2X7 activity comparable to GOF donors in all immune cell subsets analysed. This donor
was heterozygous for the T357S SNP which is a partial LOF allele (Shemon et al., 2006),
and as such may be less dominant than the wild type allele. This could account for the
higher than expected P2X7 activity in immune cells in this individual. Alternatively, the
effect of this LOF SNP may have been confounded by the presence of a GOF SNP outside
of the P2RX7 coding region in this donor. Two LOF donors also possessed the GOF
H155Y SNP alongside the E496A SNP, mirroring results by Fuller et al. (2009) who
observed that HEK293 cells transfected with P2X7 containing the H155Y and E496A
SNPs still demonstrate diminished P2X7 activity. Taken together with the current study,
these data may indicate that the H155Y SNP cannot recover the LOF caused by the
E496A SNP on the immune cell subsets investigated in the current study.
In conclusion, this chapter demonstrates that donor P2RX7 genotype affects P2X7 activity
on human T cell, monocyte and NK cell subsets. However, donor P2RX7 genotype did
not influence GVHD in this humanised mouse model. This indicates that hPBMCs,
regardless of P2RX7 genotype can be used to establish GVHD in NSG mice. However,
whether certain P2RX7 genotypes can predict GVHD and other outcomes in allo-HSCT
recipients will need to be confirmed by larger, adequately powered studies.
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Chapter 4:

A Single Nucleotide Polymorphism in the Human ENTPD1 Gene

Worsens the Development of Graft-Versus-Host Disease in a Humanised Mouse
Model
4.1

Introduction

Purinergic signalling is implicated in graft-versus-host disease (GVHD) (Wilhelm et al.,
2010, Lappas et al., 2010), and whilst donor P2RX7 genotype does not influence GVHD
in humanised NOD.Cg-PrkdcscidIl2rgnull (NSG) mice (Chapter 3), single nucleotide
polymorphisms (SNPs) in other genes encoding purinergic signalling molecules may
influence GVHD development. The ecto-enzyme ectonucleoside triphosphate
diphosphorylase-1 (CD39) is an important ecto-enzyme in purinergic signalling that
hydrolyses adenosine-5’-triphosphate (ATP) to adenosine diphosphate (ADP) and ADP
to adenosine monophosphate (AMP). AMP can be further hydrolysed to adenosine by
ecto-5’-nucleotidase (CD73) (Deaglio et al., 2007). Since GVHD is enhanced by
extracellular ATP (Wilhelm et al., 2010) and prevented by extracellular adenosine
(Lappas et al., 2010), a role for CD39 in the development of this disease is plausible.
In humans, CD39 is present on a number of leukocyte subsets, including CD4+
conventional T cells (Tcons) (Zhou et al., 2009), CD8+ T cells (Gupta et al., 2015, Parodi
et al., 2013) and natural killer (NK) cells (Morandi et al., 2015). However, CD39 is most
highly expressed on human regulatory T cells (Tregs), which protect against GVHD (Di
Ianni et al., 2011, Ruggeri et al., 2014). CD39 is central for the immunoregulatory
functions of Tregs (Rissiek et al., 2015, Gu et al., 2017, Dwyer et al., 2010, Zhou et al.,
2009) and is necessary for Treg stability by preventing the loss of forkhead box P3
(FoxP3), a key Treg marker, stopping their conversion into CD4+ Tcons (Gu et al., 2017,
Komatsu et al., 2014). This is particularly relevant in GVHD given the key roles of CD4+
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Tcons in mediating the disease (Yi et al., 2009). CD39 may also be necessary for Treg
mediated protection against GVHD since human Tregs with high CD39 expression, but
not low CD39, reduced GVHD when co-transferred with human peripheral blood
mononuclear cells (hPBMCs) in humanised mice (Gu et al., 2017).
CD39 expression on human Tregs is influenced by the rs10748643 (AG) SNP in intron
1 of the human ENTPD1 gene (Rissiek et al., 2015). In PBMCs from healthy German
(Rissiek et al., 2015) and Italian (Timperi et al., 2016a) populations, donors encoding the
G allele of the rs10748643 SNP display higher proportions of CD39+ Tregs compared to
those homozygous for the A allele. Furthermore, Tregs from donors encoding the G allele
demonstrate a higher capacity to suppress interferon (IFN)-γ and interleukin (IL)-17
release from T cells (Rissiek et al., 2015), two key cytokines in GVHD (Yi et al., 2009,
Wang et al., 2009). Consequently, the G allele of the rs10748643 SNP is associated with
protection against inflammatory disorders such as Crohn’s disease (Friedman et al.,
2009a) and neonatal sepsis (Timperi et al., 2016a).
Given the potentially important role of CD39 on Tregs for preventing GVHD, and the
importance of the rs10748643 SNP in controlling CD39 on human Tregs, a role for this
SNP in the development of GVHD is plausible but has not been investigated. Therefore,
this chapter aimed to investigate the impact of the rs10748643 genotype on human
leukocyte subsets important in GVHD in an Australian donor cohort and determine if
human donor rs10748643 genotype influences clinical outcomes in a humanised mouse
model of GVHD.
The data in this chapter formed a research article published in the journal Immunology
and Cell Biology (Adhikary et al., 2020).
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4.2

Results

4.2.1

rs10748643 genotype correlates with the proportion of CD39+ Tregs in

human donors
The rs10748643 SNP in the human ENTPD1 gene correlates with increased proportions
of CD39+ Tregs in the peripheral blood of donors from Germany (Rissiek et al., 2015)
and Italy (Timperi et al., 2016b, Timperi et al., 2016a). To determine if this SNP
influences CD39+ Tregs in a population of healthy Australian donors, the rs10748643
allele

encoding

region

was

sequenced

and

the

proportion

of

CD39+CD3+CD4+CD25+CD127lo Tregs assessed in donor PBMCs by flow cytometry
with a consistent gating strategy (Fig. 4.1a-f). CD25 and CD127 were chosen to identify
Tregs for flow cytometry as these markers are a validated approach to identify Tregs,
avoiding intracellular FoxP3 staining and maintaining cell viability (Fazekas de St Groth
et al., 2011).
Fifteen donors were sequenced for the rs10748643 SNP. Of these donors six were
homozygous for the A allele (40%), five homozygous for the G allele (33.33%) and four
heterozygous (26.67%). Based on previous observations (Rissiek et al., 2015),
preliminary analysis of Tregs revealed that the donors in the current study segregated into
two groups; those homozygous for the A allele (hereafter termed donorsAA); and those
either heterozygous or homozygous for the G allele (hereafter termed donorsAG/GG). The
proportion of CD3+CD4+CD25+CD127lo Tregs was not influenced by rs10748643
genotype, with comparable percentages between donorsAA (2.8 ± 0.6%, n = 6) and
donorsAG/GG (3.8 ± 0.5%, n = 9) (P = 0.1420) (Fig. 4.1g). As expected, donorsAG/GG
demonstrated significantly higher proportions of CD39+ Tregs than donorsAA (30.0 ±
1.2%, n = 9 vs. 14.4 ± 2.6%, n = 6, respectively, P < 0.0001) (Fig. 4.1h).
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Figure 4.1 The proportion of CD39+ Tregs in human peripheral blood correlates with rs10748643
genotype in human donors. Donors were genotyped for the rs10748643 (AG) SNP in the human
ENTPD1 gene by sequencing genomic DNA and classed as donorsAA (homozygous for the A allele) or
donorsAG/GG (homozygous or heterozygous for the G allele). hPBMCs were isolated from donor peripheral
blood and CD39 on human Tregs assessed by flow cytometry using (a-f) a consistent gating strategy. (a)
Single cells were gated by forward scatter area (FSC-A) and height (FSC-H), and (b) single lymphocytes
gated within this population using FSC-A and side scatter (SSC-A). (c) CD3+, (d) CD3+CD4+ and
CD3+CD8+ T cells and (e) CD3+CD4+CD25+CD127lo (CD4+)Tregs were identified in this population. The
proportions of (f) CD39+ Tregs were then analysed. The proportion of (g) total CD4+ Tregs and (h)
CD39+CD4+ Tregs were determined in hPBMCs from multiple donors. (g, h) Lines represent groups means
± SEM (donorsAA n = 6; donorsAG/GG n = 9). Symbols represent individual donors and are coloured based
on donor rs10748643 genotype; grey (AA), black (GG), half shaded (AG). (h) *** P < 0.001, compared to
donorsAA.

4.2.2

The proportions CD39+CD4+ Tcons or CD39+CD8+ T cells in human donors

are not influenced by donor rs10748643 genotype
CD4+ Tcons and CD8+ T cells are the predominate mediators of GVHD (Markey et al.,
2014, Fowler, 2006). Moreover, whether rs10748643 genotype influences CD39 on these
cells is not known. Therefore, CD39 was also measured on these T cell subsets in the
above donors by flow cytometry using a consistent gating strategy (Fig. 4.2 a-g). In all
donors, irrespective of rs10748643 genotype, Tregs displayed the highest proportions of
CD39+ cells than either CD4+ Tcons or CD8+ T cells (P < 0.0001 for both). However,
unlike for Tregs (Fig. 4.1h) donor rs10748643 genotype did not influence the proportions
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of CD39+CD4+ Tcons (donorsAA: 4.4 ± 0.4%, n = 3; donorsAG/GG: 4.9 ± 0.3%, n = 9) (P
= 0.3927) (Fig. 4.2i) or CD39+CD8+ T cells (donorsAA: 2.3 ± 0.6%, n = 3; donorsAG/GG:
1.4 ± 0.3%, n = 9) (P = 0.1148) (Fig. 4.2j).

Figure 4.2 CD39 on human CD3+CD4+ Tcons and CD3+CD8+ T cells is not influenced by donor
rs10748643 genotype. Donors were genotyped for the rs10748643 (AG) SNP in the human ENTPD1
gene by sequencing genomic DNA and classed as donorsAA (homozygous for the A allele) or donorsAG/GG
(homozygous or heterozygous for the G allele). hPBMCs were isolated from donor peripheral blood and
CD39 on human T cells assessed by flow cytometry using (a-g) a consistent gating strategy. (a) Single cells
were gated by forward scatter area (FSC-A) and height (FSC-H), and (b single lymphocytes gated within
this population using FSC-A and side scatter (SSC-A). (c) CD3+, (d) CD3+CD4+ and CD3+CD8+ T cells,
(e) CD3+CD4+CD25+CD127hi Tcons were identified in this population. The proportions of CD39+ (f)
CD3+CD4+ Tcons and (g) CD3+CD8+ T cells were then analysed. The proportion of (h) CD39+
lymphocytes, (i) CD39+CD3+CD4+ Tcons and CD39+ CD3+CD8+ T cells were determined in hPBMCs from
multiple donors. (h-j) Lines represent groups means ± SEM (donorsAA n = 6; donorsAG/GG n = 9). Symbols
represent individual donors and are coloured based on donor rs10748643 genotype; grey (AA), black (GG),
half shaded (AG). (h) **** P < 0.001, compared to Tregs.
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4.2.3

rs10748643 genotype does not influence the proportions of CD39+CD3-CD56+

NK cells in human donors
Natural killer cells can have pathogenic (Cooley et al., 2005) roles in GVHD, but may
also mediate the graft-versus-tumour (GVT) effect following allogeneic hematopoietic
stem cell transplantation (allo-HSCT) (Ruggeri et al., 2002), however there are limited
studies investigating CD39 on human NK cells. Therefore, CD39 was also assessed on
CD3-CD56+ NK cells (Bryceson et al., 2010) using flow cytometry with a consistent
gating strategy (Fig. 4.3a-d). Donor rs10748643 genotype did not affect the proportion of
CD39+CD3-CD56+NK cells, with similar proportions of these cells in donorsAA (2.5 ±
1.3%, n = 6) and donorsAG/GG (3.3 ± 1.3%, n = 9) (P = 0.2810) (Fig. 4.3e).

Figure 4.3 CD39 on human CD3-CD56+ NK cells is not influenced by donor rs10748643 genotype.
Donors were genotyped for the rs10748643 (AG) SNP in the human ENTPD1 gene by sequencing
genomic DNA and classed as donorsAA (homozygous for the A allele) or donorsAG/GG (homozygous or
heterozygous for the G allele). hPBMCs were isolated from donor peripheral blood and CD39 on human
natural killer (NK) cells assessed by flow cytometry using (a-d) a consistent gating strategy. (a) Single cells
were gated by forward scatter area (FSC-A) and height (FSC-H), and (b single lymphocytes gated within
this population using FSC-A and side scatter (SSC-A). (c) CD3-CD56+ NK cells were identified and the
proportions of CD39+ (d) NK cells were then analysed. (e) The proportion of CD39+ NK cells was
determined in hPBMCs from multiple donors. Lines represent groups means ± SEM (donorsAA n = 6;
donorsAG/GG n = 9). Symbols represent individual donors and are coloured based on donor rs10748643
genotype; grey (AA), black (GG), half shaded (AG).
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4.2.4

Human leukocyte engraftment at 3 weeks-post hPBMC injection in NSG

mice is not affected by donor rs10748643 genotype
To determine if donor rs10748643 genotype influences the development of GVHD, NSG
mice were injected i.p. with hPBMCs (King et al., 2009), isolated from either donorsAA
(hCD39AA mice, n = 3 donors, n = 7-10 mice per donor) or donorsAG/GG (hCD39AG/GG
mice, n = 7 donors, n = 7-10 mice per donor). Mice were monitored for the development
of clinical GVHD (Table 2.3) for up to 10 weeks (Fig. 4.4).

Figure 4.4 Humanised mouse model to investigate the effect of human donor ENTPD1 rs10748643
genotype on the development of GVHD. NSG mice were injected i.p. with 10 x 106 hPBMCs isolated
from either donorsAA (hCD39AA mice, n = 3 donors, n = 24 mice) or donorsAG/GG (hCD39AG/GG mice, n =
7 donors, n = 53 mice) for the rs10748643 SNP in the human ENTPD1 gene. Mice were monitored for the
development of GVHD by assessing weight loss and scoring GVHD clinical symptoms for up to 10 weeks
post-hPBMC injection. Mice were checked for the engraftment of human cells at 3 weeks post-hPBMC
injection, and at endpoint by immunophenotyping tail blood or spleens, respectively, by flow cytometry.
At endpoint, histological damage to GVHD target organs (liver, small intestines and skin) was assessed by
haematoxylin and eosin staining. The relative expression of inflammatory and regulatory cytokines in
spleens and GVHD target organs was assessed by qPCR. The concentration of hIFNγ in mouse sera was
assessed by ELISA.
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At 3 weeks-post hPBMC injection, mice were checked for the engraftment of human
lymphocyte subsets important in GVHD by flow cytometry of mouse tail blood using a
consistent gating strategy (Fig. 4.5a-e). At 3 weeks post-hPBMC injection, comparable
proportions of hCD45+ leukocytes were identified in the blood of hCD39AA (27.1 ± 2.3%,
n = 24) and hCD39AG/GG mice (28.1 ± 1.7 %, n = 53) (P = 0.7499) (Fig. 4.5f). The
majority of these cells were hCD3+ T cells in both groups (hCD39AA: 93.4 ± 1.1%, n =
24; hCD39AG/GG: 92.4 ± 0.9%, n = 53) (P = 0.5237) (Fig. 4.5g). hCD39AA mice and
hCD39AG/GG mice also demonstrated similar proportions of hCD3+hCD4+ T cells
(hCD39AA: 41.9 ± 2.8%, n = 24; hCD39AG/GG: 37.6 ± 1.6%, n = 53) (P = 0.1643) and
hCD3+hCD8+ T cells (hCD39AA: 45.0 ± 2.4%, n = 24; hCD39AG/GG: 45.5 ± 1.4%, n = 53)
(P = 0.8387) (Fig. 4.5h), leading to comparable hCD4+:hCD8+ T cell ratios (hCD39AA:
1.1 ± 0.1, n = 24; hCD39AG/GG: 0.9 ± 0.1, n = 53) (P = 0.3131) (Fig. 4.5i).
4.2.5

Donor rs10748643 genotype influences human T cell engraftment in NSG

mice at endpoint
At endpoint, the engraftment of human leukocytes subsets was assessed in NSG mouse
spleens using flow cytometry with a consistent gating strategy (Fig. 4.6a-g). Both
hCD39AA mice and hCD39AG/GG mice demonstrated similar percentages of splenic
hCD45+ leukocytes (hCD39AA: 67.2 ± 3.8%, n = 24; hCD39AG/GG: 70.2 ± 2.1%, n = 53)
(P = 0.4098) (Fig. 4.6h) and hCD3+ T cells (hCD39AA: 87.1 ± 1.0%, n = 24; hCD39AG/GG:
82.0 ± 1.9%, n = 53) (P = 0.0815) (Fig. 4.6i). However, a significantly higher proportion
of hCD3+hCD4+ T cells and a significantly lower proportion of hCD3+hCD8+ T cells were
observed in hCD39AG/GG mice compared to hCD39AA mice (hCD3+hCD4+ T cells: 66.1 ±
2.2%, n = 24 vs. 56.0 ± 3.6%, n = 53, respectively, P = 0.0137) (hCD3+hCD8+ T cells:
28.5 ± 1.8%, n = 53 vs. 35.1 ± 2.9%, n = 24, respectively, P = 0.0488) (Fig. 4.6j).
Subsequently, this led to a significantly higher hCD4+:hCD8+ T cell ratio in hCD39AG/GG
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mice (3.0 ± 3.3, n = 53) compared to hCD39AA mice (2.0 ± 0.3, n = 24) (P = 0.0110) (Fig.
4.6k).

Figure 4.5 Human donor rs10748643 genotype does not influence the engraftment of human T cell
subsets in NSG mice at 3 weeks post-hPBMC injection. hCD39AA and hCD39AG/GG mice were checked
for the engraftment of human cells at 3 weeks post-hPBMC injection by immunophenotyping tail blood by
flow cytometry using a (a-e) consistent gating strategy. (a) Single cells were gated by forward scatter area
(FSC-A) and height (FSC-H), and (b) single lymphocytes gated within this population using FSC-A and
side scatter (SSC-A). (c) hCD45+mCD45- leukocytes were gated and (d) hCD45+hCD3+ T cells, (e)
hCD3+hCD4+ and hCD3+hCD8+ T cells were then identified. (f) hCD45+ leukocytes are expressed as a
percentage of total mCD45+ and hCD45+ leukocytes. (g) hCD3+ T cells are expressed as a percentage of
total hCD45+ leukocytes. (h) hCD3+hCD4+ and hCD3+hCD8+ T cells are expressed as a percentage of
hCD3+ cells with the (i) calculated hCD4+:hCD8+ T cell ratio. (f-i) Lines represent group mean ± SEM
(hCD39AA mice: n = 24 mice; hCD39AG/GG mice: n = 53 mice); symbols represent individual mice.

Whilst the proportion of hCD39+hCD3+hCD4+ T cells was significantly higher than
hCD39+hCD3+hCD8+ T cells in both hCD39AA (81.7 ± 1.6%, n = 24 vs. 62.1 ± 4.1%, n
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= 24, respectively, P < 0.0001) and hCD39AG/GG (80.9 ± 2.2%, n = 53 vs. 58.8 ± 3.3%, n
= 53, respectively, P < 0.0001) mice, the proportions of these cells were similar between
both groups (hCD39+hCD3+hCD4+: P = 0.8818; hCD39+hCD3+hCD8+ T cells: P =
0.5412) (Fig. 4.6l). Human Tregs were present in all mice at end-point, but there was no
significant difference in the frequencies of total Tregs (hCD39AA: 1.5 ± 0.2%, n = 24;
hCD39AG/GG: 1.9 ± 0.2%, n = 53) (P = 0.2781) (Fig. 4.6m), or hCD39+ Tregs (hCD39AA:
74.7 ± 2.2%, n = 24; hCD39AG/GG: 76.2 ± 2.8%, n = 53) (P = 0.5915) (Fig. 4.6n).
4.2.6

Donor rs10748643 genotype does not influence human NK cell engraftment

in NSG mice at endpoint
The proportions of splenic human NK cells were assessed in NSG mice at endpoint using
flow cytometry (Fig. 4.7a-e). Splenic hCD3-hCD19-hCD56+ NK cells were present in all
mice, however human donor rs10748643 genotype did not impact the engraftment of
these cells (hCD39AA: 1.3 ± 0.2%, n = 20; hCD39AG/GG: 1.5 ± 0.1%, n = 48) (P = 0.6487)
(Fig. 4.7f), or the proportion of hCD39+hCD3-hCD19-hCD56+ NK cells (hCD39AA: 2.2 ±
0.2%, n = 20; hCD39AG/GG: 2.0 ± 0.2%, n = 48) (P = 0.7483) (Fig. 4.7g).
4.2.7

hCD39AG/GG mice develop more severe GVHD than hCD39AA mice

Humanised mice were monitored for the development of GVHD by analysing weight loss
and scoring GVHD clinical symptoms over 10 weeks (Table 2.3) (Fig. 4.8a-c). Notably,
weight loss was significantly greater in hCD39AG/GG mice compared to hCD39AA mice (P
= 0.0128) (Fig. 4.8a), with mean weights consistently decreasing from Day 21 and Day
31, respectively. Consistent with this, hCD39AG/GG mice demonstrated significantly
higher GVHD clinical scores over 10 weeks than hCD39AA mice (P = 0.0046) (Fig. 4.8b).
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Figure 4.6 hCD39AG/GG mice demonstrate significantly increased splenic hCD4+:hCD8+ T cell ratios
than hCD39AA mice at endpoint. hCD39AA and hCD39AG/GG mice were checked for the engraftment of
human cells at endpoint by immunophenotyping spleens using flow cytometry using (a-f) a consistent
gating strategy. (a) Single cells were gated by forward scatter area (FSC-A) and height (FSC-H), and (b)
single lymphocytes gated within this population using FSC-A and side scatter (SSC-A). (c)
hCD45+mCD45- leukocytes were identified (d) hCD3+ T cells were gated and (e) hCD3+hCD4+ and
hCD3+hCD8+ T cells and (f) hCD3+hCD4+hCD25+hCD127lo Tregs were identified. (g)
hCD39+hCD3+hCD4+hCD25+hCD127lo (hCD4+) Tregs were then assessed. (h) hCD45+ leukocytes are
expressed as a percentage of total mCD45+ and hCD45+ leukocytes. (i) hCD3+ T cells are expressed as a
percentage of total hCD45+ leukocytes. (j) hCD3+hCD4+ and hCD3+hCD8+ T cells are expressed as a
percentage of hCD3+ T cells with the (k) calculated hCD4+:hCD8+ T cell ratio. (l) hCD39+ Tregs are
expressed as a percentage of hCD4+ and hCD8+T cells. (m) hCD39+hCD4+ Tregs are expressed as a
percentage of hCD4+ Tregs. (n) hCD39+hCD4+ Tregs are expressed as a percentage of hCD4+ Tregs (h-n)
Lines represent group mean ± SEM (hCD39AA mice: n = 24 mice; hCD39AG/GG mice: n = 53 mice); symbols
represent individual mice. (i) * P < 0.05, compared to hCD3+hCD4+ T cells in CD39AG/GG mice, † P < 0.05
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compared to hCD3+hCD8+ T cells in CD39AG/GG mice, (j) * P < 0.05, compared to CD39AG/GG mice, (k)
**** P < 0.0001 compared to respective hCD3+hCD8+ T cells.

Figure 4.7 Human donor rs10748643 genotype does not influence the engraftment of hCD3-hCD19hCD56+ natural killer cells in NSG mice at endpoint. hCD39AA and hCD39AG/GG mice were checked for
the engraftment of human natural killer (NK) cells at endpoint by immunophenotyping spleens using flow
cytometry using (a-e) a consistent gating strategy. (a) Single cells were gated by forward scatter area (FSCA) and height (FSC-H), and (b single lymphocytes gated within this population using FSC-A and side
scatter (SSC-A). (c) hCD3-hCD19- cells were gated and (d) hCD3-hCD19-hCD56+ NK cells identified
within this population. (e) hCD39+ hCD3-hCD19- hCD56+ NK cells were also identified. (f) hCD3hCD19hCD56+ NK cells are expressed as a percentage of hCD3-hCD19- cells with the percentage of
hCD39+ NK cells shown. (f, g) Lines represent group mean ± SEM (hCD39AA mice: n = 20 mice;
hCD39AG/GG mice: n = 48 mice); symbols represent individual mice.

Clinical scores consistently increased from Day 21 in both mouse groups. Consequently,
hCD39AG/GG mice displayed significantly lower median survival times (MST) over 10
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weeks than hCD39AA mice (MST of 34 days, n = 53 vs. MST of 44.5 days, n = 24,
respectively, P = 0.0154) (Fig. 4.8c). All mice succumbed to GVHD by Day 70.

Figure 4.8 hCD39AG/GG mice develop more severe clinical GVHD than hCD39AA mice. hCD39AA and
hCD39AG/GG mice were monitored for clinical manifestation of GVHD for up to 10 weeks post-hPBMC
injection by assessing (a) weight loss, (b) GVHD clinical score and (c) survival. Data represents (a, b)
group means ± SEM or (c) percentage survival. (a - c) * P < 0.05 compared to hCD39AG/GG mice, ** P <
0.01 compared to hCD39AG/GG mice. (a - c) hCD39AA mice: n = 24 mice; hCD39AG/GG mice: n = 53 mice.

4.2.8

CD39AA and hCD39AG/GG mice demonstrate similar histological damage to

GVHD target organs
GVHD causes histological damage to the liver, small intestines and skin of NSG mice
injected with hPBMCs (King et al., 2009, Geraghty et al., 2017) (Fig. 4.9a-c). Therefore,
histological damage to these tissues from end point mice was assessed in the current
study. hCD39AA and hCD39AG/GG mice demonstrated similar leukocyte infiltration in the
liver, which was mainly focussed around hepatic vessels, and displayed similar amounts
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of apoptotic cells (Fig. 4.9a). Both groups showed similar leukocyte infiltration in the
small intestines which was complemented by comparable levels of structural damage,
including rounding of villi and damage to enterocytes and crypt epithelial cells (Fig.
4.9b). hCD39AA and hCD39AG/GG mice showed minor skin GVHD with slight dermal
detachment and epidermal thickening. Leukocyte infiltration in the skin appeared similar
between groups (Fig. 4.9c).

Figure 4.9 hCD39AA and hCD39AG/GG mice demonstrate similar histological damage to GVHD target
organs. At endpoint, 5 μm sections of formalin-fixed (a) liver, (b) small intestine and (c) skin tissue from
hCD39AA (top panel) and hCD39AG/GG mice (bottom panel) were sectioned and stained with haematoxylin
and eosin and imaged by microscopy. Representative images from four mice per group are shown; bars
represent 100 µm. Red arrows indicate infiltrating leukocytes

4.2.9

The proportion of human Tregs positively correlates with survival in

hCD39AA mice, but not hCD39AG/GG mice
Human Tregs protect against GVHD following allo-HSCT (Di Ianni et al., 2011),
therefore, the proportions of these cells in hCD39AA and hCD39AG/GG mice were plotted
against mouse survival to determine if there was a correlation between these paramaters
(Fig. 4.10a, b). Notably, there was a positive correlation between the proportions of
human Tregs and mouse survival in hCD39AA mice (r2 = 0.25, P = 0.0111) (Fig. 4.10a),
but not hCD39AG/GG mice (r2 = 0.01, P = 0.5915) (Fig. 4.10b)
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Figure 4.10 The proportion of human Tregs positively correlates with survival in hCD39AA mice but
not hCD39AG/GG mice. The proportions of hCD3+hCD4+hCD25+hCD127lo Tregs in hCD39AA and (b)
hCD39AG/GG mice were correlated to mouse survival (a, b) Pearson correlation of the percentage of splenic
hCD3+hCD4+hCD25+hCD127lo Tregs vs mouse survival for (a) hCD39AA (n = 24 mice) and (b)
hCD39AG/GG mice (n = 54 mice). Symbols represent individual mice.

4.2.10 hCD39AA and hCD39AG/GG mice demonstrate similar relative expression of
hFOXP3 and hENTPD1 in spleens and GVHD target organs
To further explore human Tregs in hCD39AA and hCD39AG/GG mice, the relative
expression of the human Treg marker FOXP3 (Rudensky, 2011), as well as human
ENTPD1 were assessed in the spleens, liver and small intestines by qPCR. Since CD25
and CD127 are present on various T cell subsets (Rodríguez-Perea et al., 2016), FoxP3,
which is predominately expressed by Tregs (Rudensky, 2011), was used to measure the
presence of Tregs in tissues.
Relative hFOXP3 expression was similar between both hCD39AA and hCD39AG/GG mice
in the spleen (hCD39AA: 2.8 ± 0.2, n = 15; hCD39AG/GG: 3.1 ± 0.4, n = 33) (P = 0.5949)
(Fig. 4.11a), liver (hCD39AA: 2.9 ± 0.2, n = 15; hCD39AG/GG: 3.0 ± 0.2, n = 34) (P =
0.6914) (Fig. 4.11b) and small intestine (hCD39AA: 2.7 ± 0.2, n = 16; hCD39AG/GG: 3.0 ±
0.1, n = 30) (P = 0.4873) (Fig. 4.11c). Likewise, there was no difference in relative
hENTPD1 expression in the spleen (hCD39AA: 2.1 ± 0.2, n = 15; hCD39AG/GG: 2.6 ± 0.2,
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n = 34) (P = 0.1869) (Fig. 4.11d), liver (hCD39AA: 2.4 ± 0.3, n = 15; hCD39AG/GG: 2.6 ±
0.3, n = 34) (P = 0.6709) (Fig. 4.11e) or small intestine (hCD39AA: 3.3 ± 0.6, n = 16;
hCD39AG/GG: 2.4 ± 0.2, n = 32) (P = 0.0906) between mouse groups (Fig. 4.11f).
4.2.11 hCD39AA mice demonstrate reduced relative hIFNG expression in the spleen
compared to hCD39AG/GG mice
IFNγ and IL-17 are key pro-inflammatory cytokines in GVHD pathogenesis (Yi et al.,
2009, Wang et al., 2009). Moreover, CD39 can limit T cell production of IL-17 (Fletcher
et al., 2009). Therefore, the expression of human IL17A and human IFNG was assessed
by qPCR in the spleen, liver and small intestines of hCD39AA and hCD39AG/GG mice (Fig.
4.12a-f).

Figure 4.11 hCD39AA and hCD39AG/GG mice demonstrate similar relative hFOXP3 and hENTPD1
expression in the spleen and GVHD target organs. RNA was extracted and cDNA synthesized from (a,
d) spleen, (b, e) liver and (c, f) small intestines of hCD39AA and hCD39AG/GG mice at endpoint. The relative
expression of (a-c) hFOXP3 and (d-f) hENTPD1 in mouse tissues was examined by qPCR. Lines represents
group mean ± SEM (n = 12-18 per group). Symbols represent individual mice.
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Both hCD39AA and hCD39AG/GG mice demonstrated comparable relative expression of
hIL17A in the spleen (hCD39AA: 4.0 ± 0.8, n = 15; hCD39AG/GG: 4.2 ± 0.7, n = 33) (P =
0.8822) (Fig. 4.12a), liver (hCD39AA: 3.3 ± 0.7, n = 15; hCD39AG/GG: 3.9 ± 0.6, n = 34)
(P = 0.5355) (Fig. 4.12b) and small intestine (hCD39AA: 5.6 ± 1.2, n = 16; hCD39AG/GG:
3.7 ± 0.6, n = 32) (P = 0.1303) (Fig. 4.12c), although the latter approached significance.
Relative splenic hIFNG expression was significantly higher (1.14-fold) in hCD39AG/GG
mice (12.4 ± 0.3, n = 33) than in hCD39AA mice (10.9 ± 0.6, n = 15) (P = 0.0159) (Fig.
4.12d). However, there was no significant difference in relative hIFNG expression
between the two mouse groups in either the liver (hCD39AA: 3.4 ± 0.2, n = 15;
hCD39AG/GG: 3.5 ± 0.1, n = 34) (P = 0.7417) (Fig. 4.12e) and small intestine (hCD39AA:
2.8 ± 0.2, n = 15; hCD39AG/GG: 3.3 ± 0.1, n = 30) (P = 0.0703) (Fig. 4.12f).

Figure 4.12 hCD39AA mice demonstrate significantly reduced relative splenic hIFNγ expression in
compared to hCD39AG/GG mice. RNA was extracted and cDNA synthesized from (a, d) spleen, (b, e) liver
and (c, f) small intestines of hCD39AA and hCD39AG/GG mice at endpoint. The relative expression of (a-c)
hIL17A and (d-f) hIFNG in the was measured in mouse tissue by qPCR. Lines represents group mean ±
SEM (n = 12-18 per group). Symbols represent individual mice. * P < 0.05 compared to hCD39AA mice.
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4.2.12 hCD39AA and hCD39AG/GG mice demonstrate similar concentrations of serum
hIFNγ in humanised mice with GVHD
Serum hIFNγ is increased in humanised NSG mice with GVHD (Geraghty et al., 2019b).
Therefore, the concentration of serum hIFNγ in humanised mice was assessed by ELISA
to further investigate the effect of donor rs10748643 genotype on the development of
GVHD in this model (Fig. 4.13). hIFNγ was detected in the serum of all mice, however
there was no significant difference in hIFNγ concentrations between hCD39AA mice(7.1
± 1.3 ng.mL-1, n = 24) and hCD39AG/GG mice (9.8 ± 1.0 ng.mL-1, n = 52) (P = 0.1185)
(Fig. 4.13).

Figure 4.13 hCD39AA and hCD39AG/GG mice demonstrate similar concentrations of serum hIFNγ. At
endpoint blood was collected from hCD39AA and hCD39AG/GG mice by cardiac puncture and serum isolated.
The concentration of serum hIFNγ was analysed by ELISA. Lines represent group mean ± SEM (hCD39AA
mice: n = 24 mice; hCD39AG/GG mice: n = 53 mice); Symbols represent individual mice.

4.3

Discussion

This study aimed to determine if the rs10748643 SNP in the human ENTPD1 gene
correlates with the proportion of CD39+ Tregs in a cohort of healthy Australian donors
and investigated if the use of donors with this SNP augments disease development in a
preclinical humanised mouse model of GVHD. The current study confirms that human
Tregs contain the highest proportions of CD39+ cells than other lymphocyte subsets
(Rissiek et al., 2015, Mandapathil et al., 2009), and that the G allele of the rs10748643
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SNP is associated with higher proportions of CD39+ Tregs (Rissiek et al., 2015, Timperi
et al., 2016a) but not on other lymphocyte subsets. Nevertheless, despite having increased
proportions of CD39+ Tregs, NSG mice engrafted with donor hPBMCs encoding the G
allele of the rs10748643 SNP displayed more severe GVHD and reduced survival rates
than NSG mice engrafted with hPBMCs homozygous for the A allele. This finding was
unexpected given the key role of CD39 for the suppressive capacity of Tregs in both mice
(Deaglio et al., 2007) and humans (Fletcher et al., 2009, Magid-Bernstein and RohowskyKochan, 2017, Borsellino et al., 2007), the importance of Treg suppression in delaying
GVHD development (Di Ianni et al., 2011, Gu et al., 2017, Ruggeri et al., 2014) and that
Tregs encoding the G allele of the rs10748643 SNP have greater immunosuppressive
function than those encoding the A allele (Rissiek et al., 2015). Furthermore, our GVHD
results are contrary to previous work indicating that CD39 is responsible for Tregmediated protection against GVHD in allogeneic (Del Papa et al., 2016) and humanised
(Gu et al., 2017) mouse models. However, unlike the current study, donor cells in these
prior studies were co-injected with high numbers of additional Tregs. Therefore, the
contrasting results may reflect the different numbers of Tregs available in the respective
studies to suppress GVHD development in mice.
In the current study the proportion of human Tregs in hCD39AA mice increased with
longer mouse survival. Since this was not apparent in hCD39AG/GG mice, our data implies
that human donor Tregs with increased CD39 expression, from donors encoding the G
allele, have impaired survival compared to Tregs from donors homozygous for the A
allele, in this humanised mouse model. This mimics the difficulties in sustaining human
Tregs in clinical trials (Tang and Vincenti, 2017). This potentially explains the more
severe GVHD development in hCD39AG/GG mice, and is consistent with clinical studies
where reduced frequencies of Tregs are associated with GVHD onset (Rezvani et al.,
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2006). Whilst the reasons why Tregs in hCD39AG/GG mice do not survive long-term is
unknown, it is speculated that Tregs from CD39AG/GG donors are more mature and have
an increased susceptibility to apoptosis following their activation in NSG mice (Fang et
al., 2016). Additionally, since CD39 is an activation marker on human T cells
(Dombrowski et al., 1998), increased CD39 may be impairing Treg survival in mice by
causing them to become exhausted (Huang et al., 2015). Lastly, whilst we observed
similar proportions of Tregs and relative splenic CD39 expression between the two
groups, there may be other functional differences between effector cells and Tregs in
hCD39AA and hCD39AG/GG mice, which may be responsible for differences in clinical
outcomes between the two groups.
The worsened GVHD in hCD39AG/GG mice was accompanied by an increase in the
hCD4+:hCD8+ T cell ratio compared to hCD39AA mice. This is in line with previous
observations, in which humanised NSG mice with clinical GVHD have higher
hCD4+:hCD8+ T cell ratios than those with subclinical GVHD (Geraghty et al., 2019b).
Notably, the increased hCD4+:hCD8+ T cell ratio, and more severe GVHD, in
hCD39AG/GG mice corresponded to increased splenic hIFNγ expression in these mice
compared to hCD39AA mice. Previous studies in this humanised mouse model have
revealed that hCD4+ and hCD8+ T cells express IFNγ (Geraghty et al., 2017), suggesting
that these cells are the most likely source of splenic hIFNγ expression in the current study.
Whilst these differences did not translate to differences in circulating hIFNγ
concentrations, the results suggest that hPBMCs encoding the G allele have an increased
ability to form T helper 1 cells, known mediators of GVHD in allogeneic (Yi et al., 2009,
Tawara et al., 2008) and humanised (Amarnath et al., 2010) mouse models and would
account for more severe GVHD in hCD39AG/GG mice. Likewise, the similar relative
expression of splenic hFoxP3 in hCD39AG/GG and hCD39AA mice is reflective of the
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comparable human Treg engraftment between the two since FoxP3 is a key transcriptional
factor on human Tregs (Rudensky, 2011, Borsellino et al., 2007) and its expression
correlates with CD127lo Tregs (Liu et al., 2006). Moreover, the similar splenic hCD39
expression between the two groups is also consistent with this since we have confirmed
that human Tregs show the highest proportions of CD39+ cells compared to other
lymphocyte subsets. This may also account for relative hIL-17 expression being similar
between hCD39AG/GG and hCD39AA mice in all tissues assessed since CD39+ Tregs are
specialised in suppressing hIL-17 in humanised mice with GVHD (Gu et al., 2017).
In the current study, histological damage to GVHD target organs in hCD39AG/GG and
hCD39AA mice did not correlate to the differences in clinical disease between the two
groups. However, this was not surprising given that all mice in the current study
eventually succumbed to GVHD and tissue was only collected for histological analysis
once mice reached ethical endpoint. It may have been more beneficial to assess
histological damage, as well as the engraftment of Tregs and other T cells, at specific
times throughout the model, rather than just at endpoint, to see if donor rs10748643
genotype influenced GVHD progression.
The current study has confirmed that human Tregs have higher proportions of CD39+
cells than CD4+ Tcons, CD8+ T cells and NK cells in freshly isolated hPBMCs. Higher
proportions of CD39+ Tregs than on other lymphocytes were expected due to the
important immunoregulatory roles of Tregs (Zhou et al., 2009, Gu et al., 2017, Rissiek et
al., 2015, Magid-Bernstein and Rohowsky-Kochan, 2017). Conversely, the detection of
low proportions of CD39+CD4+ Tcons and CD39+CD8+ T cells could indicate minor
levels of activation and exhaustion in these cells (Gupta et al., 2015, Fang et al., 2016),
as would be expected in freshly isolated PBMCs from healthy human donors. The
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identification of CD39+ NK cells in the current study is consistent with the regulatory role
of these cells in GVHD, where they can mediate the GVT effect (Ruggeri et al., 2002).
However, how CD39 influences NK cell activity in GVHD still remains unclear.
Finally, the current results demonstrated that the proportion of CD39+ Tregs in freshly
isolated hPBMCs correlates with donor rs10748643 SNP genotype, matching previous
reports (Rissiek et al., 2015). Furthermore, the current data confirms that this is not true
of human CD4+ Tcons and CD8+ T cells (Rissiek et al., 2015), and for the first time,
human NK cells. Notably, Rissiek et al. (2015) associated the G allele of the rs10748643
SNP with greater Treg immunosuppression, but this is mediated by multiple mechanisms
and requires FoxP3 (Li et al., 2015). Therefore, future studies could assess whether this
SNP influences FoxP3 expression in human Tregs to alter their function. Despite this,
donor rs107487643 genotype did not influence GVHD in our humanised mouse study as
hypothesized. Prior studies have associated the G allele of the rs10748643 SNP with a
reduced susceptibility to Crohn’s disease (Friedman et al., 2009a) and neonatal sepsis
(Timperi et al., 2016a) through Treg mediated mechanisms. Whilst these results contrast
the current study, the impact of other SNPs in the ENTPD1 gene of donor cells cannot be
excluded. For example, the rs3814159 SNP in the ENTPD1 promoter region has been
shown to impact CD39 enzymatic activity and surface expression on platelets (Maloney
et al., 2017); whilst these effects were not assessed on human immune cells in this prior
study, this SNP may be influencing the donor cells in the current study. Consequently,
despite the current results, donor ENTPD1 genotype may still have important roles in
allo-HSCT and in GVHD in humans.
In conclusion, the current study confirms that the G allele of the rs10748643 SNP
increases proportions of CD39+ human Tregs, but not other lymphocyte subsets.
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However, the use of donor hPBMCs encoding the G allele worsened GVHD severity and
reduced survival in this humanised mouse model. This may be due to the lack of
persistence of CD39+ Tregs in the humanised mice, but further studies are required to
check this and to confirm whether donor rs10748643 SNP variation influences the
development of GVHD in human patients.
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Chapter 5:

Post-Transplant Cyclophosphamide Reduces the Development of

Graft-Versus-Host Disease in a Humanised Mouse Model
5.1

Introduction

The activation and proliferation of reactive donor T cells is a central step in graft-versushost disease (GVHD) (Zhang et al., 2005a, Gendelman et al., 2003). These cells
subsequently migrate to GVHD target organs and initiate severe inflammatory tissue
damage by releasing pro-inflammatory cytokines, such as interferon (IFN)-γ and
interleukin (IL)-17 (Fowler, 2006). As a result, the depletion of alloreactive donor T cells
in vivo following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a
current therapeutic strategy to reduce GVHD (Vadakekolathu and Rutella, 2017, Kanakry
et al., 2016). However, currently, reactive donor T cell depletion does not prevent GVHD.
Cyclophosphamide (Cy) is an alkylating agent that is administered post-transplant
(PTCy), and reduces GVHD in allogeneic mouse models (Ganguly et al., 2014) and
human allo-HSCT recipients (McCurdy et al., 2015, Luznik et al., 2008). Following
metabolism by the liver, Cy intercalates with DNA and disrupts the division of rapidly
proliferating cells, such as alloreactive donor T cells in GVHD (Williams et al., 2020).
Clinically, PTCy (10-50 mg.kg-1) given on day 3 and 4 post-allo HSCT reduces, but does
not prevent, GVHD (Kanakry et al., 2016). Higher dosages (up to 100 mg.kg-1), and
altered regimes, have been investigated in allogeneic mouse models of GVHD but have
not shown improved therapeutic effect than the standard administration (Wachsmuth et
al., 2020).
Importantly, PTCy is not associated with increased rates of cancer relapse or malignancy
(Majzner et al., 2017) and is relatively inexpensive. Further, PTCy promotes the
reconstitution of regulatory T cells (Tregs)(Wachsmuth et al., 2020). Tregs are protected
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against PTCy depletion due to the expression of aldehyde dehydrogenase in these cells
(Kanakry et al., 2013a), and the absence of Tregs in allo-HSCT recipients prevents PTCy
from reducing GVHD (Kanakry et al., 2014).
PTCy is commonly used following allo-HSCT but it is still unclear how PTCy reduces
GVHD. Due to early work in skin allograft models it has long been believed that PTCy
reduces allograft rejection (Berenbaum and Brown, 1964, Berenbaum and Brown, 1963)
and induces tolerance (Nirmul et al., 1973, Nirmul et al., 1971) by eliminating reactive
CD4+ T cells (Eto et al., 1991). However, this paradigm has been recently challenged.
Using MHC matched allogeneic mouse models of GVHD, Wachsmuth et al. (2019)
convincingly demonstrated that PTCy impairs the proliferation of alloreactive CD4+ and
CD8+ T cells but does not eliminate them. Moreover, PTCy was able to induce significant
donor T cell dysfunction to reduce GVHD.
Despite a number of studies investigating PTCy and GVHD in allogeneic mouse models,
there are no well-established humanised mouse model of GVHD using PTCy, which more
accurately reflect clinical settings. Taken together, this warrants further investigation into
the mechanism of how PTCy reduces the development of GVHD. Further, since PTCy
does not completely prevent GVHD in mice or humans, this treatment may need to be
combined with other strategies. This requires well-established mouse models of GVHD
using PTCy. Therefore, this chapter aimed to determine the effect of PTCy on reactive
donor T cells and on GVHD development in the humanised NSG mouse model of GVHD,
as previously used in Chapters 3 and 4.
The data in this chapter forms a research manuscript to be submitted to the journal
Clinical and Translation Immunology with some data obtained by Mr. Peter Cuthbertson
(University of Wollongong, Australia), as indicated.
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5.2

Results

5.2.1

PTCy reduces reactive human donor T cells in the livers of humanised NSG

mice
PTCy reduces GVHD in mice (Luznik et al., 2010, Wachsmuth et al., 2019) and humans
(Wang et al., 2017, Kanakry et al., 2014), however there is conflicting data regarding the
mechanism of action of PTCy in GVHD. To determine if PTCy depletes reactive donor
T cells in vivo, NSG mice were injected i.p. with 20 x 106 human peripheral blood
mononuclear cells (hPBMCs) labelled with carboxyfluorescein succinimidyl ester
(CFSE) and treated with PTCy (33 mg.kg-1) or saline on days 3 and 4 post-hPBMC
injection (Fig. 5.1). This regime is used clinically to reduce GVHD (Kanakry et al., 2016)
and can deplete up to 50% of donor cells in allogeneic mouse models (Ross et al., 2013).
Therefore, NSG mice in the current study were injected with 20 x 106 hPBMCs to allow
human immune cell engraftment in case of 50% depletion by PTCy.
PTCy is metabolised in the liver and human (h) CD3+ T cells are known to traffic to the
livers of NSG mice (Cuthbertson et al., 2020). Therefore, mice were assessed for the
depletion of proliferating (reactive) (CFSE low) hCD3+ T cells in the liver on day 6 by
flow cytometry using a consistent gating strategy (Fig. 5.2a-f). In the liver, PTCy
significantly reduced the proportions (18.2% reduction) of reactive hCD3+ T cells in
PTCy-mice (66.9 ± 2.4% hCD45+hCD3+CFSElow cells, n = 9) compared to saline-mice
(82.0 ± 1.5% hCD45+hCD3+CFSElow cells, n = 8) (P = 0.0453) (Fig.5.2h). Flow
cytometry of mouse livers was performed by Mr. Peter Cuthbertson.
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Figure 5.1 Humanised mouse model to investigate if PTCy depletes reactive human donor T cells.
NSG mice were injected i.p. with 20 x 106 hPBMCs stained with CFSE, and subsequently injected i.p. with
PTCy (33 mg.kg-1), or saline, on days 3 and 4 post-hPBMC injection. Mice were euthanised at day 6 and
checked for the presence of reactive human donor T cells by immunophenotyping the liver, spleen and
blood using flow cytometry

Figure 5.2 PTCy reduces reactive human donor T cells in the livers of humanised NSG mice at day 6
post-hPBMC injection. PTCy- and saline-mice were assessed for the presence of reactive human donor T
cells at day 6 post-hPBMC injection by immunophenotyping mouse livers by flow cytometry using (a-f) a
consistent gating strategy. (a) Lymphocytes were gated based on forward scatter (FSC)-A and side scatter
(SSC)-A and live cells identified using (b) Zombie NIR staining. (c) hCD45+ leukocytes were gated and
(d) hCD3+ T cells identified within this population. (e,f) Reactive (CFSElow) and non-reactive (CFSEhi)
hCD3+ T cells were identified in livers of (e) saline and (f) PTCy mice. (g) hCD3+ T cells are expressed as
a percentage of total of hCD45+ Leukocytes (h) Alloreactive hCD3+CFSElow T cells are expressed as a
percentage of total of hCD3+ T cells. (g, h) Lines represent group mean ± SEM (PTCy: n = 8 mice; saline:
n = 9 mice); symbols represent individual mice. * P < 0.05 compared to PTCy-mice.
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5.2.2

PTCy does not reduce reactive donor T cells in the spleens of humanised NSG

mice
Humanised NSG mice injected i.p. with hPBMCs engraft large proportions of human T
cells in the spleen (Geraghty et al., 2017). Therefore, spleens from the above mice (section
1.2.1) were also assessed for the depletion of reactive hCD3+ T cells on day 6 using flow
cytometry (Fig. 5.1) using a consistent gating strategy (Fig. 5.3a-f). PTCy-mice
demonstrated slightly reduced proportions (14.4% reduction) of splenic reactive hCD3+
T cells compared to saline-mice (47.3 ± 7.14%, n = 7 vs. 61.5 ± 3.95%, n = 9,
respectively), and this approached significance (P = 0.0753) (Fig. 5.3h). Attempts were
made to measure the proportions of reactive hCD3+ T cells in mouse blood at day 6,
however too few human cells were detected to allow statistical analysis (data not shown).

Figure 5.3 PTCy does not reduce reactive human donor T cells in the spleens of humanised NSG mice
at day 6 post-hPBMC injection. PTCy- and saline-mice were assessed for the presence of reactive human
donor T cells at day 6 post-hPBMC injection by immunophenotyping mouse spleens by flow cytometry
using (a-f) a consistent gating strategy. (a) Lymphocytes were gated based on forward scatter (FSC)-A and
side scatter (SSC)-A and live cells identified using (b) Zombie NIR staining. (c) hCD45+ leukocytes were
gated and (d) hCD3+ T cells identified within this population. (e,f) Reactive (CFSElow) and non-reactive
(CFSEhi) hCD3+ T cells were identified in spleens of (e) saline and (f) PTCy mice. (g) hCD3+ T cells are
expressed as a percentage of total of hCD45+ Leukocytes (h) Alloreactive hCD3+CFSElow T cells are
expressed as a percentage of total of hCD3+ T cells. (g, h) Lines represent as a group mean ± SEM (PTCy:
n = 8 mice; saline: n = 9 mice); symbols represent individual mice.
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5.2.3

PTCy does not influence the engraftment of human T cell subsets in NSG

mice at 3 weeks post-hPBMC injection
To determine the therapeutic effect of PTCy on the development of GVHD in this
humanised mouse model, NSG mice were injected i.p. with 20 x 106 CFSE labelled
hPBMCs, followed by either PTCy (33 mg.kg-1) (n = 17 mice) or saline (n = 16 mice) on
days 3 and 4 post-hPBMC injection. Mice were monitored for clinical GVHD (Table 2.3)
for up to 10 weeks (Fig. 5.4).

Figure 5.4 Humanised mouse model to investigate the therapeutic effect of PTCy on the development
of GVHD. NSG mice were injected i.p. with 20 x 106 hPBMCs stained with CFSE, and subsequently
injected i.p. with PTCy (33mg.kg-1), or saline, on days 3 and 4 post-hPBMC injection (PTCy: n = 17, n =
2 donors; saline: n = 16, n = 2 donors). Mice were monitored for clinical GVHD by monitoring weight loss
and GVHD clinical score (Table 2.3) for up to 10 weeks post-hPBMC injection. Mice were checked for the
engraftment of human T cell subsets at 3 weeks post-hPBMC injection by immunophenotyping tail blood
using flow cytometry. At endpoint human T cell engraftment was checked by immunophenotyping mouse
spleens. Histological damage and the relative expression of inflammatory cytokines in GVHD target organs
(liver, small intestines and skin) was assessed by haematoxylin and eosin staining and qPCR, respectively.
The concentration of inflammatory cytokines in mouse sera was assessed by LEGENDplex.

At 3 weeks post-hPBMC injection the engraftment of human lymphocytes was checked
by flow cytometry of mouse tail blood using a consistent gating strategy (Fig. 5.5a-e).
PTCy- and saline-mice demonstrated similar proportions of hCD45+ leukocytes (32.9 ±
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5.1% hCD45+mCD45- cells, n = 16 vs. 40.9 ± 4.2% hCD45+mCD45- cells, n = 13,
respectively) (P = 0.2492) (Fig.5.5f), which were mainly hCD3+ T cells (PTCy: 97.4 ±
0.6% hCD3+ cells, n = 16; saline: 97.5 ± 0.5% hCD3+ cells, n = 13) (P = 0.9310) (Fig.
5.5g). Moreover, PTCy- and saline-mice demonstrated comparable frequencies of
hCD3+hCD4+ T cells (35.8 ± 3.6%, n = 16 vs. 43.2 ± 3.3%, n = 13, respectively) (P =
0.1538) and hCD3+hCD8+ T cells (57.1 ± 4.1%, n = 16 vs. 49.2 ± 3.7%, n = 13) (P =
0.1733) (Fig. 5.5h). While the proportions of hCD3+hCD8+ T cells was significantly
higher than hCD3+hCD4+ T cells in PTCy-mice (P = 0.0004), but not saline-mice (P =
0.2365) (Fig. 5.5h), both groups demonstrated similar hCD4+:hCD8+ T cell ratios (PTCy:
0.8 ± 0.1, n = 16; saline: 1.0 ± 0.1, n =13) (P =0.3648) (Fig. 5.5i).
5.2.4

PTCy increases the hCD4+:hCD8+ T cell ratio and reduces the proportions

of hCD4+hCD25+hCD127lo Tregs in NSG mice at endpoint
At endpoint, the engraftment of human leukocytes was assessed in mouse spleens using
flow cytometry with a consistent gating strategy (Fig. 5.6a-f). PTCy- and saline-mice
demonstrated comparable proportions of splenic hCD45+ leukocytes (PTCy: 77.4 ± 3.1%
hCD45+mCD45- cells, n = 16; saline: 72.3 ± 3.0% hCD45+mCD45- cells, n = 17) (P =
0.2538) (Fig. 5.6g). hCD3+ T cells comprised the majority of this population in both
groups (PTCy: 86.4 ± 2.1%, n = 16; saline: 85.0 ± 2.1%, n = 17) (P = 0.6570) (Fig. 5.6h).
However, PTCy-mice displayed significantly higher proportions of hCD3+hCD4+ T cells
(68.2 ± 4.6%, n = 16) and significantly lower proportions of hCD3+hCD8+ T cells (28.3
± 3.5%, n = 16) compared to saline-mice (hCD3+hCD4+ cells: 50.1 ± 4.6%, n =17, P =
0.0088; hCD3+hCD8+ cells: 68.2 ± 4.6%, n = 17, P = 0.0063) (Fig. 5.6i). This resulted in
significantly higher hCD4+:hCD8+ T cell ratios in PTCy-mice compared to saline-mice
(3.1 ± 0.5, n = 16 vs. 1.5 ± 0.5, n = 17) (P = 0.022) (Fig. 5.6j).
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Figure 5.5 PTCy does not influence the engraftment of human T cells in humanised mice at 3 weeks
post-hPBMC injection. PTCy- and saline-mice were checked for the engraftment of human T cells at 3
weeks post-hPBMC injection by immunophenotyping tail blood by flow cytometry using (a-e) a consistent
gating strategy. (a) Single cells were identified based on forward scatter area (FSC-A) and height (FSC-H)
and (b) lymphocytes were gated based on FSC-A and side scatter (SSC)-A. (c) hCD45+ and mCD45+
leukocytes were gated and (d) hCD3+ T cells identified. (f) hCD45+ leukocytes are expressed as a
percentage of total mCD45+ and hCD45+ leukocytes. (g) hCD3+ T cells are expressed as a percentage of
total hCD45+ leukocytes. (h) hCD4+ and hCD8+ T cells are expressed as a percentage of hCD3+ T cells with
the (i) hCD4+:hCD8+ T cell ratio. (f-h) Lines represent group means ± SEM (PTCy: n = 16; saline: n = 13);
symbols represent individual mice. (h) * P < 0.05 compared to hCD4+ T cells in PTCy-mice.

Tregs are required for PTCy to reduce GVHD (Ganguly et al., 2014), and are protected
against PTCy depletion (Kanakry et al., 2013a). Notably, PTCy-mice demonstrated
significantly reduced proportions of hCD4+hCD25+hCD127lo Tregs (2.5 ± 0.3%, n = 16)
than saline-mice (5.3 ± 0.6%, n = 17) (P = 0.0003) (Fig. 5.6k). CD39 is important for
Tregs to reduce GVHD in humanised mice (Gu et al., 2017). However, PTCy-mice and
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saline-mice demonstrated similar proportions of hCD39+ Tregs (62.4 ± 2.2%, n = 16 vs.
55.7 ± 1.4%, n = 17, respectively) (P = 0.6284) (Fig. 5.6l).

Figure 5.6 PTCy increases the hCD4+:hCD8+ T cell ratio and reduces hCD4+hCD25+hCD127lo Tregs
in humanised NSG mice. PTCy- and saline-mice were checked for the engraftment of human T cell subsets
at endpoint by immunophenotyping mouse spleens with flow cytometry using (a-g) a consistent gating
strategy. (a) Single cells were identified based on forward scatter (FSC) area and height and (b)
lymphocytes were gated based on FSC-A and side scatter (SSC)-A. (c) hCD45+ and mCD45+ leukocytes
were gated and (d) hCD3+ T cells identified. (e) hCD4+ and hCD8+ T cells were gated and (f)
hCD3+hCD4+hCD25+hCD127lo (hCD4+) Tregs (g) hCD39+ Tregs were identified. (h) hCD45+ leukocytes
are expressed as a percentage of total mCD45+ and hCD45+ leukocytes. (i) hCD3+ T cells are expressed as
a percentage of total hCD45+ leukocytes. (j) hCD4+ and hCD8+ T cells are expressed as a percentage of
hCD3+ T cells with the (k) calculated hCD4+:hCD8+ T cell ratio. (l) hCD4+CD25+CD127lo Tregs (hCD4+
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Tregs) are expressed as a percentage of hCD4+ T cells. (m) hCD39+hCD4+ Tregs are expressed as a
percentage of hCD4+Tregs. (h-m) Lines represent group means ± SEM (PTCy: n = 17 mice; saline: n = 16
mice); symbols represent individual mice. (j) ** P < 0.01, compared to hCD4+ T cells in PTCy-mice, †† P
< 0.01 compared to hCD8+ T cells in PTCy-mice; (k) * P < 0.05, compared to saline-mice. (l) *** P <0.001,
compared to PTCy-mice.

5.2.5

PTCy reduces the proportions of hCD38+hCD8+ effector memory cells in

NSG mice at endpoint
In human allo-HSCT recipients, increases in CD4+ and CD8+ memory T cells are
associated with an increased risk for GVHD (de Latour et al., 2013, Loschi et al., 2015)
In the current study, the proportions of splenic hCD4+ and hCD8+ memory T cell subsets
were assessed at endpoint by flow cytometry using a consistent gating strategy (Fig. 5.7
a-h). hCD4+ and hCD8+ memory T cells were classed into four subsets based on CD45RA and CCR7; naive (hCD45-RA+hCCR7+), effector memory (EM) (hCD45-RAhCCR7-), central memory (CM) (hCD45-RA-hCCR7+) and terminally differentiated
effector memory (TEMRA) (hCD45-RA+hCCR7-) (Mullen et al., 2012).
PTCy- and saline-mice engrafted similar proportions of hCD4+ EM T cells (PTCy: 93.0
± 1.4%, n = 16; saline: 96.4 ± 0.7%, n =11) (P = 0.075), which was significantly higher
than all other CD4+ T cell subsets in both groups (P < 0.0001 for all) (Fig. 5.7i). Similarly,
both mouse groups demonstrated similar engraftment of hCD4+ naive (PTCy: 0.1 ± 0.1%,
n = 16; saline: 0.2 ± 0.1%, n = 11) (P = 0.1051), hCD4+ CM (PTCy: 0.6 ± 0.2% cells, n
= 16; saline: 2.4 ± 1.2%, n = 11) (P = 0.1311) and hCD4+ TEMRA cells (PTCy: 2.3 ±
0.8% cells, n = 16; saline: 2.9 ± 0.9% cells, n = 11) (P = 0.7891) cells (Fig. 5.7i).
hCD8+ EM cells were found at significantly higher proportions than all other CD8+ T cell
subsets in both PTCy- and saline-mice (P < 0.0001 for all), however both groups
demonstrated similar proportions of hCD8+ EM cells (94.3 ± 1.4%, n = 13 vs. 93.6 ±
1.35%, n = 11, respectively) (P = 0.6935) (Fig. 5.7k). Both groups demonstrated small,
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but similar, proportions of hCD8+ naïve (PTCy: 0.9 ± 0.5%, n = 13; saline: 0.1 ± 0.1%, n
= 11) (P = 0.1321), hCD8+ CM (PTCy: 0.7 ± 0.3%, n = 13; saline: 2.0 ± 1.1%, n = 11)
(P = 0.2858) and hCD8+ TEMRA cells (PTCy: 2.1 ± 0.8%, n = 13; saline: 4.6 ± 1.2%, n
= 11) (P = 0.1009) (Fig. 5.7j).
In human allo-HSCT recipients, the proportions of CD38bright EM cells may predict
GVHD severity (Khandelwal et al., 2015). Therefore, hCD38 was assessed on hCD4+ and
hCD8+ EM T cells in the current study (Fig 5.7a-l). Too few hCD38bright hCD4 and hCD8
EM cells were identified to allow statistical analysis (Fig 5.7 f, h). Therefore the
proportions of hCD38+ EM cells were assessed. hCD38+hCD4+ EM were present in both
PTCy- (19.0 ± 6.1%, n = 16) and saline-mice (23.5 ± 6.1%, n = 11), at similar levels (P
= 0.6165) (Fig. 5.7k). In contrast, PTCy-mice demonstrated lower proportions (26.4%
reduction) of hCD38+hCD8+ EM cells than saline-mice (39.6 ± 7.2%, n = 17 vs. 53.8 ±
10.3%, n = 13), which approached significance (P = 0.0506) (Fig. 5.7l).
5.2.6

PTCy significantly reduces GVHD development in humanised NSG mice

GVHD development in humanised NSG mice was assessed by monitoring weight loss
and clinical symptoms (Table 2.3) for up to 10 weeks (Fig. 5.8a-c). Weight loss was
observed from day 33 in PTCy-mice and day 17 in saline-mice (Fig. 5.8a). Overall weight
loss was significantly reduced in PTCy-mice compared to saline-mice (P = 0.0447). Both
groups began exhibiting clinical GVHD symptoms from day 14, however PTCy-mice
demonstrated significantly reduced clinical scores over 10 weeks compared to salinemice (P = 0.0473) (Fig. 5.8b). PTCy-mice began to exhibit GVHD-related mortality from
day 28, however 21% of PTCy-mice survived to day 70 with a median survival time
(MST) of 58 days. Conversely, saline-mice exhibited GVHD-related mortality from day
13 and all succumbed to GVHD by day 68, with a MST of 30.5 days. PTCy-mice
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demonstrated significantly greater overall survival than saline-mice (P = 0.004) (Fig.
5.8c).

Figure 5.7 PTCy lowers the proportion of hCD38+hCD8+ EM cells in humanised NSG mice. PTCyand saline-mice were checked for the engraftment of human memory T cell subsets at endpoint by flow
cytometric analysis of mouse spleens. (a-h) a consistent gating strategy. Single cells were gated by forward
scatter area (FSC-A) and height (FSC-H), and (b) viable single lymphocytes gated within this population
using FSC-A and side scatter (SSC-A). (c) hCD3+ T cells, (d) hCD3+hCD4+ and hCD3+hCD8+ T cells were
then identified. (e, g) hCD45-RA+hCCR7+ naive, hCD45-RA-hCCR7+ CM, hCD45-RA-hCCR7- EM and
hCD45-RA+hCCR7- TEMRA memory T cell subsets were then identified within (e) hCD3+hCD4+ and (g)
hCD3+hCD8+ T cell subsets. CD38+ (f) hCD4+ and (h) hCD8+ EM cells were then identified. (f, h)
hCD38bright and hCD38+ EM cells are highlighted. (i, j) Memory T cell subsets are expressed as a percentage
of total (i) hCD3+hCD4+ T cells and (j) hCD3+hCD8+ T cells. (k, l) CD38+ EM cells are expressed as a
percentage of (k) hCD4+ and (l) hCD8+ EM cells. (i-l) Lines represent group means ± SEM (PTCy: n = 17
mice; saline: n = 13 mice); symbols represent individual mice. (i, j) * P < 0.0001, compared to
corresponding naive, CM and TEMRA cells in PTCy-mice, † P < 0.0001 compared to naive, CM and
TEMRA cells in saline-mice.
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Figure 5.8 PTCy reduces the development of GVHD in humanised mice. PTCy- and saline-mice were
monitored for the development of clinical GVHD for up to 10 weeks post-hPBMC injection by assessing
(a) weight loss, (b) GVHD clinical score and (c) survival. Data represents (a, b) group means ± SEM or (c)
percentage survival. (a) P = 0.0447, (b) P = 0.0473, (c) P = 0.004. (a-c) PTCy: n = 17 mice; saline: n =
16 mice.

5.2.7

PTCy-treated mice demonstrate reduced histological damage to GVHD

target organs than saline-treated mice
GVHD damages the liver, small intestine and skin of NSG mice injected with hPBMCs
(Cuthbertson et al., 2020). Therefore, histological assessment of these tissues was
performed in the current study (Fig. 5.9a-c).
Leukocyte infiltration was dramatically reduced in the livers of PTCy-mice compared to
saline-mice (Fig. 5.9a). PTCy-mice demonstrated greater preservation of hepatic
structures including portal veins and bile ducts, which was not apparent in saline-mice
136

(Fig. 5.9a). Both groups showed little signs of GVHD in the small intestines (Fig. 5.9b).
Slight

skin

GVHD

was

apparent

in

both

PTCy-

and

saline-mice

with

minimal amounts of leukocyte infiltration and dermis detachment (Fig. 5.9c).
5.2.8

The proportion of human Tregs negatively correlates with survival in PTCy-

mice, but not saline-mice
Tregs demonstrate poor survival following transplantation in clinical trials (Tang and
Vincenti, 2017), but are thought to be necessary for PTCy mediated protection against
GVHD (Wang et al., 2017, Wachsmuth et al., 2019, Ganguly et al., 2014). Therefore, the
association between human Treg proportions and mouse survival in the current study was

Figure 5.9 PTCy reduces histological damage to GVHD target organs in humanised mice. PTCy- and
saline-mice were assessed for histological damage to GVHD target organs at endpoint. 5 μm sections of (a)
liver, (b) small intestine and (c) skin tissue from saline-mice and PTCy-mice were cut and stained with
haematoxylin and eosin and imaged by microscopy. Representative images from four mice per group are
shown; bars represent 100 µm. (a) Infiltrating leukocytes in the liver are indicated by red arrows.

assessed (Fig. 5.10 a,b). Notably, the proportions of human Tregs in PTCy-mice
negatively correlated with mouse survival (r2 = 0.2664, P = 0.0342) (Fig. 5.10b). This
correlation was not present in saline-mice (r2 = 0.1237, P = 0.1816) (Fig. 5.10a).
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Figure 5.10 PTCy reduces human Treg survival in humanised NSG mice. PTCy- and saline-mice were
checked from the engraftment of human hCD3+hCD4+hCD25+hCD127lo Tregs (hCD4+ Tregs) a, b Pearson
correlation of the percentage of hCD4+ Tregs, within hCD4+ T cells, vs mouse survival for a saline-mice
and b PTCy-mice (PTCy: n = 17 mice; saline: n = 16 mice). Symbols represent individual mice.

5.2.9

PTCy- and saline-mice show similar relative hFoxP3 expression in spleens

and GVHD target organs
Forkhead box P3 (FoxP3) is a characteristic marker of human Tregs (Hori et al., 2003),
where its expression inversely correlates with CD127 (Liu et al., 2006). Therefore, the
relative expression of hFOXP3 was assessed in spleens and GVHD target organs in
PTCy- and saline-mice in the current study by qPCR (Fig. 5.11a-c).
hFOXP3 was detected in all tissues, but PTCy- and saline-mice demonstrated similar
relative hFOXP3 expression in the spleen (4.5 ± 2.1, n = 11 vs. 5.8 ± 2.4, n = 9,
respectively) (P = 0.7047) (Fig. 5.11a), liver (PTCy: 0.6 ± 0.3, n = 9; saline: 1.0 ± 0.3, n
= 7) (P = 0.4125) (Fig. 5.11b) and small intestine (PTCy: 1.5 ± 0.2, n = 11; saline: 1.4 ±
0.2, n = 11) (P = 0.7649) (Fig. 5.11c).
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Figure 5.11 PTCy does not affect the relative hFOXP3 expression in spleen or GVHD target organs
of humanised mice. RNA was extracted and cDNA synthesized from (a) spleen, (b) liver and (c) small
intestines of PTCy- and saline-mice at endpoint. The relative expression of hFOXP3 was measured in
mouse tissue by qPCR Lines represent group mean ± SEM (n = 7-11 mice per group); symbols represent
individual mice.

5.2.10 PTCy-mice demonstrate significantly lower relative hIL17 expression in the
small intestines compared to saline-mice
PTCy alters the amounts of pro-inflammatory cytokines in human patients with GVHD
(Pirogova et al., 2017). Therefore, in the current study, the relative expression of hIFNγ
(hIFNG) and hIL-17A (hIL17A) were assessed by qPCR (Fig. 5.13a-c).
Both PTCy- and saline-mice demonstrated comparable relative hIL17A expression in the
spleen (3.35 ± 0.71, n = 11 vs. 3.76 ±1.21, n = 11, respectively) (P = 0.3883) (Fig. 5.12a)
and liver (2.99 ± 1.01, n = 10 vs. 3.43 ± 0.91, n = 10, respectively) (P = 0.7562) (Fig.
5.12b). However relative hIL17A expression in the small intestine was significantly
reduced (60.8% reduction) in PTCy-mice (3.31 ± 0.56, n = 11) compared to saline-mice
(8.43 ± 2.02, n = 9) (P = 0.0157) (Fig. 5.12c). Whilst not significant, relative splenic
hIFNG expression was 2-fold higher in PTCy-mice (4.90 ± 1.26, n = 11) than saline-mice
(2.42 ± 0.71, n = 9) (P = 0.1004) (Fig. 5.12d). In contrast, the relative hIFNG expression
in the liver (PTCy: 2.62 ± 0.68, n = 9; saline: 2.46 ± 0.43, n = 10) (Fig. 5.12e) and small
intestine (PTCy: 2.07 ± 0.78, n = 11; saline: 1.80 ± 0.52, n =11) (Fig. 5.12f) was similar
in both treatment groups (liver: P = 0.8358; small intestines: P = 0.6790).
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Figure 5.12 PTCy reduces relative hIL17A expression in the small intestines of humanised mice. RNA
was extracted and cDNA synthesized from the (a, d) spleen, (b, e) liver and (c, f) small intestine of PTCyand saline-mice at endpoint. The relative expression of (a-c) hIFNG and (d-f) hIL17A expression measured
in mouse tissue by qPCR. Lines represent group mean ± SEM (n = 9-11 mice per group); symbols represent
individual mice. * P < 0.05 compared to PTCy-mice.

5.2.11 PTCy does not affect the concentration of T cell cytokines in the sera of
humanised mice
T cell cytokines play crucial roles in GVHD pathogenesis (Blazar et al., 2012), and are
reduced in the sera of mice treated with PTCy in allogeneic models of GVHD
(Wachsmuth et al., 2019). In the current study, a flow cytometric cytokine assay was
performed on mouse sera to determine if PTCy influences the concentrations of T cell
cytokines (hIL-2, hIL-6, hIL-10, hTNFα and hIFNγ) in humanised NSG mice (Fig. 5.13ae).
The hIL-2 concentration in PTCy-mice (4.1± 0.6 pg.mL-1, n = 12) was 1.4-fold higher
than saline-mice (2.9 ± 0.2 pg.mL-1, n = 12), and this approached statistical significance
(P = 0.0728) (Fig. 5.13a). Both PTCy- and saline-mice demonstrated similar low
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concentrations of serum hIL-6 (9.5 ± 3.8 pg.mL-1, n = 14 vs 5.9 ± 1.6 pg.mL-1, n = 15,
respectively) (P = 0.3742) (Fig. 5.13b), hIL-10 (32.9 ± 5.6 pg.mL-1, n = 15 vs 50.1 ± 11.9
pg.mL-1, n = 14, respectively) (P = 0.1949) (Fig. 5.13c) and hTNFα (26.7 ± 3.4 pg.mL-1,
n = 14 vs. 28.8 ± 5.2 pg.mL-1, n = 14, respectively) (P = 0.7414) (Fig. 5.13d). Finally,
both groups also demonstrated similar, and relatively high, concentrations of serum
hIFNγ (19500 ± 2078 pg.mL-1, n = 14 vs 15934 ± 2371 pg.mL-1, n = 14, respectively) (P
= 0.2684).

Figure 5.13 PTCy does not affect the concentration of Th1 cytokine in the sera of humanised mice.
At endpoint blood was collected from PTCy- and saline-mice by cardiac puncture and serum isolated. The
concentration of (a) hIL-2, (b) hIL-6, (c) hIL-10, (d) hTNFα and (e) hIFNγ were analysed analysed using
a Th1 LEGENDplex kit. Lines represent group mean ± SEM (n = 11-16 mice per group); symbols represent
individual mice.

5.3

Discussion

This study demonstrates that PTCy lowers the severity, and delays the onset, of GVHD
in humanised NSG mice. This corresponded to reduced reactive human donor T cells in
the liver and to a lesser extent, the spleen at day 6. PTCy reduced the engraftment of
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hCD38+hCD8+ EM T cells, improved mouse survival and reduced both histological liver
damage and the expression of hIL17A in the small intestines. However, inconsistent with
less severe GVHD, PTCy-mice demonstrated increased hCD4+:hCD8+ T cell ratios and
reduced proportions of human Tregs.
The current study demonstrates that PTCy reduces proliferating reactive human donor T
cells in humanised NSG mice. This parallels allogeneic mouse models of GVHD where
PTCy has been shown to deplete reactive donor T cells (Eto et al., 1991, Eto et al., 1990a,
Ross et al., 2013). However, it remains unclear if PTCy impact the number of reactive
donor T cells in humanised NSG. This could be determined in future studies using count
beads. Other studies have reported that 25 mg.kg-1 PTCy on day 3 and 4 post allo-HSCT
reduces proliferating CD3+CD4+ conventional T cells in the blood and spleen on day 7
(Wachsmuth et al., 2020). In the current study, reactive human donor T cells in PTCymice were greatly reduced in the liver and less so in the spleen, which almost reached
significance. This was most likely a result of PTCy being metabolised in the liver
(McDonald et al., 2003), but this chapter is the first to demonstrate organ specific effects
of PTCy in GVHD. In contrast to the current results, a recent allogeneic mouse study has
suggested that PTCy reduces GVHD by inducing T cell functional impairment and not
depletion (Wachsmuth et al., 2019). The possibility remains that reactive human donor T
cells in humanised NSG mice in the current study were also functionally impaired,
however this was not assessed. Furthermore, whether PTCy depletes specific T cell
subsets in this model remains unclear. Although PTCy-mice demonstrated reduced
splenic hCD3+hCD8+ T cells, whether these cells were divided could not be determined
due to an inability to detect CFSE at endpoint. This may have explained the increased
hCD4+:hCD8+ T cell ratios in PTCy-mice despite the reduced GVHD.
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PTCy can reduce GVHD by exerting effects on GVHD effector T cells or by enhancing
Tregs (Ikegawa et al., 2019). The current data suggests that PTCy is functioning
predominantly through the effector arm in this humanised mouse model. In this chapter
PTCy reduced human Tregs in humanised NSG mice. This was unexpected given the
important role for Tregs in preventing GVHD (Di Ianni et al., 2011, Ruggeri et al., 2014),
and that Tregs are necessary for PTCy to reduce GVHD in mice and humans (Ganguly et
al., 2014, Wachsmuth et al., 2019, Wang et al., 2017). Moreover, Tregs are reported to be
resistant to PTCy depletion (Kanakry et al., 2013a), reconstitute rapidly following PTCy
(Kanakry et al., 2014) and inversely correlate to GVHD severity in humanised NSG mice
(Bruck et al., 2013, Achita et al., 2018). The contrasting results may reflect the timing
when Tregs were assessed. These previous studies assessed Tregs before day 30, whereas
Tregs in the current study were only assessed at endpoint. Since the MST of PTCy-mice
in our study was 58 days, the possibility remains that Tregs may have been preserved
earlier. Other studies in humanised NSG mice have observed splenic human Tregs as
early as day 14 (Ehx et al., 2018). Importantly, hFOXP3 was detected in GVHD target
organs, suggesting the presence of Tregs in these tissues. Therefore, future studies could
use immunohistochemistry to quantify tissue resident Tregs and, in the liver, see if
increased Tregs are associated with the reduced histological damage. Human Tregs in
humanised NSG mice with GVHD have been previously observed by our laboratory
(Geraghty et al., 2019c, Geraghty et al., 2019a, Geraghty et al., 2019d, Geraghty et al.,
2017), however PTCy is the first treatment in our laboratory to show that a drug can
impact the proportions of these cells in humanised NSG mice.
EM cells were the main memory T cell subset in humanised NSG mice in the current
study, consistent with other xenogeneic mouse models of GVHD (Ehx et al., 2018). The
reduced GVHD in PTCy-mice corresponded to reduced proportions of hCD38+hCD8+
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EM cells. CD38+CD8+ EM cells have been associated with more severe GVHD
(Khandelwal et al., 2015) and may propagate the disease since they are activated and have
enhanced cytotoxic capabilities (Khandelwal et al., 2020). This chapter is the first to
report hCD38+hCD8+ EM cells as a potential effector cell subset in GVHD in humanised
mouse models, and their lower engraftment in PTCy-mice reflects the less severe GVHD,
consistent with clinical settings (Khandelwal et al., 2020, Khandelwal et al., 2015). Whilst
this difference approached significance, it will need to be validated by more highly
powered studies. Notably, CXCR6, a trafficking marker involved in the recruitment of
human leukocytes to the liver (Sato et al., 2005), is up-regulated on CD38+CD8+ EM cells
(Khandelwal et al., 2020). This may account for the reduced liver infiltrates in PTCymice where there are fewer of these cells.
Studies investigating PTCy in humanised mouse models of GVHD are limited, but our
results parallel Ganguly et al. (2014), Kanakry et al. (2013a) who showed abrogated
GVHD, and reduced reactive human donor T cells in humanised mice receiving 100
mg.kg-1 PTCy on day 3. Although the current study used a lower dose of PTCy, 33mg.kg1

is a standard clinical dosage following allo-HSCT (Kanakry et al., 2016). Furthermore,

PTCy administration on day 3 and 4 is an optimal dosage regime in allogeneic mouse
models of GVHD (Wachsmuth et al., 2020) and clinical settings (Kanakry et al., 2016).
Additionally, this Chapter is the first to examine organ specific effects of PTCy in
humanised mouse and a potential mechanism of action. Finally the lower GVHD severity
and delayed onset in PTCy-mice is consistent with clinical allo-HSCT, as PTCy does not
prevent GVHD in this setting.
The reduced GVHD in PTCy-mice was accompanied by a reduction in the relative
expression of hIL17A in the small intestines. This is consistent with previous studies
144

implicating Th17 cells in directing small-intestine damage in allogeneic mouse models of
GVHD (Iclozan et al., 2010). Whilst the reduced expression of hIL17A did not correspond
to reduced histological gut GVHD, humanised NSG mice injected with PBMCs have
shown minimal gut damage in previous studies in our laboratory (Cuthbertson et al.,
2020). Therefore, our results imply that PTCy impacts molecular GVHD in this tissue. In
the current study, PTCy did not impact the final concentration of T cell cytokines in
mouse sera, contrasting allogeneic mouse models (Wachsmuth et al., 2019). This may
reflect a cytokine surge earlier in this humanised mouse model.
In conclusion, this study has demonstrated that PTCy reduces proliferating reactive
human donor T cells in a humanised mouse model of GVHD. Although this resulted in
delayed GVHD, the majority of PTCy-mice still developed GVHD by experimental
endpoint. Taken together, the current study confirms that PTCy alone does not prevent
GVHD in this humanised mouse model. Since human Tregs protect against GVHD (Lu
et al., 2012), and were reduced in PTCy-mice in the current study, investigation into
strategies to increase Tregs alongside PTCy depletion is warranted. This could include
combining PTCy with low-dose IL-2 (Kennedy-Nasser et al., 2014) alone, or in
combination with rapamycin (Battaglia et al., 2005, Hu et al., 2020) to further reduce
GVHD in this model and in clinical allo-HSCT.
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Chapter 6:

Combinational Therapy of Post-Transplant Cyclophosphamide and

Low-Dose Interleukin-2 does not Further Reduce Graft-Versus-Host Disease
Compared to Post-Transplant Cyclophosphamide Alone in a Humanised Mouse
Model
6.1

Introduction

Post-transplant cyclophosphamide (PTCy) reduces the development of clinical graftversus-host

disease

(GVHD)

following

allogeneic

hematopoietic

stem

cell

transplantation (allo-HSCT) (Kanakry et al., 2013b). In humanised NSG mice, PTCy
reduces both GVHD and the proportions of reactive human donor T cells (Chapter 5).
However, in both pre-clinical models and clinical allo-HSCT, PTCy does not prevent
GVHD (Kanakry et al., 2016), as also observed in Chapter 5. Therefore, studies are now
investigating the efficacy of combining PTCy with other GVHD therapeutic strategies.
For example, the use of PTCy with antithymocyte globulin (Salas et al., 2020) or
mycophenolate mofetil (Luznik et al., 2008) in clinical trials provides improved GVHD
prophylaxis than each treatment alone.
Regulatory T cells (Tregs) are necessary for PTCy to reduce GVHD (Wachsmuth et al.,
2019, Ganguly et al., 2014, Kanakry et al., 2013a). However, in Chapter 5, PTCy reduced
the proportions of human Tregs in humanised NSG mice. Since PTCy delayed GVHD in
this humanised mouse model, combining PTCy with strategies to enhance human donor
Tregs may further reduce GVHD.
Interleukin (IL)-2 is a critical homeostatic cytokine for human T cells (Boyman and
Sprent, 2012), including Tregs (Barron et al., 2010, Yu and Malek, 2006). However,
unlike conventional T cell subsets, Tregs constitutively express the high affinity IL-2
receptor CD25 (Matsuoka et al., 2013). Therefore, Tregs have a 10-20 fold lower
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activation threshold for IL-2 compared to other T cells and can be expanded in humans
by low doses of IL-2 in the range of 0.18 - 3 Mega International Units (MIU) (Klatzmann
and Abbas, 2015). Moreover, IL-2 at this dose does not promote GVHD effector T cells
(Klatzmann and Abbas, 2015) and is a novel therapeutic strategy to prevent GVHD (Kim
et al., 2016a).
In clinical trials, daily administration of low-dose IL-2 (1 MIU for eight weeks) rapidly
expands circulating Tregs without increasing conventional CD4+ T cells (Tcons) or CD8+
T cells, and reduces GVHD (Matsuoka et al., 2013, Koreth et al., 2011a). Other studies
are limited in number, but in humanised NSG mice low-dose IL-2 at 0.25 MIU (daily for
the first 10 days) can increase human Tregs (Pérol et al., 2014). However, low dose IL-2
did not impact GVHD severity in this prior study. In another humanised mouse model,
Hu et al. (2020) demonstrated that low-dose IL-2 (0.3 MIU daily for the first three weeks),
in combination with rapamycin, expands Tregs and reduces GVHD in humanised NSG
mice. This effect was most likely observed because rapamycin also actively boosts Tregs
(Battaglia et al., 2005), allowing greater Treg expansion and increased suppression of
GVHD effector T cells.
The administration scheme for low-dose IL-2 can impact the levels of Treg expansion
(Klatzmann and Abbas, 2015). The ideal regime varies depending on the required length
of treatment. Although daily continuous administration allows greatest Treg expansion,
it risks inducing T cell activation which may drive GVHD (Koreth et al., 2011b). A
promising strategy proposed for long term inflammatory conditions involves a 5-day
course to induce Tregs followed by less frequent

administration to ensure Treg

maintenance (Klatzmann and Abbas, 2015).
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Since PTCy reduces GVHD, but also human Tregs, in humanised NSG mice (Chapter 5),
combining PTCy with low-dose IL-2, may further reduce GVHD in this humanised
mouse model compared to PTCy alone. This combinational therapy has not been
investigated in clinical studies or pre-clinical models of GVHD. Therefore, this chapter
aimed to determine the effect of combining PTCy with low dose IL-2 on human Tregs,
and on the development of GVHD in a pre-clinical humanised NSG mouse model.
6.2

Results

6.2.1

Combinational therapy of PTCy and low-dose IL-2 does not impact human

T cell engraftment in NSG mice at 3 weeks compared to PTCy alone
Low-dose IL-2 can expand human Tregs without promoting GVHD effector T cells
(Hirakawa et al., 2016, Koreth et al., 2011a). To determine if low-dose IL-2 could
increase human Tregs in humanised NSG mice treated with PTCy, NSG mice were
injected i.p. with 20 x 106 hPBMCs, followed by PTCy or saline (days 3 and 4 posthPBMC injection), and subsequently injected i.p. with low-dose IL-2 (0.3 MIU) or saline
(days 0-4 post-hPBMC injection and then thrice weekly until endpoint) and monitored
for clinical GVHD for up to 10 weeks (Fig. 6.1). This treatment regime of low-dose IL-2
was based on previous studies in humanised mouse models of GVHD (Hu et al., 2020).
At 3 weeks post-hPBMC injection, human T cell engraftment was assessed in mouse tail
blood using flow cytometry with a consistent gating strategy (Fig. 6.2a-e). hCD45+
leukocytes were present in all mice, and a one-way ANOVA indicated a significant
difference in the proportions of these cells between certain groups (F = 10.23, P < 0.0001).
Whilst the proportions of hCD45+ leukocytes in PTCy+IL-2-mice (7.8 ± 4.6%
hCD45+mCD45- cells, n = 9) were similar to PTCy-mice (7.5 ± 2.4%, n = 8, P = 0.9400),
they were reduced compared to both saline-mice (30.1 ± 8.1%, n = 6, P < 0.0001) and
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IL-2-mice (32.1 ± 4.6%, n = 7) (P = 0.0068) (Fig. 6.2f). Low-dose IL-2 alone did not
impact the engraftment of hCD45+ leukocytes, with similar proportions between IL-2mice and saline-mice (P = 0.9895). Unlike in Chapter 5, PTCy-mice in the current study
demonstrated significantly reduced proportions of hCD45+ leukocytes than saline-mice
at week 3 (P = 0.0064). This may have resulted from cyclophosphamide batch differences
or the increased number of saline injections received by PTCy-mice and saline-mice in
the current study compared to mice in Chapter 5.

Figure 6.1 Humanised mouse model of GVHD to investigate combinational therapy of PTCy with
low-dose IL-2. NSG mice were injected i.p. with 20 x 106 hPBMCs (day 0) and subsequently injected i.p.
with 33 mg/kg PTCy or saline on days 3 and 4 post-hPBMC injection as well as low-dose (0.3 MIU) IL-2
or saline i.p. daily from days 0-4 then thrice weekly until endpoint (saline: n = 8 mice, n = 2 donors; IL-2:
n = 8 mice, n = 2 donors; PTCy: n = 8 mice, n = 2 donors; PTCy+IL-2: n = 9 mice n = 2 donors). Mice
were monitored for the development of clinical GVHD by monitoring weight loss and scoring GVHD
clinical symptoms (Table 2.3) for up to 10 weeks post-hPBMC injection. Mice were checked for the
engraftment of human T cell subsets at 3 weeks post-hPBMC injection by immunophenotyping tail blood
using flow cytometry. At endpoint human immune cell engraftment was checked by immunophenotyping
mouse spleens. Histological damage and the relative expression of inflammatory cytokines in GVHD target
organs (liver, small intestines and skin) was assessed by haematoxylin and eosin staining and qPCR,
respectively. The concentration of inflammatory human cytokines in mouse sera was assessed by a
LEGENDplex assay.

hCD3+ T cells comprised the bulk of hCD45+ leukocytes in all mouse groups, at similar
proportions (saline: 93.1 ± 2.2%, n = 6; IL-2: 90.6 ± 4.2%, n = 9; PTCy: 95.0 ± 1.4%, n
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= 6; PTCy+IL-2: 93.0 ± 1.6%, n = 7, F = 0.4543, P = 0.7397) (Fig. 6.2g). Moreover, a
one-way ANOVA demonstrated no significant difference in the proportions of
hCD3+hCD4+ (saline: 68.7 ± 11.2%, n = 6; IL-2: 77.1 ± 6.7%, n =7 ; PTCy: 51.7 ± 11.0%,
n = 5; PTCy+IL-2: 39.3 ± 18.0%, n = 3, F = 2.450, P = 0.0989) and hCD3+hCD8+ T
cells (saline: 20.5 ± 7.7 %, n = 6; IL-2: 14.2 ± 4.7%, n =7 ; PTCy: 42.8 ± 9.8%, n = 5;
PTCy+IL-2: 55.1 ± 17.0%, n = 3, F = 3.789, P = 0.0702) between any group (Fig. 6.2h).
Although the proportions of these T cells subsets were similar between PTCy+IL-2-mice
and PTCy-mice, PTCy+IL-2-mice demonstrated reduced hCD3+hCD4+ T cells and
increased hCD3+hCD8+ T cells compared to both IL-2-mice and saline-mice, which
displayed similar engraftment. This trend was also apparent between PTCy-mice and
saline-mice.
hCD3+hCD4+ T cells demonstrated significantly higher engraftment than hCD3+hCD8+
T cells in saline-mice (P = 0.0025) and IL-2-mice (P < 0.0001), but not in PTCy-mice (P
= 0.1256) or PTCy+IL-2-mice (P = 0.1332). However, a one way ANOVA demonstrated
no significant difference in the hCD4:hCD8 T cell ratios between any group (saline: 2.5
± 0.5, n = 4; IL-2: 10.8 ± 4.1, n = 6; PTCy: 1.4 ± 0.7, n = 3; PTCy+IL-2: 1.0 ± 0.6, n =
4), (F = 0.6446, P = 0.1663) (Fig. 6.2i). Notably, the hCD4:hCD8 T cell ratio in PTCy+IL2-mice was reduced (90.8 % reduction) compared to IL-2-mice, but similar to both PTCymice and saline-mice. IL-2-mice also demonstrated increased (4.6-fold) hCD4:hCD8 T
cell ratios compared to saline-mice.
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Figure 6.2 Combinational therapy of PTCy and low-dose IL-2 does not impact human T cell
engraftment in NSG mice at 3 weeks compared to PTCy alone. Mice were checked for the engraftment
of human T cell subsets at 3 weeks post-hPBMC injection by immunophenotyping tail blood using flow
cytometry with (a-e) a consistent gating strategy. (a) Single cells were gated by forward scatter area (FSCA) and height (FSC-H), and (b) viable single lymphocytes gated within this population using FSC-A and
side scatter (SSC-A). Viable (c) hCD45+mCD45- leukocytes were gated and (d) hCD45+hCD3+ T cells, (e)
hCD3+hCD4+ and hCD3+hCD8+ T cells were identified. (f) hCD45+ leukocytes are expressed as a
percentage of total mCD45+ and hCD45+ leukocytes. (g) hCD3+ T cells are expressed as a percentage of
total hCD45+ leukocytes. (h) hCD4+ and hCD8+ T cells are expressed as a percentage of hCD3+ cells. (i)
hCD4+:hCD8+ T cell ratios were calculated. (f-i) Lines represent group mean ± SEM (saline: n = 6 mice,
IL-2: n = 6-8 mice, PTCy: n = 3-8 mice, PTCy+IL-2: n = 4-8 mice); symbols represent individual mice.
(f) **** P < 0.0001, ** P = 0.0068, compared to PTCy+IL-2-mice. (h) ** P = 0.0025 compared to CD8+
T cells in saline-mice, **** P < 0.0001 compared to CD8+ T cells in IL-2-mice.

6.2.2

Combinational therapy of PTCy and low-dose IL-2 does not impact human

T cell engraftment in NSG mice at endpoint compared to PTCy alone
PTCy increases the splenic hCD4:hCD8 T cell ratio in humanised NSG mice at endpoint
(Chapter 5). Therefore, splenic human T cell engraftment was also assessed at endpoint
in the current study using flow cytometry with a consistent gating strategy (Fig. 6.3a-g).
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A one-way ANOVA demonstrated no significant difference in the proportions of hCD45+
leukocytes (F = 0.1898, P = 0.9025) between any group (saline: 51.2 ± 8.5%, n = 8; IL2: 45.5 ± 8.0 %, n = 8; PTCy: 45.1 ± 7.1 %, n = 8; PTCy+IL-2: 51.0 ± 7.2%, n = 9) (Fig.
6.3h). Likewise, there was no significant difference in the proportions of hCD3+ T cells
between groups (saline: 92.9 ± 2.5%, n = 8; IL-2: 96.2 ± 2.0 %, n = 8; PTCy: 98.2 ±
2.1%, n = 8; PTCy+IL-2: 94.2 ± 1.7%, n = 9, F = 0.7428, P = 0.8914) (Fig. 6.3i).
A one-way ANOVA indicated no significant difference in the proportions of
hCD3+hCD4+ T cells (saline: 51.1 ± 7.2%, n = 8; IL-2: 66.6 ± 3.4%, n = 8; PTCy: 49.2
± 4.4%, n = 8; PTCy+IL-2: 52.5 ± 5.6% n = 9) (F = 2.153, P = 0.1152) and hCD3+hCD8+
T cells (saline: 35.6 ± 8.5%, n = 8; IL-2: 19.2 ± 3.1%, n = 8; PTCy: 42.8 ± 5.0%, n = 8;
PTCy+IL-2: 39.1 ± 6.5%, n = 9, F = 2.844, P = 0.0701) between any mouse group (Fig.
6.3j). Despite this, there was a trend of reduced hCD3+hCD4+ T cells and increased
hCD3+hCD8+ T cells in PTCy+IL-2-mice compared to IL-2-mice, but not saline-mice and
PTCy-mice, which were similar. This trend was also apparent between IL-2-mice and
saline-mice. Subsequently, IL-2-mice demonstrated higher proportions of hCD3+hCD4+
T cells than hCD3+hCD8+ T cells (P < 0.0001), which was not present in the other groups
(saline: P = 0.3446; PTCy: P = 0.4824; PTCy+IL-2: P = 0.3369). However, this did not
result in a significant difference in the hCD4:hCD8 T cell ratios between PTCy+IL-2
mice (2.12 ± 0.53, n = 9) and any other group (saline: 2.15 ± 0.78, n =8, P > 0.9999; IL2: 4.30 ± 0.75, P = 0.0546; PTCy: 1.41 ± 0.36, P = 0.8131) (Fig. 6.3k). Notably, IL-2mice demonstrated 2-fold higher hCD4+:hCD8+ T cell ratios compared to both salinemice (P = 0.0686) and PTCy+IL-2-mice (P = 0.0545), which approached significance.
PTCy-mice and saline-mice displayed similar hCD4:hCD8 ratios at endpoint (P =
0.8095).
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PTCy reduces the proportions of splenic human Tregs in humanised NSG mice at
endpoint (Chapter 5). Therefore, splenic hCD3+hCD4+hCD25+hCD127lo Tregs were
assessed at endpoint in the current study. A one way ANOVA demonstrated no significant
difference in the proportions of human Tregs (saline: 2.1 ± 0.6%, n = 8; IL-2: 1.7 ± 0.3%,
n = 8; PTCy: 1.4 ± 0.2%, n = 8; PTCy+IL-2: 2.1 ± 0.4%, n = 9, P = 0.5369) between any
group (F = 0.7399, P = 0.5369). CD39 on human Tregs is associated with protection
against GVHD in humanised mice (Gu et al., 2017). In the current study the proportions
of hCD39+ Tregs were similar in all mouse groups (saline: 69.7 ± 4.6%, n = 8; IL-2: 72.1
± 4.5%, n = 8; PTCy: 66.7 ± 6.27%, n = 8; PTCy+IL-2: 73.8 ± 5.5%, n = 9, F = 0.3744,
P = 0.7721) (Fig. 6.3m).
6.2.3

Combinational therapy of PTCy and low-dose IL-2 does not influence the

engraftment of hCD3+hCD4+hCD25+hFoxP3+ Tregs in NSG mice at endpoint
Forkhead box protein 3 (FoxP3) is a key marker for human Tregs and has been historically
used to detect Tregs by flow cytometry (Sakaguchi et al., 2006). Therefore, to further
ascertain if treatments altered Tregs the proportions of splenic hFoxP3+ Tregs were
assessed at endpoint using flow cytometry with a consistent gating strategy (Fig. 6.4a-f).
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hCD3+hCD4+hCD25+hFoxP3+ Tregs in all mouse groups (saline: 1.8 ± 0.8%, n = 3; IL2: 2.2 ± 0.9%, n = 4; PTCy: 2.2 ± 0.1%, n = 3; PTCy+IL-2: 2.4 ± 0.9%, n = 4, F = 0.5422,
P = 0.6958) (Fig. 6.4g). Notably, the proportions of hCD3+hCD4+hCD25+hFoxP3+ Tregs
were similar to the proportions of hCD3+hCD4+hCD25+hCD127lo Tregs in each mouse
group (section 6.2.2).
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Figure 6.3 Combinational therapy of PTCy and low-dose IL-2 does not impact human T cell
engraftment in NSG mice compared to PTCy alone at endpoint. Mice were checked for the engraftment
of human T cell subsets at endpoint by immunophenotyping spleens using flow cytometry with (a-g) a
consistent gating strategy. (a) Single cells were gated by forward scatter area (FSC-A) and height (FSCH), and (b) viable single lymphocytes gated within this population using FSC-A and side scatter (SSC-A).
(c) Live lymphocytes were identified using Zombie NIR staining and (d) hCD45+hCD3+ T cells, (e)
CD3+CD4+ and CD3+CD8+ T cells were identified. (f) hCD3+hCD4+hCD25+hCD127lo (hCD4+) Tregs and
(g) hCD39+ hCD4+ Tregs were then identified. (h) hCD45+ leukocytes are expressed as a percentage of
total mCD45+ and hCD45+ leukocytes. (i) hCD3+ T cells are expressed as a percentage of total hCD45+
leukocytes. (j) hCD3+hCD4+ and hCD3+hCD8+ T cells are expressed as a percentage of hCD3+ T cells. (k)
hCD4+:hCD8+ T cell ratios were calculated. (l)hCD4+ Tregs are expressed as a percentage of hCD4+ T cells
and (m) hCD39+hCD4+Tregs are expressed as a percentage of hCD4+ Tregs. (h-m) Lines represent group
mean ± SEM (saline: n = 8 mice, IL-2: n = 8 mice, PTCy: n = 8 mice, PTCy+IL-2: n = 9 mice); symbols
represent individual mice. (j) **** P < 0.0001 compared to CD8+ T cells in IL-2-mice.
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Figure 6.4 Combinational therapy of PTCy and low-dose IL-2 does not impact the engraftment of
hCD3+hCD4+hCD25+hFoxP3+ Tregs in NSG mice at endpoint. Mice were checked for the engraftment
of human T cell subsets at endpoint by immunophenotyping spleens using flow cytometry with (a-f) a
consistent gating strategy. (a) Single cells were gated by forward scatter area (FSC-A) and height (FSCH), and (b) viable single lymphocytes gated within this population using FSC-A and side scatter (SSC-A).
(c) Live lymphocytes were identified using Zombie NIR staining and (d) hCD45+hCD3+ T cells, (e)
CD3+CD4+ and CD3+CD8+ T cells were identified. (f) hCD3+hCD4+hCD25+hFoxP3+ Tregs were then
gated. (g) hCD3+hCD4+hCD25+hFoxP3+ Tregs are expressed as a percentage of hCD3+hCD4+ T cells. (g)
Line represent group mean ± SEM (saline: n = 4 mice, IL-2: n = 4 mice, PTCy: n = 3 mice, PTCy+IL-2: n
= 4 mice); symbols represent individual mice.

6.2.4

Combinational therapy of PTCy and low-dose IL-2 does not further reduce

GVHD compared to PTCy in a humanised mouse model
Humanised NSG mice were monitored for the development of GVHD for up to 10 weeks,
as outlined (Table 2.3) (Fig. 6.5a-c). PTCy+IL-2-mice gained weight until day 30
(reaching 123% of starting weight), and demonstrated weight loss between days 33 and
day 40 after which it plateaued. PTCy-mice gained weight until day 35 (116% of starting
weight) before plateauing (Fig. 6.6a). Weight variation in PTCy+IL-2-mice was similar
to PTCy-mice (P = 0.2939), However, PTCy+IL-2-mice demonstrated significantly
reduced weight loss compared to both saline-mice (P < 0.0001) and IL-2-mice (P <
155

0.0001). IL-2-mice exhibited weight loss between day 30 and 35, after which it plateaued
until endpoint. Saline-mice demonstrated fluctuating weight between days 20 and 40 and
steadied from day 40 until endpoint. IL-2-mice demonstrated comparable weight loss to
saline-mice (P = 0.9515). Consistent with Chapter 5, PTCy showed dramatically reduced
weight loss compared to saline-mice (P < 0.0001).
PTCy+IL-2-mice and PTCy-mice first begun showing signs of clinical GVHD at day 24
and demonstrated mean clinical scores of 6 and 6.4 at endpoint, respectively. Clinical
GVHD development was similar between these two groups (P = 0.459). However,
PTCy+IL-2 mice demonstrated reduced GVHD development compared to saline-mice (P
< 0.0001) and IL-2-mice (P < 0.0001). Saline-mice and IL-2 mice began showing clinical
GVHD symptoms from days 15 and 19, respectively, which continued to increase until
day 60 before plateauing in both groups. Saline-mice and IL-2-mice demonstrated mean
clinical scores of 8 at endpoint, and overall GVHD development was similar between
these groups (P = 0.5091). Consistent with Chapter 5, PTCy-mice demonstrated
drastically reduced clinical GVHD development compared to saline (P < 0.0001).
PTCy+IL-2-mice demonstrated 55.6% mortality with a median survival time (MST) 56
days (n = 9). PTCy-mice demonstrated 50% mortality with MST of 65 days (n = 8).
Despite this overall survival was not significantly different between these groups (P =
0.6855). Whilst PTCy+IL-2-mice demonstrated improved survival compared to IL-2mice (MST = 33.5 days, n = 8, 87.5% mortality) (P = 0.0097), it was similar to that
observed in saline-mice (MST = 38.5 days, n = 8, 75% mortality) (P = 0.2453). Overall
survival was similar between IL-2-mice and saline-mice (P = 0.4973). Finally, as
demonstrated in Chapter 5, PTCy-mice demonstrated prolonged survival compared to
saline-mice (P = 0.006).
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Figure 6.5 Combinational therapy of PTCy and low-dose IL-2 does not further reduce the
development of GVHD compared to PTCy alone in humanised NSG mice. Mice were monitored for
clinical GVHD for up to 10 weeks post-hPBMC injection by assessing (a) weight loss, (b) GVHD clinical
score and (c) survival. Data represents (a, b) group means ± SEM or (c) percentage survival. (a, b) ****
P < 0.0001, (c) ** P < 0.01 compared to PTCy+IL-2-mice and PTCy-mice. (a-c) saline: n = 8 mice, IL-2:
n = 8 mice, PTCy: n = 8 mice, PTCy+IL-2: n = 9 mice.

6.2.5

Combinational therapy of PTCy and low-dose IL-2 improves human Treg

survival in NSG mice
In Chapter 5, PTCy-treated mice that survived longer displayed reduced Tregs than those
that did not survive late. Therefore, in the current study, the proportions of human Tregs
in NSG mice were plotted against mouse survival to determine if there was a correlation
between these parameters (Fig. 6.6a-d).
PTCy+IL-2-mice demonstrated a strong positive correlation between the proportions of
hCD4+ Tregs and mouse survival (r2 = 0.501, P = 0.0327) (Fig. 6.6a). Likewise, there was
a similar positive correlation between the proportion of human Tregs and mouse survival
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in IL-2 mice which approached significance (r2 = 0.4961, P = 0.0618) (Fig. 6.6b). This
correlation was not apparent in PTCy-mice (r2 = 0.0781, P = 0.5012) (Fig. 6.6c) or salinemice (r2 = 0.1326, P = 0.4635) (Fig. 6.6d).

Figure 6.6 Combinational therapy of PTCy with low-dose IL-2 improves Treg survival in humanised
NSG mice. At endpoint the proportions of splenic hCD3+hCD4+hCD25+hCD127lo (hCD4+) Tregs were
correlated to mouse survival. (a-d) Pearson correlation of the percentage of splenic hCD4+ Tregs vs mouse
survival for (a) PTCy+IL2-mice (n = 9 mice), (b) IL-2-mice (n = 8 mice), (c) PTCy-mice (n = 8 mice) and
(d) saline-mice (n = 8 mice). Symbols represent individual mice.

6.2.6

Combinational therapy of PTCy and low-dose IL-2 does not further reduce

histological damage to the liver compared to PTCy alone
Previously, PTCy appeared to reduce damage to the bile ducts and portal veins and reduce
infiltrating cells in the livers of humanised NSG mice (Chapter 5). Therefore, in the
current study liver histology was assessed, including quantifying infiltrating leukocytes
(Fig. 6.7 a-e). Overall liver damage in PTCy+IL-2-mice (Fig. 6.7d) appeared similar to
158

that in PTCy-mice (Fig. 6.7c), but it was dramatically reduced around the portal veins and
bile ducts compared to both saline-mice (Fig. 6.7a) and IL-2-mice (Fig. 6.7b).
A one-way ANOVA demonstrated significant differences in the number of infiltrating
leukocytes between certain groups (F = 5.444, P = 0.0083). Similar numbers of
infiltrating cells were observed between PTCy+IL-2-mice (104.6 ± 17.5 cells/field of
view, n = 5) and PTCy-mice (138.6 ± 42.1 cells/field of view, n = 5, P = 0.4778) (Fig.
6.7e). However, infiltrating leukocytes were significantly lower in PTCy+IL-2-mice
(104.6 ± 17.5 cells/field of view, n = 5) than both saline- (563.5 ± 92.8 cells/field of view,
n = 5, P = 0.0024) and IL-2-mice (519.5 ± 153.2 cells/field of view, n = 6, P = 0.0375),
which were similar (P = 0.7851) (Fig. 6.7e). PTCy-mice also demonstrated reduced
infiltrating leukocytes compared to saline-mice (P = 0.0052) (Fig. 6.7e).

Figure 6.7 Combinational therapy of PTCy with low-dose IL-2 does not further reduce histological
damage to the liver compared to PTCy alone. At endpoint, 5 μm sections of liver tissue from (a) salinemice, (b) IL-2-mice, (c) PTCy-mice and (d) PTCy+IL2-mice were cut and stained with haematoxylin and
eosin and imaged by microscopy. Representative images from five to six mice per group are shown (e) The
numbers of infiltrating leukocytes in liver tissue sections were quantified using FIJI is just ImageJ software.
Bars represent 100 μm. (a-d) Red arrows indicate infiltrating leukocytes (e) Lines represent group means
± SEM (n = 5-6 mice per group). Symbols represent individual mice. ** P < 0.01 compared to saline-mice
* P < 0.05 compared to PTCy+IL-2-mice.
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6.2.7

Combinational therapy of PTCy and low-dose IL-2 does not impact apoptotic

cells in the livers of humanised mice
PTCy is metabolised in the liver and can cause toxicity at high dosages (McDonald et al.,
2003), therefore the livers of humanised NSG mice were assessed for apoptotic cells using
a terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay (Fig.
6.8a-e). Apoptotic cells were present in the livers of all mice and were localised around
portal veins (Fig. 6.8 a-d). The numbers of apoptotic cells were similar between all groups
(saline: 325.9 ± 6.3 cells/field of view, n = 3; IL-2: 318.6 ± 179.0 cells/field of view, n =
4; PTCy: 346.1 ± 105.1 cells/field of view, n = 3; PTCy+IL-2:328.8 ± 95.6 cells/field of
view, n = 4) (Fig. 6.8 e). A one-way ANOVA demonstrated no significant difference in
the numbers of apoptotic liver cells between groups (F = 3.457, P = 0.8632).

Figure 6.8 Combinational therapy of PTCy with low-dose IL-2 does not influence apoptotic cells in
the livers of humanised NSG mice. At endpoint, 5 μm sections of liver tissue from (a) saline-mice, (b)
IL-2-mice, (c) PTCy-mice and (d) PTCy+IL2-mice were cut and assessed using TUNEL staining and
imaged by microscopy. Representative images from three to four mice per group are shown. (a-d)
Apoptotic cells (brown-stained cells) are indicated by red arrows. (e) The numbers of apoptotic cells in
liver tissue sections were quantified using FIJI is just ImageJ software. Lines represent group means ± SEM
(n = 3-4 mice per group). Symbols represent individual mice.
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6.2.8

Combinational therapy of PTCy and low-dose IL-2 does not impact

histological damage to the small intestine and skin in humanised mice with GVHD
The small intestines and skin are target organs for GVHD damage in humanised NSG
mice (Cuthbertson et al., 2020, Geraghty et al., 2019c). In the current study histological
damage to these tissues was comparable between all treatment groups (Fig. 6.9a-d). In
the small intestine slight damage to crypt cells was observed, with similar amounts of
rounded villi and infiltrating leukocytes (Fig. 6.7a-d, left panel). All groups also displayed
signs of minor skin GVHD, with comparable thickening of the dermal layers and
detachment of the dermis from epidermis. Leukocyte infiltration appeared similar in the
skin between all groups (Fig. 6.9 a-d, top panel).

Figure 6.9 Combinational therapy of PTCy with low-dose IL-2 does not impact histological damage
to the small-intestines and skin of humanised NSG mice. At endpoint, 5 μm sections of skin (top panel)
and small-intestines (bottom panel) from (a) saline-mice, (b) IL-2-mice, (c) PTCy-mice and (d) PTCy+IL2mice were cut and stained with haematoxylin and eosin and imaged by microscopy. Representative images
from five to six mice per group are shown.

6.2.9

Combinational therapy of PTCy and low-dose IL-2 does not impact the

expression of hIL17A or hIFNG in GVHD target organs in humanised NSG mice
IL-17 and IFNγ are important inflammatory cytokines in GVHD pathogenesis (Kappel et
al., 2009, Zhao et al., 2016). Therefore, the relative expression of hIL17A and
hIFNG were assessed in the current study by qPCR (Fig. 6.10a-f). PTCy+IL-2-mice
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demonstrated slightly increased relative hIL17A expression in the spleen (9.0 ± 1.9, n =
7) compared to PTCy-mice (4.4 ± 1.7, 2.1-fold, n = 7) and IL-2-mice (3.6 ± 2.0, 2.5-fold,
n = 7), but not saline-mice (6.4 ± 3.3, n = 6) (Fig. 6.6a). However, a one-way ANOVA
demonstrated no statistically significant differences in relative hIL17A expression in the
spleen (F = 1.227, P = 0.3225) (Fig. 6.10a) or liver (saline: 4.2 ± 2.1, n = 6; IL-2: 7.0 ±
3.4, n = 7; PTCy: 3.5 ± 2.1, n = 7; PTCy+IL-2: 3.8 ± 1.8, n = 7) (F = 0.4355, P = 0.7297)
between groups (Fig. 6.10b). Likewise, relative hIL17A expression in the small intestines
was similar in all groups (saline: 4.1 ± 1.9, n = 6; IL-2: 4.2 ± 1.5, n = 7; PTCy: 5.2 ± 1.6,
n = 7; PTCy+IL-2: 4.4 ± 1.3, n = 8, F = 0.0934, P = 0.9630) (Fig. 6.10c).
Relative hIFNG expression was similar in the spleen (saline: 0.7 ± 0.2, n = 7; IL-2: 1.0
± 0.1, n = 7; PTCy: 1.5 ± 0.4, n = 6; PTCy+IL-2: 1.3 ± 0.4, n = 7, F = 1.1820 P = 0.3390)
(Fig. 6.10d), liver (saline: 2.4 ± 1.0, n = 7; IL-2: 3.9 ± 1.1, n = 7; PTCy: 4.8 ± 2.3, n = 6;
PTCy+IL-2: 3.8 ± 1.4, n = 6, F = 0.4507, P = 0.7194) (Fig. 6.10e) and small intestine
(saline: 2.2 ± 0.6, n = 7; IL-2: 2.6 ± 0.6, n = 7; PTCy: 2.8 ± 0.9, n = 6; PTCy+IL-2: 1.8
± 0.9, n = 7, F = 0.4325 P = 0.7317) (Fig. 6.10f).
6.2.10 Combinational therapy of PTCy and low-dose IL-2 does not affect the
expression of hFOXP3 or hIL10 in spleens or target organs in humanised NSG mice
FoxP3 (Liu et al., 2006) and IL-10 (Abraham et al., 2015) are important regulatory genes
involved in human Treg responses, which protect against GVHD (Di Ianni et al., 2011).
Therefore, the relative expression of hFOXP3 and hIL10 were also assessed in the current
study by qPCR (Fig. 6.11a-f). There was no significant difference in relative splenic
hFOXP3 expression between mouse groups (saline: 2.2 ± 1.0, n = 7; IL-2: 4.9 ± 1.6, n =
7; PTCy: 3.1 ± 2.0, n = 6; PTCy+IL-2: 4.6 ± 2.6, n = 6), (F = 0.5157, P = 0.6758).
However, PTCy+IL-2-mice demonstrated higher relative splenic hFOXP3 expression
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compared to both saline-mice (2.1-fold) and PTCy-mice (1.5-fold) (Fig. 6.11a). Relative
hFOXP3 expression in the liver (saline: 1.1 ± 0.5, n = 7; IL-2: 1.3 ± 0.6, n = 7; PTCy:
1.3 ± 0.9, n = 6; PTCy+IL-2: 0.9 ± 0.3, n = 6) (F = 0.1016, P = 0.9582) (Fig. 6.11b) and
small intestine (saline: 0.9 ± 1.0, n = 7; IL-2: 1.7 ± 0.6, n = 7; PTCy: 0.7 ± 0.3, n = 6;
PTCy+IL-2: 1.0 ± 0.6, n = 6) (F = 0.6353, P = 0.6002) (Fig. 6.11c) was similar between
all groups.

Figure 6.10 Combinational therapy of PTCy with low-dose IL-2 does not influence the relative
expression of hIFNG and hIL17A in humanised NSG mice. RNA was extracted and cDNA synthesized
from the (a, d) spleen, (b, e) liver and (c, f) small intestines of mice at endpoint. The relative expression of
(a-c) hIL17A and (d-f) hIFNG in mouse tissue was examined by qPCR. Lines represent group mean ± SEM
(n = 6-8 per group). Symbols represent individual mice.

Likewise, the relative hIL10 expression in the spleen (saline: 3.2 ± 1.4, n = 6; IL-2: 3.6 ±
0.5, n = 7; PTCy: 4.0 ± 0.8, n = 7; PTCy+IL-2: 2.7 ± 1.0, n = 7) (F = 0.3501, P = 0.7894)
(Fig. 6.11d), liver (saline: 5.4 ± 1.7, n = 6; IL-2: 5.5 ± 1.6, n = 7; PTCy: 4.6 ± 1.2, n = 7;
PTCy+IL-2: 2.6 ± 0.8, n = 7) (F = 0.9644, P = 0.4263) (Fig. 6.11e) and small intestine
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(saline: 2.2 ± 1.0, n = 7; IL-2: 4.9 ± 1.6, n = 7; PTCy: 3.1 ± 2.0, n = 6; PTCy+IL-2: 4.6
± 2.6, n = 6) (F = 0.3806, P = 0.6758) was not significantly different between groups
(Fig. 6.11f). Notably relative hIL10 expression in the liver was on average 50% lower in
PTCy+IL-2-mice compared to the other three groups.

Figure 6.11 Combinational therapy of PTCy with low-dose IL-2 does not influence the relative
expression of hFOXP3 and hIL10 in humanised NSG mice. RNA was extracted and cDNA synthesized
from the (a, d) spleen, (b, e) liver and (c, f) small intestines of mice at endpoint. The relative expression of
(a-c) hFOXP3 and (d-f) hIL10 in mouse tissue was examined by qPCR. Lines represent group mean ± SEM
(n = 6-8 per group). Symbols represent individual mice.

6.2.11 Combinational therapy of PTCy and low-dose IL-2 does not influence the
concentration of inflammatory or regulatory cytokines in humanised NSG mice
Pro-inflammatory cytokines play crucial roles in GVHD pathogenesis (Blazar et al.,
2012), and are reduced in the sera of mice treated with PTCy in allogeneic models of
GVHD (Wachsmuth et al., 2019). Therefore, in the current study, a flow cytometric multiplex cytokine assay was performed to determine the serum concentrations of pro164

inflammatory and regulatory T cell cytokines (hIL-2, hIL-6, hIL-10, hTNFα, hIFNγ and
hIL-17) in humanised NSG mice (Fig. 6.12a-f).
A one-way ANOVA demonstrated no significant difference in the levels of serum hIL-2
between any groups (saline: 20.2 ± 14.1 pg.mL-1, n = 7; IL-2: 47.5 ± 33.3 pg.mL-1, n =
8; PTCy: 5.6 ± 0 pg.mL-1, n = 8; PTCy+IL-2: 10.2 ± 4.5 pg.mL-1, n = 9) (F = 1.109, P
= 0.3619) (Fig. 6.12a). However, the majority of mice displayed serum hIL-2
concentrations below the threshold limit. Similarly, there was no significant difference in
the concentration of serum hIL-6 (saline: 24.2 ± 10.1 pg.mL-1, n = 7; IL-2: 31.6 ± 16.9
pg.mL-1, n = 8; PTCy: 21.4 ± 7.6 pg.mL-1, n = 8; PTCy+IL-2: 17.33 ± 10.6 pg.mL-1, n
= 9) (F = 0.2667, P = 0.8488) between groups (Fig. 6.12b).
There was no statistically significant difference in serum hIL-10 concentration between
PTCy+IL-2-mice (9.76 ± 4.12 pg.mL-1, n = 9) and all other groups (saline: 28.5 ± 9.3
pg.mL-1, n = 7; IL-2: 62.4 ± 23.5 pg.mL-1, n = 8; PTCy: 8.9 ± 4.0 pg.mL-1, n = 8), (P
> 0.05 for all). PTCy-mice demonstrated lower (65.8% reduction) serum hIL-10 than
saline-mice, but this was not significant (P = 0.2336). Serum hIL-10 was similar between
saline-mice and IL-2-mice (P = 0.4569) (Fig. 6.12c).
Concentrations of serum hIFNγ (saline: 22893 ± 7961 pg.mL-1, n = 7; IL-2: 29774 ±
7220 pg.mL-1, n = 8; PTCy: 18217 ± 8073 pg.mL-1, n = 8; PTCy+IL-2: 19326 ± 6141
pg.mL-1, n = 9) (F = 0.5170, P = 0.67408 ) (Fig. 6.12d) and hIL-17A (saline: 16.1 ± 8.9
pg.mL-1, n = 7; IL-2: 29.8 ± 17.6 pg.mL-1, n = 8; PTCy: 8.9 ± 4.7 pg.mL-1, n = 8;
PTCy+IL-2: 6.7 ± 4.7 pg.mL-1, n = 9) (F = 1.067, P = 0.3789) (Fig. 6.12e) were also
similar between groups. Finally, concentrations of serum hTNFα were similar between
PTCy+IL-2-mice (24.8 ± 14.5 pg.mL-1, n = 9) and all other groups (saline: 76.0 ± 34.9
pg.mL-1, n = 7; IL-2: 71.1 ± 25.3 pg.mL-1, n = 8; PTCy: 5.1 ± 2.5 pg.mL-1, n = 8), (P
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> 0.05 for all). In contrast, serum hTNFα concentrations in PTCy-mice were 94% lower
on average compared to saline-mice (P = 0.0487). Saline-mice and IL-2-mice
demonstrated similar levels of serum hTNFα (P = 0.9165) (Fig. 6,12f).

Figure 6.12 Combinational therapy of PTCy with low-dose IL-2 does not influence the concentration
of inflammatory or regulatory cytokines in humanised mice. At endpoint sera was isolated from mouse
blood and the (a-f) concentrations of (a) hIL-2, (b) hIL-6, (c) hIL-10, (d) hIFNγ, (e) hIL-17and (f) hTNFα
was assessed via a LEGENDplex assay. Lines represent group mean ± SEM (n = 7-8 per group). Symbols
represent individual mice. (d) * P < 0.05 compared to PTCy mice.

6.3

Discussion

This chapter is the first study to investigate combinational therapy of PTCy with lowdose IL-2 in a humanised NSG mouse model of GVHD. Although mice treated with this
combined therapy displayed a positive correlation between the levels of Tregs and mouse
survival, it did not impact the engraftment of human Tregs at endpoint, or the
development of clinical GVHD compared to PTCy alone. Consistent with Chapter 5, mice
treated with PTCy demonstrated prolonged survival, reduced clinical GVHD and
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improved liver pathology compared to both saline-mice and IL-2-mice. This is consistent
with Chapter 5, where PTCy reduced GVHD in humanised NSG mice.
The positive correlation between the proportions of human Tregs and mouse survival in
the PTCy+IL-2 treatment group was expected since IL-2 promotes the development,
longevity and function of Tregs, and its absence causes Treg apoptosis (Barron et al.,
2010). This accounts for IL-2-mice also demonstrating a similar positive correlation,
which almost reached statistical significance, and also the lack of correlation of the PTCyand saline-mice groups, which did not receive IL-.2 Other studies using low-dose IL-2 in
humanised NSG mouse models of GVHD are limited in number. However, a recent study
demonstrated that 0.3 MIU IL-2, administered once daily for 3 weeks alongside
rapamycin, prolongs allograft survival, expands Tregs and reduces histological GVHD
damage to target organs in a humanised mouse model (Hu et al., 2020). However, this
prior study did not directly correlate the proportions of Tregs with mouse survival. Thus,
this chapter is the first study to directly examine the impact of low-dose IL-2 on human
Treg survival in humanised NSG mice. Furthermore, the results in the current study
mirror clinical studies where daily administration of 1 MIU IL-2 for 12 weeks in GVHD
patients promoted Treg survival (Hirakawa et al., 2016).
This chapter demonstrates that combinational therapy of PTCy with low-dose IL-2 does
not further reduce the development or severity of GVHD compared to PTCy alone. Whilst
the reasons for this are unclear, it is possible that low-dose IL-2 triggered the expansion
of GVHD effector T cells in PTCy+IL-2-mice. Although CD4+ Tcons are not expanded
by low dose IL-2, the majority of splenic hCD4+ T cells in humanised NSG mice are
CD39+ (Chapter 4), indicating high levels of activation (Fang et al., 2016). Since CD25
is increased on CD4+ Tcons following activation (Kmieciak et al., 2009), these cells may
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have competed with Tregs for exogenous IL-2 and could have propagated GVHD. Similar
results were obtained by Perol et al. (2014) who demonstrated that low-dose IL-2 (0.25
MIU daily for 10 days) expanded CD4+ Tcons and caused severe GVHD in humanised
NSG mice. Moreover, the injection of plasmids expressing hIL-2 into humanised mice
can trigger large expansion of CD4+ Tcons and drive GVHD (Abraham et al., 2017). The
current results suggest that PTCy is depleting CD4+ Tcons since PTCy-mice and
PTCy+IL-2-mice had similar CD4+:CD8+ T cell ratios but reduced compared to IL-2mice at week 3 and endpoint. Despite this, low-dose IL-2 still did not impede the ability
of PTCy to reduce GVHD. Given the impact of IL-2 on CD4+ Tcons and Tregs is dosedependent (Kmieciak et al., 2009), it is possible that, a lower dose of IL-2 may be more
effective in this humanised mouse model. Clinical trials have demonstrated that ultralow-dose IL-2 (0.1-0.2 MIU) can reduce GVHD and expand Tregs in humans (KennedyNasser et al., 2014), and it may have similar effects in this humanised mouse model.
The improved Treg survival in PTCy+IL-2-mice did not result in increased proportions
of human Tregs at endpoint. This was unexpected since Tregs constitutively express
CD25, allowing them to be selectively expanded by low-dose IL-2 (Matsuoka et al.,
2013). Notably, the proportions of hCD3+hCD4+hCD25+hFoxP3+ Tregs was similar to
the proportions of hCD3+hCD4+hCD25+hCD127lo Tregs in all mice. This was expected
considering that CD127 expression inversely correlates with FoxP3 expression on human
CD4+ Tregs (Liu et al., 2006). Moreover, this FoxP3 staining protocol was optimised by
staining FoxP3+ Tregs in freshly isolated hPBMCs. The current results contrast other
studies in humans (Koreth et al., 2011a, Hirakawa et al., 2016, Koreth et al., 2016) and
mice (Pérol et al., 2014) with GVHD where low dose-IL-2 increased Tregs. These
conflicting results most likely reflect the timing when Tregs were assessed in the
respective studies. In the current study Tregs were only assessed at endpoint, but may
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have been expanded at earlier time points. These results may also indicate that an altered
regime of IL-2 may be required to maintain Tregs for longer periods in humanised NSG
mice. Since Tregs rapidly recover following PTCy (Kanakry et al., 2013a, Wachsmuth et
al., 2019), 0.3 MIU IL-2 was injected daily for the first five days to induce Treg
development and facilitate their recovery. IL-2 was then administered thrice weekly to
maintain Tregs and minimise their apoptosis (Barron et al., 2010). Although 0.3 MIU IL2 was recently used in humanised NSG mice to expand Tregs, daily treatment of IL-2, in
conjunction with rapamycin, was required to expand these cells (Hu et al., 2020). Further
low dose IL-2 (0.3MIU) alone did not delay GVHD, whereas low dose IL-2 with
rapamycin was more effective (Hu et al., 2020). Therefore, it may be viable for future
studies to combine PTCy and low-dose IL-2 with additional therapeutics such as
rapamycin (Battaglia et al., 2005, Hu et al., 2020) or IL-2/IL-2R antibody complexes
(Wang and Alexander, 2013) to help maintain Tregs in this model. Further,
hypomethylating agents could also be combined with PTCy and low-dose IL-2 to promote
Tregs. These agents increase FoxP3 expression on donor T cells and drive Treg
development (Choi et al., 2010, Ehx et al., 2017). Moreover these agents increase Tregs
and reduce GVHD in human allo-HSCT recipients (Goodyear et al., 2012) and humanised
mouse models (Ehx et al., 2017).
In the current study PTCy-mice and PTCy+IL-2-mice also demonstrated significantly
improved liver histology, with reduced infiltrating cells, than saline-mice and IL-2 mice.
This is consistent with the improved liver histology in humanised NSG mice receiving
PTCy in Chapter 5. Moreover, the localised effect on the liver is most likely due to the
metabolism of PTCy occurring by cytochrome P450 in the liver (Emadi et al., 2009),
potentially resulting in higher local concentrations of Cy. Whilst it is likely that the
reduction is due to PTCy depleting alloreactive human donor CD4+ T cells in the liver,
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the exact identity of these cells were not elucidated. This could be achieved by
immunohistochemistry. Although PTCy is believed to induce alloreactive T cell
apoptosis (Al-Homsi et al., 2015), TUNEL assays of liver sections revealed similar
numbers of apoptotic cells in all mouse groups at end-point. Importantly, this highlights
that PTCy at 33 mg/kg shows minimal toxicity in the livers of humanised NSG mice.
Combinational therapy of PTCy with low-dose IL-2 did not influence the engraftment of
human leukocyte subsets compared to PTCy alone. However, in contrast to Chapter 5
PTCy (either alone or with low-dose IL-2) reduced proportions of hCD45+ leukocytes in
mice treated with at 3 weeks post-hPBMC injection. Whilst batch differences in
cyclophosphamide or donor differences cannot be excluded, these two chapters also used
different injection regimes which could be impacting human T cell engraftment.
In conclusion, this chapter demonstrates that combinational therapy of PTCy with lowdose IL-2 does not further reduce GVHD compared to PTCy alone in a humanised mouse
model. However, this combined therapy did improve human Treg survival in humanised
NSG mice and did not impede the ability of PTCy to reduce GVHD. This may indicate
that combinational of PTCy and low-dose IL-2 with additional strategies to boost Tregs
may be a viable strategy to prevent GVHD in this model.
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Chapter 7:
7.1

General Discussion

Introduction

Graft-versus-host disease (GVHD) is a severe complication of allogeneic hematopoietic
stem cell transplantation (allo-HSCT) that occurs when donor T cells in the graft become
reactive against host tissues (Blazar et al., 2012). GVHD has a complex pathophysiology
(Ferrara and Reddy, 2006), which makes early diagnosis difficult and restricted the
development of effective therapeutics. Two key approaches to improve GVHD outcomes
are to identify predictive GVHD biomarkers in allo-HSCT donors and develop
therapeutic strategies that target reactive donor T cells in the graft.
Humanised mouse models of GVHD are useful preclinical models to investigate
signalling pathways and potential therapeutic strategies in GVHD (Hogenes et al., 2014,
Brehm et al., 2010, Walsh et al., 2017). Humanised mice display an immune system that
more accurately resembles humans than allogeneic mouse models, and allow easy
identification of donor (human) or host (murine) cells (Schroeder and DiPersio, 2011).
This makes them valuable for investigating therapeutic strategies for GVHD that target
donor cells. Using NOD.Cg-PrkdcscidIl2rgnull (NSG) mice, our laboratory has established
a humanised mouse model of GVHD (Geraghty et al., 2017), thus this model was used
for Chapters 3-6.
Purinergic signalling is an extracellular signalling network that is implicated in GVHD
(Apostolova and Zeiser, 2016). Extracellular ATP activates P2X7 on host antigen
presenting cells, leading to activation and proliferation of reactive donor T cells that
mediate GVHD (Wilhelm et al., 2010). However, extracellular ATP can be hydrolysed
by ectonucleotidase triphosphate diphosphohydrolase-1 (CD39) to promote antiinflammatory functions (Zimmermann, 2000). P2X7 and CD39 are present on donor T
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cells in allo-HSCT. Therefore donor P2X7 and CD39 may influence GVHD, or be
potential predictive GVHD biomarkers, but this not been investigated prior to this thesis.
The proliferation of reactive donor T cells is a central step in GVHD pathogenesis.
Therefore the in vivo depletion of reactive donor T cells is a current GVHD therapeutic
strategy (Busca and Aversa, 2017, Saad and Lamb, 2017, Zhang and Tey, 2019).
Cyclophosphamide (Cy) given post-transplant (PTCy) is clinically used to reduce GVHD
by targeting reactive donor T cells (Kanakry et al., 2016, Williams et al., 2020). However,
it is unclear how PTCy impacts reactive donor T cells and reduces GVHD. PTCy has
been thoroughly studied in allogeneic mouse models of GVHD, (Ganguly et al., 2014,
Kanakry et al., 2013a, Wachsmuth et al., 2019, Wachsmuth et al., 2020) but there are few
studies in humanised mice (Kanakry et al., 2014). Therefore, this thesis also examined
how PTCy influences reactive human donor T cells, and GVHD development in
humanised NSG mice. Since PTCy does not prevent GVHD in pre-clinical models or
clinical settings, this thesis lastly examined whether combining PTCy with another
therapeutic (low dose IL-2) further reduces GVHD.
7.2

Donor SNPs in purinergic signalling genes as predictive GVHD biomarkers

The identification of reliable predictive GVHD biomarkers could strongly reduce GVHD
following allo-HSCT. There are a small number of validated GVHD biomarkers, the most
prominent being elevated levels of suppressor of tumerogenicity 2 (McDonald et al.,
2015), regenerating-islet-derived 3-α (Ferrara et al., 2011) and tumour necrosis factor
receptor (TNFR) 1 (McDonald et al., 2015). However, these biomarkers are exclusive to
the host and there are few validated biomarkers that predict if donor cells will cause
GVHD. Single nucleotide polymorphisms (SNPs) in donor inflammatory genes have
been highlighted as potential biomarkers (Martínez-Laperche et al., 2018). Therefore,
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Chapters 3 and 4 assessed if SNPs in donor genes for purinergic signalling, which is
implicated in GVHD (Apostolova and Zeiser, 2016), could be biomarkers in donor cells
for predicting GVHD outcomes in HSCT recipients (Fig. 7.1).

Figure 7.1 The impact of donor SNPs in purinergic signalling genes on the development of GVHD in
a humanised NSG mouse model. The injection i.p. of hPBMCs into NSG mice causes tissue damage and
the release of extracellular ATP. Extracellular ATP can activate P2X7 on NSG APCs leading to the
activation, proliferation and differentiation of reactive human donor T cells. Donor T cells migrate to
GVHD target organs to initiate further tissue damage and extracellular ATP release in a positive feedback
loop. Extracellular ATP can also directly activate P2X7 on human donor T cells. The use of hPBMCs from
human donors with increased (GOF P2RX7 genotype donors; green arrows) or decreased P2X7 activity
(LOF P2RX7 genotype donors; red arrows) on immune cell subsets important in GVHD does not influence
GVHD severity or mouse survival in humanised NSG mice (red and green crosses, respectively).
Extracellular ATP can be hydrolysed by CD39 on Tregs, which can protect against GVHD and suppress
reactive donor T cells. The use of hPBMCs from human donors with increased CD39+ Tregs (CD39AG/GG
donors) resulted in reduced human Treg survival which corresponded to increased splenic hCD4+:hCD8+
T cell ratios and increased GVHD severity, including greater weight loss and reduced mouse survival (blue
arrows).

Chapters 3 and 4 are the first studies to directly examine the roles of donor P2X7 and
CD39, respectively, in GVHD (Sluyter and Stokes, 2010, Wiley et al., 2011). P2X7 is
found on human leukocytes where its activity is influenced by SNPs in the human P2RX7
gene. P2X7 is up-regulated in the peripheral blood and small intestines in human GVHD
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patients (Wilhelm et al., 2010), and P2X7 blockade reduces GVHD in mice (Wilhelm et
al., 2010, Zhong et al., 2016, Fowler et al., 2014). Conversely CD39 is integral for the
stability and suppressive functions of regulatory T cells (Tregs) (Dwyer et al., 2010),
which protect against GVHD (Di Ianni et al., 2011, Ruggeri et al., 2014). CD39 is
required for Tregs to reduce GVHD (Gu et al., 2017), and its expression on Tregs is
influenced by the rs10748643 (AG) SNP in the human ENTPD1 gene (Rissiek et al.,
2015).
This thesis demonstrated that P2X7 activity on human monocytes and CD3+, CD4+ and
CD8+ T cells correlates with donor P2RX7 genotype (Chapter 3) and is the first to show
this correlation on Tregs, and invariant natural killer T cells (Fig. 7.1). Further, this thesis
shows that the G allele of the rs10748643 SNP (CD39AG/GG donors) correlates with
increased proportions of CD39+ Tregs, but not other leukocyte subsets, in Australian
donors (Chapter 4) (Fig. 7.1). This latter finding is consistent with donors from Italy
(Timperi et al., 2016a) and Germany (Rissiek et al., 2015). Tregs with reduced P2X7
activity may be less susceptible to ATP-induced apoptosis or conversion into
conventional T cells (Tcons) (Schenk et al., 2011). Moreover, Tregs from CD39AG/GG
donors have increased capacity to suppress interferon (IFN)-γ and interleukin (IL)-17
(Rissiek et al., 2015), two key cytokines in GVHD (Yi et al., 2009). Thus, it was
hypothesized that human immune cells from donors with lower P2X7 activity, or
increased CD39+ Tregs, would cause reduced GVHD in humanised NSG mice.
Donor P2RX7 genotype did not influence the engraftment of human immune cells or
GVHD development in humanised NSG mice (Chapter 3). Thus, this data indicates that
human donors, regardless of P2RX7 genotype, can be used to investigate donor cell
engraftment or GVHD in this mouse model. Whilst the current results contrast previous
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studies where genetic deletion of P2X7, and P2X7 blockade reduced GVHD (Wilhelm et
al., 2010), it is P2X7 on host APCs that is thought to promote GVHD (Wilhelm et al.,
2010). Our laboratory has shown that NSG mice express functional P2X7 (Geraghty et
al., 2017), and that P2X7 blockade reduces serum hIFNγ (Geraghty et al., 2017) and liver
inflammation (Geraghty et al., 2019c) in this model. Therefore, Chapter 3 provides
indirect evidence that host, rather than donor, P2X7 is more important in GVHD in
humanised NSG mice. This could be further elucidated by using a nanobody to block
mouse (host), but not human (donor), P2X7 (Danquah et al., 2016). Whilst other studies
have demonstrated that donor P2RX7 SNPs can influence clinical outcomes following
allo-HSCT (Lee et al., 2007a), these studies focused on survival after allo-HSCT and not
GVHD. During this thesis, a clinical study in 453 allo-HSCT donors showed that donor
P2RX7 SNPs have minimal impact on allo-HSCT outcomes and GVHD (Koldej et al.,
2020). Alongside Chapter 3, this indicates that donor P2RX7 genotype is not a predictive
GVHD biomarker and is unlikely to influence GVHD outcomes in HSCT recipients.
In contrast, Chapter 4 showed that CD39AG/GG donors yield increased splenic human (h)
CD4+:hCD8+ T cell ratios in NSG mice (Fig. 7.1). Moreover, mice injected with CD39AA,
but not CD39AG/GG, donor cells displayed a positive correlation between the levels of
Tregs and mouse survival (Fig. 7.1). Since CD39AG/GG donors have high proportions of
CD39+ Tregs, CD39 may indicate higher levels of Treg activation (Raczkowski et al.,
2018) or exhaustion (Gupta et al., 2015) and may cause them to become CD4+ Tcons in
NSG mice to drive GVHD. Prolonged imbalance of Tregs and CD4+ Tcons has been
identified as a potential biomarker for GVHD (Alho et al., 2016, Matsuoka et al., 2010),
therefore these results support that donor rs10748643 genotype is a potential biomarker
for GVHD in this model. Given that many biomarkers are assessed between days 3-14
post-HSCT (McDonald et al., 2015, Hartwell et al., 2017), future studies could investigate
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if donor rs10748643 genotype influences engraftment at these earlier time-points, and
their infiltration into GVHD target organs.
The observation that CD39AG/GG donors, compared to CD39AA donors, worsened GVHD
and mouse survival (Fig. 7.1) contrasts studies in allogeneic (Del Papa et al., 2016) and
humanised (Gu et al., 2017) mouse models where Tregs expressing high CD39 reduced
GVHD. However, these previous studies co-transfused high numbers of CD39hi Tregs
alongside donor cells but did not investigate the rs10748643 SNP. To determine if the
effects in Chapter 4 are due to donor Tregs, NSG mice could be co-transfused with Tregs
from CD39AA and CD39AG/GG donors alongside human peripheral blood mononuclear
cells (hPBMCs) and assessed for GVHD. Additionally, CD39 promotes the production
of adenosine to activate A2A receptors on Tregs and reduce GVHD (Lappas et al., 2010).
Since no study has shown whether the rs10748643 SNP influences extracellular ATP
hydrolysis and adenosine generation, future studies could assess if this SNP influences
adenosine production or A2A activation on donor Tregs. Collectively, Chapter 4 shows
the potential of donor rs10748643 SNP genotype as a predictive biomarker for GVHD
severity, but this needs to be validated in human HSCT donors and recipients.
Furthermore, this highlights the potential of donor SNPs in other purinergic signalling
genes as GVHD biomarkers, such as the NT5E gene encoding CD73 (Tsukamoto et al.,
2012, Wang et al., 2013), or the ADORA2A gene encoding A2A (Cannata et al., 2020).
Given that this thesis generated a databank of donors sequenced for P2RX7 and ENTPD1
genotype, it may also be valuable to stratify donors based on these two genotypes and
examine if there is interplay between the two which may influence GVHD in humanised
NSG mice
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A potential limitation of this study is that it remains unknown whether human T cells
from hP2X7GOF and hP2X7LOF mice demonstrate increased or decreased P2X7 activity,
respectively, in vivo. This could be assessed in future studies by assessing ATP-induced
YO-PRO-12+ uptake human T cells isolated from hP2X7GOF and hP2X7LOF mice
following engraftment. Additionally, the presence of immunosuppressive Tregs in
humanised NSG mice may be masking an effect of donor P2RX7 genotype on GVHD
effector T cells and disease outcomes. Therefore, future studies could use anti-CD25
monoclonal antibodies to deplete Tregs in this mouse model to assess this (Buszko et al.,
2020). Furthermore, it remains unknown whether GOF and LOF P2RX7 genotypes
impact P2X7 expression following engraftment, which could be measured via
quantitative PCR on cDNA synthesized from NSG mouse spleens. It also remains
unknown if specific P2RX7 SNPs, rather than broad haplotypes, in donor hPBMCs may
influence GVHD in this model. Likewise, the human ENTPD1 genes gives rise to other
polymorphisms. For example, the rs10748643 SNP is thought to be in tight linkage
disequilibrium with rs3814159 SNP, which is in linkage disequilibrium with the
rs3176891 SNP (Maloney et al., 2017). How these SNPs may be impacting donor
hPBMCs and GVHD in NSG mice is unclear.
7.3

Depleting reactive donor T cells in a humanised mouse model of GVHD

GVHD is mediated by reactive donor T cells in the graft, therefore the depletion of
reactive donor T cells is a current GVHD therapeutic strategy. There are many methods
to deplete reactive donor T cells (Table 1.3), however T cell depletion can lead to cancer
relapse and opportunistic infection (Villa et al., 2016). PTCy is commonly used clinically
to target reactive donor T cells (Kanakry et al., 2016), however it is unclear how PTCy
impacts these cells and reduces GVHD. Prior to this thesis no study had investigated the
mechanism of PTCy in humanised mice. Therefore, Chapter 5 aimed to determine the
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effect of PTCy on reactive donor T cells and GVHD in humanised NSG mice. This
included the opportunity to examine how PTCy impacts donor cells at different time
points, and then, in Chapter 6, how PTCy with low-dose IL-2, as a combinational therapy
further influenced donor T cells and GVHD.
Chapter 5 is the first study to show that PTCy depletes reactive human donor T cells in
humanised NSG mice (Fig. 7.2). Similar observations have been reported in skin allograft
models (Eto et al., 1991, Eto et al., 1990a) and allogeneic mouse models of GVHD
(Huyan et al., 2011, Ross et al., 2013). During the course of this thesis, Wachsmuth et al.
(2019) showed that PTCy reduces GVHD by inducing alloreactive T cell dysfunction and
not their elimination in allogeneic mouse models of GVHD. In this thesis, PTCy reduced
the proportion of human donor T cells at day 6, and unexpectedly caused increased
hCD4+:hCD8+ T cell ratios at endpoint (Fig. 7.2), which is associated with worsened
GVHD in humanised NSG mice (Geraghty et al., 2019b). Therefore, the possibility
remains that remaining reactive hCD4+ T cells may have been functionally impaired. The
functionality of these cells could be assessed in future studies by measuring tolerance,
anergy or exhaustion of the remaining reactive human donor T cells in humanised NSG
mice (Schietinger and Greenberg, 2014). Furthermore, PTCy may be impacting specific
CD4+, including T helper (Th) 1 and Th17, and CD8+ T cell subsets. These cells could be
assessed in future using intracellular staining and flow cytometry. Notably, PTCy reduced
proportions of hCD38+hCD8+ effector memory (EM) cells at endpoint (Fig. 7.2). This
has not been previously observed in any mouse model of GVHD. Thus, high proportions
of CD38+CD8+ EM cells may be a biomarker for GVHD in mice, as it is in humans
(Khandelwal et al., 2015, Khandelwal et al., 2020). The mechanism of PTCy in GVHD
could be further explored by assessing the depletion of other donor leukocyte subsets.
Human NK cells (Ono et al., 2019), B cells (Cuthbertson, unpublished) and dendritic cells
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(DCs) (Geraghty et al., 2017) also engraft in humanised NSG mice, but it is unknown if
PTCy impacts these cells in GVHD.

Figure 7.2 Targeting reactive human donor T cells as a therapeutic strategy to prevent GVHD in
humanised NSG mice. The injection i.p. of hPBMCs into NSG mice results in the activation of host APCs
and the proliferation of reactive human donor T cells which illicit inflammatory damage to GVHD target
organs, promoting further extracellular ATP release in a positive feedback cycle. The administration i.p. of
33 mg.kg-1 PTCy on day 3 and 4 post-hPBMC injection leads to the depletion of a proportion of reactive
donor T cells in the liver at day 6, corresponding to reduced GVHD, including reduced weight loss,
leukocyte infiltration in the liver and reduced proportions of hCD38+hCD8+ EM cells (orange arrows).
However, in contrast to the reduced GVHD, PTCy increased the splenic hCD4+: hCD8+ T cell ratio and
reduced human Tregs and their survival in humanised NSG mice (orange arrows). The addition of lowdose IL-2 (0.3 MIU daily from day 0-4 followed by thrice weekly until endpoint) to PTCy increases human
Treg survival in humanised NSG mice (blue arrows). Combinational therapy of PTCy and low-dose IL-2
does not further reduce GVHD, including leukocyte infiltration in the liver, weight loss or mouse survival,
compared to PTCy-alone (blue dashes). Neither PTCy nor PTCy+IL-2 impacted apoptotic cells in the liver.
Low-dose IL-2 does not impede the ability of PTCy to reduce GVHD in humanised NSG mice. Colours
indicate the effect of PTCy (orange) and PTCy+IL-2 (blue).

Chapter 5 is the first to demonstrate localised effects of PTCy on GVHD target organs.
The most pronounced effect of PTCy occurred in the liver (Fig. 7.2). Since the liver is
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responsible for Cy metabolism (Forrester et al., 1992), Cy may have been at the highest
concentration in this tissue. Moreover, although livers were not perfused, we did not
observe a detectable quantity of human cells in the blood of these mice at this timepoint.
Whilst there were minimal signs of GVHD in the small intestines and skin in Chapters 5
and 6, these organs also demonstrated minimal damage in Chapters 3 and 4. Since these
chapters used either 10 x 106 or 20 x 106 hPBMCs, this indicates that prior preconditioning, and not increased human immune cells, is required to drive GVHD damage
to these tissues in humanised NSG mice (Denton et al., 2012). Notably, mice in all studies
began showing signs of clinical GVHD between day 17 and 25, regardless of hPBMC
dosage. However, it must be noted that mice in Chapters 5 and 6 received additional saline
injections, which did not occur in Chapters 3 and 4. Future studies could assess the
infiltration of specific immune cell subsets in these tissue for further assessment on the
organ specific effects of PTCy. This could be performed using immunohistochemistry
(Duraiyan et al., 2012) for CD4+ or CD8+ T cells, or imaging mass cytometry (Giesen et
al., 2014) for more cell types, including those with multiple markers such as
CD4+CD25+FoxP3+ Tregs (Hu et al., 2020), which are important for reducing GVHD (Di
Ianni et al., 2011, Ruggeri et al., 2014). Moreover, these tissue could be assessed at
different time points using these techniques to determine if PTCy is influencing cell
migration to them, which would further elucidate the mechanism of PTCy in GVHD.
In Chapter 5, PTCy reduced GVHD and improved survival in humanised NSG mice (Fig.
7.2). Although this has been shown previously using 100 mg.kg-1 PTCy administered i.p.
on day 3 (Kanakry et al., 2013a), this previous study did not provide any evidence that
reactive donor T cells were depleted. Chapter 5 used a more clinically relevant dose of
PTCy (33 mg.kg-1 on days 3 and 4) to reduce the chances of toxicity, and this did not
increase apoptosis in the liver in Chapter 6 (Fig. 7.2). Notably, Chapter 5 is the first to
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use PTCy in humanised NSG mice without prior pre-conditioning. Although allo-HSCT
patients still undergo some condition to reduce tumour burden and allow donor cell
engraftment (Nakasone et al., 2015), conditioning is not required for NSG mice to engraft
human cells. Therefore, chapter 5 more closely resembles reduced intensity conditioning
regimens, which aim to minimise conditioning caused tissue damage. Furthermore,
similar to our model, reduced conditioning allo-HSCT patients still develop severe
GVHD. Since PTCy reduced but did not prevent GVHD (Chapter 5), and other dosages
and regimes of Cy have shown no improved benefit than the standard regime (Wachsmuth
et al., 2020), this indicates that PTCy needs to be combined with other strategies to further
reduce or prevent GVHD. This could include strategies to increase reactive donor T cell
depletion such as antithymocyte globulin or αβ T cell depletion. However, T cell
depletion can increase risks of infection or relapse (Villa et al., 2016), so alternative
strategies that prevent GVHD, such as using mesenchymal stem cells to inhibit cytotoxic
activity of reactive donor T cells (Sivanathan et al., 2014), targeting CD83+ donor DCs to
restrict reactive T cell activation (Li et al., 2019) or increased Treg survival (Chapter 6)
could be used alongside PTCy.
Tregs protect against GVHD (Di Ianni et al., 2011) and reconstitute rapidly in mice
following PTCy (Kanakry et al., 2014). Importantly, Tregs are required for PTCy to
reduce GVHD (Ganguly et al., 2014). In Chapter 5, despite reducing GVHD, PTCy
reduced the proportions of human Tregs, and their survival in humanised NSG mice (Fig.
7.2). This is consistent with the poor survival of Tregs following transplantation (Tang
and Vincenti, 2017, MacDonald et al., 2019). In vivo expansion of human Tregs is an
affordable and promising therapeutic strategy for GVHD (Kennedy-Nasser et al., 2014,
Zhao et al., 2014, Koreth et al., 2016). Human Tregs constitutively express CD25, the
interleukin (IL)-2 receptor α chain (Sakaguchi et al., 1995), and can be expanded with
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low-doses of IL-2 (Kennedy-Nasser et al., 2014, Barron et al., 2010). Therefore, Chapter
6 aimed to combine PTCy with low-dose to enhance human Tregs and further reduce
GVHD in humanised NSG mice.
The combination of low-dose IL-2 to PTCy resulted in a positive correlation between
mouse survival and the proportions of Tregs. However, this therapy did not improve the
proportions of Tregs in humanised NSG mice at endpoint (Fig. 7.2). This latter finding
may indicate that Tregs in humanised mice receiving combinational therapy of PTCy with
low-dose IL-2 have increased function. Although the lack of difference in Tregs at
endpoint contrasts studies in human GVHD patients (Koreth et al., 2011a, Hirakawa et
al., 2016, Koreth et al., 2016) and humanised mouse models of GVHD (Pérol et al., 2014,
Hu et al., 2020) where low dose-IL-2 increased Tregs. However, in these previous
humanised mouse studies, Tregs were assessed in spleens at day 10 (Pérol et al., 2014)
and blood at week 5 (Hu et al., 2020), not at endpoint. Therefore, future studies using the
current model could assess human Tregs in multiple tissues, including the blood and
GVHD target organs, at earlier time-points. Other strategies could also be utilised to
enhance human Tregs in this model. Rapamycin is routinely used clinically to reduce
GVHD by enhancing Tregs (Amarnath et al., 2010, Battaglia et al., 2005), and the
combination of low-dose IL-2 and rapamycin increases the proportions of human Tregs
in humanised NSG mice (Hu et al., 2020). However, the combination of PTCy, low-dose
IL-2 and rapamycin has not been investigated as a GVHD therapeutic strategy. Tregs can
also be expanded in vivo by targeting TNFR (Wolf et al., 2017) or with drugs such as
sirolimus (Peccatori et al., 2015), azacytidine (Schroeder et al., 2013) or vorinostat (Choi
et al., 2015). Therefore, these compounds could also be investigated in combination with
PTCy.
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Low-dose IL-2 did not impede the ability of PTCy to reduce GVHD, however
combinational therapy did not further reduce GVHD compared to PTCy alone (Fig. 7.2).
These results align with Pérol et al. (2014), where low-dose IL-2 alone did not reduce
GVHD in humanised NSG mice due to an expansion of IFNγ and TNFα releasing CD4+
and CD8+ Tcons in the spleen and liver. Since Tcons express CD25 following activation
(Kmieciak et al., 2009), it is possible that Tcons were expanded and drove GVHD in
Chapter 6. This could be confirmed by intracellular staining for T helper (Th) 1, Th2 and
Th17 cells, which are important for GVHD pathogenesis (Yi et al., 2009). These results
may also indicate that an altered regime of low dose IL-2 may be required to maintain
Tregs for longer periods in humanised NSG mice. Given the impact of IL-2 on CD4+
Tcons and Tregs is dose-dependent (Kmieciak et al., 2009), a lower dose of IL-2 may be
more effective in this humanised mouse model. Clinical trials have demonstrated that
ultra-low-dose IL-2 (0.1-0.2 mega international units) can reduce GVHD and expand
Tregs in humans (Kennedy-Nasser et al., 2014). This may have similar effects in
humanised NSG mice. Moreover, in humanised NSG mice, human anti-IL-2 antibodies,
such as F5111.2 (Trotta et al., 2018), can promote human Treg expansion without
expanding Tcons. Therefore, it may be valuable to investigate how PTCy and human antiIL-2 antibodies impact GVHD in humanised NSG mice.
The primary benefit of allo-HSCT is the graft-versus-tumour (GVT) effect whereby
donor cells recognize and destroy malignant host cells (Fowler, 2006). Therefore, a
successful GVHD therapeutic strategy must reduce GVHD without negatively impacting
GVT. A potential limitation of Chapters 5 and 6 is that the impact of PTCy and low-dose
IL-2 on the ability of donor T cells to mediate GVT effects was not assessed. This could
be performed using humanised GVT models by injecting NSG mice with hPBMCs
alongside cancer cell lines such as THP-1 acute monocytic leukaemia cells (Ehx et al.,
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2017; Ehx et al., 2018; Delens et al., 2019) or P815 mouse mastocytoma cells (Burlion
et al., 2017) transfected to express luciferase (luc). Mice can then be treated as in Chapters
5 and 6, for example, and GVT effects monitored by assessing tumour weight or
bioluminescence over time. Subsequently, additional therapeutic strategies could be
added to minimise GVHD whilst maximising GVT.
7.4

Conclusion

GVHD is a severe complication of allo-HSCT. Currently, there are no therapies which
consistently prevent the disease. This thesis attempted to identify novel therapeutic
strategies for GVHD by identifying potential predictive GVHD biomarkers in human
donors and depleting reactive donor T cells using the humanised NSG mouse model.
Firstly, this thesis showed that donor P2RX7 genotype correlated to altered P2X7 activity
on donor T cells important in GVHD. However, altered P2X7 activity on donor T cells
did not influence clinical GVHD in humanised NSG mice. Donors encoding the G allele
of the rs10748643 SNP, which increases the suppressive capacity of Tregs, demonstrated
increased proportions of CD39+ Tregs. However, these donors caused more severe
GVHD and reduced Treg survival in humanised NSG mice. This may indicate that donor
rs10748643 SNP genotype is a potential biomarker for GVHD severity, but needs to be
confirmed by clinical studies.
Since reactive donor T cells are central to GVHD pathogenesis, this thesis also examined
strategies to target these cells in humanised NSG mice. The use of PTCy in humanised
NSG mice reduced reactive human donor T cells in the liver and clinical GVHD.
Conversely, PTCy reduced human Tregs, which protect against GVHD. Attempts to
enhance Tregs using low-dose IL-2 alongside PTCy did not further reduce GVHD
compared to PTCy alone. However, combinational therapy did improve human Treg
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survival and did not impede the ability of PTCy to reduce GVHD. This may indicate that
additional therapies that increase Tregs are required alongside PTCy, with or without lowdose IL-2 to further reduce, or prevent, GVHD in humanised NSG mice. Although GVHD
is still a major problem in clinical allo-HSCT, this thesis demonstrates the potential of
donor SNPs as GVHD biomarkers and combinational therapy with PTCy as strategies to
reduce GVHD following allo-HSCT in humans.
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Appendices: Publications arising from this thesis
Appendix 1: Altered donor P2X7 activity in human leukocytes correlates with donor
P2RX7 genotype but does not affect the development of graft-versus-host disease in
humanised mice
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Appendix 2: A single nucleotide polymorphism in the human ENTPD1 gene
encoding CD39 is associated with worsened graft-versus-host disease in a
humanised mouse model
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